## University of Kentucky

# **UKnowledge**

Graduate Center for Nutritional Sciences Faculty Patents

**Nutritional Sciences** 

5-28-2002

# Genes Encoding Several Poly (ADP-Ribose) Glycohydrolase (PARG) Enzymes, the Proteins and Fragments Thereof, and Antibodies Immnoreactive Therewith

Myron Jacobson University of Kentucky

Elaine L. Jacobson University of Kentucky

Jean-Christoph Amé

Winston Lin University of Kentucky, winston.lin@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/nutrisci\_patents

Part of the Medical Pharmacology Commons Right click to open a feedback form in a new tab to let us know how this document benefits you.

### **Recommended Citation**

Jacobson, Myron; Jacobson, Elaine L.; Amé, Jean-Christoph; and Lin, Winston, "Genes Encoding Several Poly (ADP-Ribose) Glycohydrolase (PARG) Enzymes, the Proteins and Fragments Thereof, and Antibodies Immnoreactive Therewith" (2002). *Graduate Center for Nutritional Sciences Faculty Patents*. 21. https://uknowledge.uky.edu/nutrisci\_patents/21

This Patent is brought to you for free and open access by the Nutritional Sciences at UKnowledge. It has been accepted for inclusion in Graduate Center for Nutritional Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.



US 6,395,543 B1

May 28, 2002

# (12) United States Patent

#### Jacobson et al.

#### (54) GENES ENCODING SEVERAL POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) ENZYMES, THE PROTEINS AND FRAGMENTS THEREOF, AND ANTIBODIES IMMUNOREACTIVE THEREWITH

- (75) Inventors: Myron K. Jacobson; Elaine L. Jacobson, both of Lexington, KY (US); Jean-Christophe Amé, Obernai (FR); Winston Lin, Lexington, KY (US)
- (73) Assignce: University of Kentucky Research Foundation, Lexington, KY (US)
- (\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
- (21) Appl. No.: 09/511,507
- (22) Filed: Feb. 23, 2000

#### **Related U.S. Application Data**

- (62) Division of application No. 09/302,812, filed on Apr. 30, 1999.
- (60) Provisional application No. 60/083,768, filed on May 1, 1998.
- (51) Int. Cl.<sup>7</sup> ..... Cl2Q 1/68; C07H 21/04; C12N 15/85; C12N 15/86

#### (56) References Cited

(10) Patent No.:

(45) Date of Patent:

#### PUBLICATIONS

Lin et al."Isolation and characterization of the cDNA encoding Bovein poly(ADP-ribose) glycohydrolase" JBC, vol. 272 No. 18, pp. 11895–11901, May 1997.\*

\* cited by examiner


Primary Examiner—John S. Brusca


Assistant Examiner—Karen A Lacourciere (74) Attorney, Agent, or Firm—Fulbright & Jaworski, LLP

#### (57) ABSTRACT


The isolation and characterization of cDNAs encoding poly (ADP-ribose) glycohydrolase (PARG) enzymes and the amino acid sequences of PARGs from several species are described. PARG is involved in the cellular response to DNA damage and its proper function is associated with the body's response to neoplastic disorder inducing agents and oxidative stress. Expression vectors containing the cDNAs and cells transformed with the vectors are described. Probes and primers that hybridize with the cDNAs are described. Expression of the cDNA in E. coli results in an enzymatically active protein of about 111 kDa and an active fragment of about 59 kDa. Methods for inhibiting PARG expression or overexpressing PARG in a subject for therapeutic benefit are described. Exemplary of PARG inhibitors are anti-sense oligonucleotides. The invention has implications for treatment of neoplastic disorder, heart attack, stroke, and neurodegenerative diseases. Methods for detecting a mutant PARG allele are also described. Antibodies immunoreactive with PARGs and fragments thereof are described.


#### 18 Claims, 18 Drawing Sheets






**U.S.** Patent









Sheet 3 of 18

bPARG (422)	ED KRKEQCEMKHQRTE RKIPKYIPPH	SEQ	ID	NO:	19
hPARG (421)	EDRRKEQWETKHQRTERKIPKYVPPH	SEQ	ID	NO:	20
mPARG (413)	EDRRKEQCEVRHQRTERKIPKYIPPN	SEQ	ID	NO:	21
CePARG (29)	HQVPTMKRRKLTEHGNTTESLLLKEDPEEPKS	SEQ	ID	NO:	22
hPARP (205)	EG KRKGD.EVDG.VDEVAKKKSKKEKDK	SEQ	ID	NO:	23
mPARP (205)	EGKRKGD.EVDG.TDEVAKKKSRKEKDK	SEQ	ID	NO:	24
bPARP (208)	EGKRKGD.EVDG.IDEVAKKKSKKEKDK	SEQ	ID	NO:	25
aPARP (205)	EGKRKGE.EVDGNVVAKKKSRKEKEK	SEQ	11	NO:	26
XIPARP (204)	EGKRKAD.EVDG.HSAARKKKIKKEKEK	SEQ	ID	NO:	27
DmPARP (202)	EELPDTKRAKM.ELSDTNEEGEKKQR	SEQ	ID	NO:	28
SpPARP (205)	EGVSSAKKAKI.EKIDEEDAASIKELTEKIKK	SEQ	ID	NO:	29



















FIG. 8B






















# FIG. 16A

Datg 23/ QSAAFJGUVFLEVVAEGTTEDEGTGLLEDEGTGLLQVFFAGSVLGGGVLGGGVLGGGVLGGGVLGELTEVVLCFELLGGGVLGFFF
---


Ceparg 787


	RCEKLL. TRLEVIYEGTIEGNGQGMLQVDFAHRFVGGGVTSAGLVQEEIRFLIHPELIVSRLFIEVLDHNEC RCEKPL. TRLEVIYEGTIEENGQGMLQVDFAHRFVGGGVTSAGLVQEEIRFLIHPELIISRLFIEVLDHNEC
Mparg 702 Dparg 410	RCEKPL. TRLEVIYEGTIEGNGRGMLQVDFAHRFVGGGVTGAGLVQEEIRFLIHPELIVSRLFIEVLDHNEC LVMLGAERYSNYTGIAGSFEWSGNFEDSTP.RDSSGRROTAIVAIDALHFA.OSHHOYREDL
d D	KDIFNEEW. XDXXLRSLPEVEFFDEMLIEDTAL. CTQVDFAHEHLGGGVLNHGSVQEEIRFLMCPEMMVGMLL
Bparg 888 Eparg 887 Mparg 773	LIITGTEQISEYTGIAETYRWARSHEDRSE.RDDWQRRTTEIVAIDALHFR.RYLDQFVPEKIR LIITGTEQISEYTGIAETYRWSRSHEDRSE.RDDCERRCTEIVAIDALHFR.RYLDQFVPEKMR LIITGTEQISEYTGIAETYRWARSHEDRSE.KDDWQRRCTEIVAIDALHFR.RYLDQFVPEKVR
g	VTPPPGVAT VFSSYTGYGHT
Bparg 951 Eparg 950 Mparg 835	RELHKAYCGFLRPGVSSEHLSAVATGNWGCGAFGGDARLKALIQYLAAAVAERDVVIFTFGDSELMRDIYSMH RELHKAYCGFLRPGVSSEHLSAVATGNWGCGAFGGDARLKALIQYLAAAVAERDVVIFTFGDSELMRDIYSMH RELHKAYCGFLRPGVPSEHLSAVATGNWGCGAFGGDARLKALIQYLAAAAAERDVVIFTFGDSELMRDIYSMH
d Q Q	HEMWLLFRNDGTTVQQ.LWS.ILRSYSRLIKEKSSKEPRENKASKKKLYDFIKEELKKVRDVPGEGAS EQLNKANIIREMKKASIGFMSQGPKFTHIP.IVTGWWGCGAFNGDKPLKFIIQVIAAGVADRPLHFCSFGEPE
Bparg 1021 Eparg 1020	
Mparg 907 Dparg 611	TFLTERKLDVGK. VYKLLLRYYNEECRNCSTPGP DIKLYPFIYHAVESSAETTDMPGQKAGT – – – – A AEAGSSRVAGLGEGKSETSAKSSPELNKQPARPQITITQQSTDLLPAQLSQDNSNSSEDQALLMLSDDEEA
Ceparg 759	LAAXCKKI I ERMKQKDVTLGKSCFSI FSL
Bparg 1087	
трага 969 Мрага 969	
	NAMMEAASLEAKSSVEISNSSTTSKTSSTATKSMGSGGRQLSLLEMLDTHYEKGSASKRPRKSPNCSKAEG


I


J.S. I atent	<b>Wiay 28,</b>	2002 Sne	et 15 01 18
TDKDEKDDIVD			
Bparg 1 Eparg 1 Mparg 1 Dparg 410 Ceparg 543	Bparg 101 Eparg 100 Mparg 97 Dparg 472 Ceparg 614	Bparg 201 Eparg 200 Mparg 197 Dparg 543 Ceparg 687	

# FIG. 16D










Sheet 18 of 18



15

30

35

40

#### GENES ENCODING SEVERAL POLY(ADP-**RIBOSE) GLYCOHYDROLASE (PARG) ENZYMES, THE PROTEINS AND** FRAGMENTS THEREOF, AND ANTIBODIES **IMMUNOREACTIVE THEREWITH**

#### CROSS REFERENCE TO RELATED APPLICATION

This application is a divisional of U.S. application Ser. No. 09/302,812 filed Apr. 30, 1999, which claims benefits of U.S. provisional Application No. 60/083,768 filed May 1, 1998. The entire disclosure of U.S. application Ser. No. 09/302,812 and U.S. Provisional Application No. 60/083, 768 is incorporated herein by reference.

#### STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

The present invention was supported in part by the National Institutes of Health (Grant CA43894). The United 20 States Government may have certain rights in the invention.

#### TECHNICAL FIELD

The present invention relates to poly(ADP-ribose) glycohydrolases (PARGs) and peptides having poly(ADP-ribose)<sup>25</sup> glycohydrolase activity. In addition, the invention also relates to antibodies, including monoclonal antibodies and antibody fragments, that have specific interaction with epitopes present on poly(ADP-ribose) glycohydrolases. Methods of treatment and diagnosis using the poly(ADPribose) glycohydrolases, and antibodies specific for poly (ADP-ribose) glycohydrolases are disclosed. The present invention has implications for the treatment of neoplastic disorder, reperfusion following ischemia, neurological disorders, and related conditions.

#### BACKGROUND OF THE INVENTION

Genomic damage, if left unrepaired, can lead to malignant transformation, or cell death by senescence (aging), necrosis or apoptosis. Among the variables that can affect the ultimate biological consequence of DNA damage to a particular cell are (i) the amount, type, and location of the DNA damage and (ii) the efficiency and bioavailability of the cellular DNA repair mechanism.

The activation of poly(ADP-ribose) polymerase (PARP) by DNA strand breaks is often one of the first cellular responses to DNA damage. PARP catalyzes the conversion of nicotinamide adenine dinucleotide (NAD) to multibranched polymers containing up to 200 ADP-ribose resi-50 dues. Increases in polymer levels of more than 100-fold may occur within minutes of DNA damage. Once synthesized, polymers are rapidly turned over, being converted to free ADP-ribose by the action of poly(ADP-ribose) glycohydrolase (PARG) (1). An ADP-ribosyl protein lyase has been 55 proposed to catalyze removal of protein-proximal ADPribose monomers (2). FIG. 1 illustrates these processes schematically.

The process of activating PARP upon DNA damage can rapidly lead to energy depletion because each ADP-ribose 60 unit transferred by PARP consumes one molecule of NAD, which in turn, requires six molecules of ATP to regenerate NAD. Additionally, NAD is a key carrier of electrons needed to generate ATP via electron transport and oxidative phosphorylation or by glycolysis. The overactivation of PARP 65 due to substantial DNA damage can significantly deplete the cellular pools of NAD and ATP (3). ADP-ribose polymer

2

metabolism, and thus PARP and PARG have been linked to the enhancement of DNA repair (4), limitation of malignant transformation (5), enhancement of necrotic cell death (6), and involvement in programmed cell death (7). To date, studies of the structure and function of the enzymes of ADP-ribose polymer metabolism have been mainly limited to PARP (8). Little is known about the function and regulation of PARG.

#### BRIEF SUMMARY OF THE INVENTION

As embodied and broadly described herein, the present invention is directed to nucleic acids molecules, peptides, methods, vectors and antibodies that are related to the poly(ADP-ribose) glycohydrolase (PARG) enzyme.

One embodiment of the invention is directed to an isolated and purified nucleic acid molecule or nucleic acid molecule analog comprising a sequence that encodes a polypeptide having poly(ADP-ribose) glycohydrolase (PARG) activity. The nucleic acid molecule may encode the complete full-length PARG gene or a fragment of the PARG gene. The nucleic acid molecule may be DNA, RNA or peptide nucleic acid (PNA). The nucleic acid molecule can be linear, such as, for example, an isolated fragment or a linear phage DNA. In addition, the isolated nucleic acid molecule may be circular, such as for example in a plasmid. The nucleic acid molecule may also be a single stranded DNA or RNA such as the single stranded DNA or RNA in a single stranded DNA virus or single stranded RNA virus. The nucleic acid molecule may be of yeast, insect or mammalian origin.

The nucleic acid molecule of the invention, may be of mammalian origin, such as, for example of bovine or murine origin. In a preferred embodiment of the invention, the nucleic acid molecule may be of human origin. While the sequence of the nucleic acid molecule is of mammalian origin, the nucleic acid molecule may be replicated in another organism such as an insert in a viral genome, a plasmid in a bacterium or a 2-micron plasmid in a yeast.

Preferably, the nucleic acid molecule has, a high degree of sequence similarity with a sequence shown in SEQ ID NO: 1 (Genbank Accession Number U78975), SEQ ID NO: 3 (Genbank Accession Number AF005043), SEQ ID NO: 5 (Genbank Accession Number AF079557), SEQ ID NO: 7 45 (Genbank Accession Number AF079556) or SEQ ID NO: 9 (Genbank Accession Number CEF20C5). The high degree of sequence similarity may be, for example, about 70%, preferably about 80%, even more preferably about 90% and most preferably substantially identical such as for example about 100% identity.

The nucleic acid molecule that encodes a polypeptide having poly(ADP-ribose) glycohydrolase (PARG) activity may be single or double stranded nucleic acid molecule of any length such as, for example, about 20 bases in length, about 30 bases in length, about 40 bases in length, about 50 bases in length, about 100 bases in length, about 200 bases in length, about 500 bases in length, about 1000 bases in length, about 1500 bases in length, about 2000 bases in length, about 3000 bases in length. It is understood that "bases" in this patent application means "basepairs" when referring to double stranded nucleic acid molecules and bases when referring to single stranded nucleic acid molecules. In a preferred embodiment of the invention, the nucleic acid molecule may be at least about 1000 base or basepairs long and have at least about 80% sequence similarity with a sequence shown in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9.

In one embodiment of the invention, the nucleic acid molecule may have sequence similarity to one region of the PARG sequence. The region may be, for example, from about base residue 2113 to about residue 3105 of SEQ ID NO: 3. Alternatively, the region may be, from residue 1240 to about residue 3105 of SEQ ID NO: 3 or from residue 175 to about residue 3105 of SEQ ID NO: 3.

Another embodiment of the invention is directed to the expression and overexpression of PARG in a cell. Expression vectors may mediate the expression of a polypeptide 10 with poly (ADP-ribose) glycohydrolase (PARG) enzyme activity. Expression systems and expression vectors are known in the art. For example, one expression vector may comprise a regulatory sequence which is operatively linked to a nucleotide sequence at least about 1000 base pairs in 15 length, which has at least 70% sequence similarity with a sequence shown in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9. In a preferred embodiment, the sequence similarity is at least about 80% identity, more preferably at least about 90% identity and  $_{20}$ most preferably about 100% identity. The expression vector may be any expression vector that is capable of directing expression of a gene in a host cell including, prokaryotic, eukaryotic, mammalian and viral vector. Examples of such vectors include pCMV-Script cytomeglovirus expression 25 vectors for expression in mammalian cells, pESP and pESC vectors for expression in S. pombe and S. cerevesiae, pET vectors for expression in bacteria, pSPUTK vectors for high-level transient expression, and pPbac and pMbac vectors for expression in fall army worm (SF9) cells. Such 30 vectors are available commercially from suppliers such as, for example, Invitrogen (Carlsbad, Calif.) or Stratagene (La Jolla, Calif.). In the use of viral vectors, it is understood that defective viral vectors-vectors that are genetically engineered to deliver a gene or gene product to a host but which 35 cannot replicate in a host is preferred. Procedures for the practice of in vitro and in vivo expression are well known to those of skill in the art and are further available with the specific expression products and cell lines from commercial suppliers.

Another embodiment of the invention is directed to a host cell transformed with a vector containing a nucleic acid molecule with a sequence that encodes a polypeptide having poly(ADP-ribose) glycohydrolase (PARG) activity. The host cell may be any eukaryotic or prokaryotic cell such as, for 45 example a human, murine, rattus, bovine, insect, yeast or bacteria. Specific cell lines are well known to those of skill in the art and are available from suppliers such as the American Tissue Type Collection (ATCC, Manassas, Va.) and Stratagene (La Jolla, Calif.) and the like. A preferred 50 embodiment of the invention is directed to cells transformed with the PARG expression vector which shows an elevated level of PARG relative to non-transformed cells. Especially preferred are cells transformed with an inducible PARG expression vector that have normal or slightly elevated 55 lar weight less than about 40 kDa and has at least about 90% PARG levels before induction and have significantly elevated PARG levels after induction.

An embodiment of the invention is directed to an isolated protein having poly(ADP-ribose) glycohydrolase (PARG) activity. The protein may comprise an amino acid sequence 60 with at least 70% sequence similarity with a sequence shown in SEQ ID NO: 2 (Genbank Accession Number U78975), SEQ ID NO: 4 (Genbank Accession Number AF005043), SEQ ID NO: 6 (Genbank Accession Number AF079557), SEQ ID NO: 8 (Genbank Accession Number AF079556), or 65 SEQ ID NO: 10 (Genbank Accession Number CEF20C5). The sequence similarity is preferably at least about 80%,

more preferably at least about 90% and most preferably substantially identical with a sequence shown in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or SEO ID NO: 10. In a preferred embodiment of the invention, the preferred isolated protein having poly(ADP-ribose) glycohydrolase (PARG) activity and has a molecular weight greater than about 100 kDa.

Another embodiment of the invention is directed to an oligonucleotide which is greater than about 10 bases in length and less than about 1000 bases in length which is complementary to a sequence shown SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or SEQ ID NO: 9. The oligonucleotide may be, for example, greater than about 20 bases in length, greater than about 30 bases in length, greater than about 40 bases in length, greater than about 50 bases in length, greater than about 100 bases in length, greater than about 200 bases in length or greater than about 300 bases in length. The oligonucleotide, which may be optionally labeled with a detectable marker, may be DNA, RNA or PNA. A detectable marker may be, for example, a radioactive isotope such as <sup>32</sup>p or <sup>125</sup>I, an epitope such as FLAG.

One preferred oligonucleotide is an antisense oligonucleotide directed to the mRNA of PARG. Antisense oligonucleotide as a method of suppression is well known to those in the art. For example, the phosphorothioate oligonucleotide, ISIS 2922, has been shown to be effective against cytomeglovirus retinitis in AIDS patients (9). It is thus well known that oligonucleotides, when administered to animals and humans, can have a useful therapeutic effect. In a preferred embodiment, the oligonucleotide is at least about 10 nucleotides in length, such as, greater than about 20 bases in length, greater than about 30 bases in length, greater than about 40 bases in length, greater than about 50 bases in length, greater than about 100 bases in length, greater than about 200 bases in length or greater than about 300 bases in length. In another preferred embodiment, the oligonucleotide has a ribozyme activity.

Another embodiment of the invention is directed to an isolated polypeptide of at least 6 amino acid residues in length and having a molecular weight less than about 65 kDa, which has at least about 80% sequence similarity with a sequence shown in any one of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10. The polypeptide may be, for example, at least about 10 amino acids in length, at least about 20 amino acids in length, at least about 30 amino acids in length, at least about 40 amino acids in length, at least about 50 amino acids in length, at least about 75 amino acids in length, at least about 100 amino acids in length, at least about 150 amino acids in length, at least about 250 amino acids in length or at least about 500 amino acids in length or more.

In a preferred embodiment, the polypeptide has a molecusequence similarity with a sequence shown in any one of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10. The polypeptide preferably has poly(ADP-ribose) glycohydrolase (PARG) activity or is immunogenic and elicits antibodies immunoreactive with a poly(ADP-ribose) glycohydrolase (PARG) enzyme. In a more preferred embodiment, the polypeptide comprises an amino acid sequence substantially identical with SEQ ID NO: 4 from about residue 647 to about residue 977.

Another embodiment of the invention is directed to an isolated polypeptide of at least 10 amino acid residues in length and which has at least about 80% sequence similarity with a sequence shown in any one of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10. Preferably, the polypeptide is at least about 20 amino acids in length, such as, for example at least about 30 amino acids, about 40 amino acids, about 50 amino acids, about 100 amino acids, about 200 amino acids and about 500 amino acids in length.

Another embodiment of the invention is directed to an antibody immunoreactive with an isolated polypeptide of at least about 6 amino acid residues in length and having a 10 molecular weight less than about 65 kDa, which has at least about 80% sequence similarity with a sequence shown in any one of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10. In a preferred embodiment, antibody is immunoreactive with a polypep-15 tide with a molecular weight less than about 40 kDa and has at least about 90% sequence similarity with a sequence shown in any one of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID No: 8 or SEQ ID NO: 10. In another preferred embodiment, the antibody is immunoreactive with  $_{20}$ a polypeptide comprising an amino acid sequence substantially identical with SEQ ID NO: 4 from about residue 647 to about residue 977.

Another embodiment of the invention is directed to a method of detecting a polypeptide having PARG activity 25 comprising the steps of contacting the polypeptide with an antibody immunoreactive with an isolated polypeptide of at least about 6 amino acid residues in length and having a molecular weight less than about 65 kDa, which has at least about 80% sequence similarity with a sequence shown in  $_{30}$ any one of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10, and determining whether the antibody immunoreacts with the polypeptide.

Another embodiment of the invention is directed to a method of preventing, treating, or ameliorating a disease 35 condition or disorder in an individual comprising the step of administering a therapeutically effective amount of a poly (ADP-ribose) glycohydrolase (PARG) inhibitor or activator to the individual. The disease condition or disorder may be any condition associated with responses to DNA damage, 40 examples of which include a neoplastic disorder, a myocardial infarction, a vascular stroke or a neurodegenerative disorder. The PARG inhibitor or activator may be a small molecule inhibitor or activator of PARG or may be an antisense oligonucleotide that can hybridize in vivo to 45 method of gene therapy comprising the step of delivering an messenger RNA encoded by a PARG gene. PARG based treatment may be directed to new methods for preventing, treating or ameliorating disorders associated with DNA damage. These disorders include neoplastic disorders, inborn genetic errors, myocardial infarctions, vascular 50 strokes, aging, and neurodegenerative disorders such as Alzheimer's disease, Huntington's disease, Parkinson's disease, and neurotoxicity generally.

Another embodiment of the invention is directed to the identification of novel PARG modulators which can activate 55 or inhibit DNA repair and/or apoptosis. A PARG modulator is a compound that can activate or inhibit PARG. These modulators are preferably more efficacious and do not have the known side effects of present modulators. One method of identifying an agent that inhibits or activates poly(ADP-60 ribose) glycohydrolase (PARG) activity comprise the steps of providing a liquid medium that contains a polypeptide having PARG activity contacting the polypeptide with a candidate agent, in the presence of a reference compound having affinity for the polypeptide, under predetermined 65 assay conditions, and determining the affinity of the candidate agent for the polypeptide relative to the reference

compound. Thus, the modulation activity of the candidate agent relative to the reference compound is determined. In this method, the polypeptide may be immobilized on a solid support. Further, the polypeptide may be generated in vitro by culturing a cell transformed with a nucleic acid molecule encoding PARG under conditions effective to express the polypeptide.

Another embodiment of the invention is directed to a method of identifying a mutant PARG allele in an individual comprising the step of obtaining genomic material from the individual; digesting the genomic material with a restriction enzyme having a recognition site inclusive of the mutant allele; fractionating the restriction fragments obtained from the digestion; and comparing the fractionation pattern with that obtained for a normal allele, thereby determining the presence or absence of the mutant allele. The fractionating step may be performed with electrophoresis.

Another embodiment of the invention is directed to a method of identifying a mutant PARG allele in an individual comprising the steps of hybridizing an oligonucleotide with genomic material from the individual, which oligonucleotide hybridizes under predetermined hybridization conditions to a region immediately 5' of a predetermining mutation site in the PARG alleles with the 3' terminus of the oligonucleotide complementary to an unmutated PARG allele; extending the oligonucleotide using PCR amplification; and determining the degree to which extension occurs, thereby determining the presence or absence of the mutant allele. The PCR extension reaction may be performed at a temperature above about 50° C. The determination may be performed by conducting electrophoresis (using for example, acrylamide at about 4% to about 10% or agarose and low melting temperature agarose from about 0.8% to about 4%) on the products of PCR amplification.

Another embodiment of the invention is directed to a method of screening molecules for PARG modulating activity (inhibition or activation) comprising the steps of providing a purified PARG enzyme; assaying the enzyme in the presence of a molecule to be screened; and comparing the activity of the PARG enzyme in the presence of the molecule to the activity of the PARG enzyme in the absence of the molecule.

Another embodiment of the invention is directed to a oligonucleotide having a sequence complementary to at least a portion of a polynucleotide encoding a PARG enzyme to a cell to be treated. In the method, the oligonucleotide may have a sequence complementary to a sequence encoding a C-terminal portion of a PARG enzyme. Further, in the gene therapy method, the oligonucleotide may further comprise a ribozyme.

Another embodiment of the invention is directed to a method of delivering to a cell surface, an oligonucleotide having a sequence complementary to at least a portion of a polynucleotide encoding a PARG enzyme to a cell to be treated. In the method, the oligonucleotide may have a sequence complementary to a sequence encoding a C-terminal portion of a PARG enzyme. Further, in the method, the oligonucleotide may further comprise a ribozyme. The portion of a polynucleotide encoding a PARG enzyme may be, for example, the polynucleotide encoding the N terminus third of PARG, the middle third of PARG, or the C terminus third of PARG. The portion of a polynucleotide may encode a smaller part of PARG such as the N terminus 10% of PARG, the C terminus 10% of PARG, or any 10% portion in between such as from 10% to 20%, from

20% to 30%, from 30% to 40%, from 40% to 50%, from 50% to 60%, from 60% to 70%, from 70% to 80%, from 80% to 90%. The percent value used means a percent of the linear amino acid sequence. Thus, for a 1000 amino acid protein, the N terminus 10 percent is from amino acid 1 to 100; 10% to 20% percent would be from amino acid 100 to 200 and so on. For a 970 amino acid protein, the N terminal 10% would be from amino acid 1 to 97; 10% to 20% would be from amino acids 98 to 194 amino acids.

Another embodiment of the invention is directed to a 10 probed with PARG cDNA. method of sensitizing a cell to a chemotherapeutic agent comprising the step of contacting the cell with a molecule that modulates the activity of a PARG enzyme. The molecule may be an oligonucleotide having a sequence complementary to at least a portion of a polynucleotide encoding a PARG enzyme. For example, the oligonucleotide may have a sequence complementary to a sequence encoding a C-terminal portion of a PARG enzyme. The portion of a polynucleotide encoding a PARG enzyme may be, for example, the polynucleotide encoding the N terminus third  $_{20}$ of PARG, the middle third of PARG, or the C terminus third of PARG. The portion of a polynucleotide may encode a smaller part of PARG such as the N terminus 10% of PARG, the C terminus 10% of PARG, or any 10% portion in between such as from 10% to 20%, from 20% to 30%, from  $_{25}$ 30% to 40%, from 40% to 50%, from 50% to 60%, from 60% to 70%, from 70% to 80%, from 80% to 90%. The oligonucleotide may further comprise a ribozyme. The method may be used, for example, as a method of treating a diseased cell characterized by the presence of DNA strand breaks. In the treatment, the cell is contacted with a molecule that modulates an enzymatic activity of a PARG enzyme.

Another embodiment of the invention is directed to a pharmaceutical composition comprising an oligonucleotide having a sequence complementary to at least a portion of a 35 polynucleotide encoding a PARG enzyme. The produced molecule may be an oligonucleotide having a sequence complementary to at least a portion of a polynucleotide encoding a PARG enzyme. For example, the oligonucleotide may have a sequence complementary to a sequence encod- $_{40}$ ing a C-terminal portion of a PARG enzyme. The oligonucleotide may comprise a ribozyme activity.

Another embodiment of the invention is directed to a virus that causes the production of an oligonucleotide having a sequence complementary to a polynucleotide encoding a 45 PARG enzyme. This may be, for example, a viral vector which after the infection of a host cell, causes the production of an antisense RNA of PARG. The molecule may be an oligonucleotide having a sequence complementary to at least a portion of a polynucleotide encoding a PARG enzyme. For  $\ 50$ example, the oligonucleotide may have a sequence complementary to a sequence encoding a C-terminal portion of a PARG enzyme. The oligonucleotide may further comprise a ribozyme activity.

Other embodiments and advantages of the invention are 55 set forth, in part, in the description that follows and, in part, will be obvious from this description and may be learned from the practice of the invention.

### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts the cellular biochemical process that occurs after DNA damage.

FIG. 2 depicts the SDS-PAGE analysis of purified bovine thymus PARG.

FIG. 3 depicts the alignment of the DNA sequences of two 65 PCR products and eight \lambda gt11 cDNA clones used to identify the cDNA coding for bovine PARG.

FIG. 4 depicts a northern blot analysis of bovine kidney cells mRNA transcripts.

FIG. 5 depicts an alignment of the putative bipartite NLS of bovine, human, and murine PARG and comparison with the bipartite NLS of PARP from different organisms.

FIG. 6 depicts expression of bPARG enzyme activity in E. coli (10).

FIG. 7 depicts a Southern blot analysis of bovine DNA

FIG. 8 depicts activity gel autoradiogram of E. coli expressed bovine PARG.

FIG. 9 depicts the analysis by anion exchange HPLC of material released from ADP-ribose polymers by PARG 15 action.

FIG. 10 depicts the SDS-PAGE analysis of the purification of *E. coli* expressed GST-PARG.

FIG. 11 depicts a schematic representation of the portions of the bovine PARG cDNA expressed as GST fusion constructs.

FIG. 12 depicts the cloning of the 1.8 kb PCR EcoRI fragment encoding for the 65 kDa catalytic domain of PARG.

FIG. 13 depicts an autoradiogram of an activity gel of GST-PARG fusion constructs expressed in E. coli and PARG expressed in baculovirus.

FIG. 14 depicts a schematic representation of the strategy used to isolate cDNA molecules encoding PARG from various organisms.

FIG. 15 depicts the domain organization of PARGs from different organisms.

FIG. 16 depicts an amino acid sequence alignment of bovine, murine, human, drosophila and C. elegans PARG enzymes.

FIG. 17 depicts a western blot of recombinant PARGs.

FIG. 18 depicts western blots of natural and recombinant expressed PARG.

FIG. 19 depicts the characterization of PARG by Western Blot in mouse cells of different PARP genotypes.

FIG. 20 depicts a partial restriction map of the mouse PARG locus.

FIG. 21 depicts a schematic representation of the strategy used to create PARG knockout mice.

#### DETAILED DESCRIPTION OF THE INVENTION

#### DEFINITIONS

#### List of Abbreviations

adenosine diphosphate

ADP
ADPR
AMP
ASPCR
op
PARG
CePARG
dPARG
DTT
GSH-Sepharose
GST
hPARG
HPLC

60

ADP-ribose adenosine monophosphate allele-specific PCR base pair(s) bovine PARG C. elegans PARG Drosophila melanogaster PARG dithiothreitol Glutathione-Sepharose 4B glutathione-S transferase human PARG high pressure liquid chromatography

35

60

	4	1
-con	Inn	nec

ICE	interleukin-1 b converting enzyme
IPTG	isopropyl-β-D-thiogalactoside
kb	kilobase pair(s)
MDBK	Madin-Darby bovine kidney cells
mPARG	murine PARG
NAD	nicotinamide adenine dinucloetide
NLS	nuclear location signal
PADPR DHB-Sepharose	poly(ADP-ribose)-dihydroxyboronyl-Sepharose
PAGE	polyacrylamide-gel electrophoresis
PARG	poly(ADP-ribose) glycohydrolase
PARP	poly(ADP-ribose) polymerase [EC 2.4.2.30]
PCR	polymerase chain reaction
PEG-6,000	polyethylene glycol 6,000
PEG	polyethylene glycol
PMSF	phenylmethylsulfonyl fluoride
PR-AMP	phosphoribosyl-adenosine monophosphate
RFLP	restriction fragment length polymorphism
SDS	sodium dodecyl sulfate
SSCP	single-strand conformation polymorphism
TPCK	Trypsin: L-1-tosylamido-2-phenylethyl
	chloromethyl ketone.

An "agonist" as defined herein refers to a molecule which, when bound to PARG, increases or prolongs the effect of PARG. Agonist may include proteins, nucleic acid molecules, carbohydrates, or any other molecules that bind <sup>25</sup> to and modulate the effect of PARG.

An "allele" or "allelic sequence", as defined herein refers to an alternative form of PARG. Alleles may result from at least one mutation in the nucleic acid molecule sequence and may result in altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give rise to alleles, are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

An "ortholog" as defined herein refers to a nucleotide or amino acid sequence that is related to a reference nucleotide or amino acid sequence through speciation, and is therefore identical or structurally similar to the reference sequence.

A given nucleotide or amino acid sequence is said to be "substantially identical" with another sequence when the compared sequences have the same residues in the same order, excepting for any degeneracy (nucleotides) and conservative substitutions (amino acids).

A"regulatory sequence" of an expression vector is a DNA sequence necessary for inducing transcription of a gene, and includes a functional promoter and/or enhancer sequence. 50 The term "operatively linked" as used herein means that a first nucleotide sequence, such as a regulatory element, is fused in frame with a second nucleotide sequence so as to afford a faithful transcription of the entire nucleotide sequence, which upon translation yields the desired protein. 55 described in Altschul (13).

The term "immunoreactivity" and related terms refers to the ability of antibodies and fragments thereof to bind to particular regions (antigens) presented by polypeptides and proteins, presented to the antibodies either as immunogens or targets. Typically, the binding affinity of the antibodies for their antigen is in the range  $10^5$  to  $10^{11}$ , with higher affinities being preferred.

The term "specific immunoreactivity" refers to the ability of antibodies and fragments thereof to bind to particular regions (antigens) presented by polypeptides and proteins, 65 sequences. presented to the antibodies either as immunogens or targets and not to unrelated antigens. For example, an antibody with

specific immunoreactivity to actin will bind actin but would not bind another protein, such as a polymerase, which do not share epitopes with actin.

The term "nucleic acid molecule" refers to DNA, RNA and nucleic acid molecule analogs such as PNA and the like. PNA or "Peptide Nucleic Acid" is a nucleic acid molecule analog that has a neutral "peptide-like" backbone with nucleobases that allow the molecule to hybridize to complementary RNA or DNA with higher affinity and specificity than corresponding oligonucleotides. PNA can be made to 10 be more resistant to normal nucleases and are especially desirable, for example, in gene therapy. PNA is known to one of skill in the art and can be purchased or custom synthesized in numerous commercial laboratories including PerSeptive Biosystems, Inc. (Framingham, Ma.). 15

The term "modulate" means to activate or inhibit. For example, a PARG modulator may activate or inhibit PARG activity. "Modulation activity" means the amount of activation or inhibition. For example, a compound that increase <sup>20</sup> PARG (or any other enzyme) activity by 10% will have a modulation activity of 10%. Conversely, a compound that decreases PARG activity by 10% will have a modulation activity of -10%.

As used herein, a given nucleotide or amino acid sequence is said to have a defined percentage of sequence similarity with another sequence when the two sequences differ by no more than the specified sequence similarity, including conservative substitutions, insertions, and deletions. Degenerate codons do not result in a change in amino acid upon translation, therefore, it is appreciated that identical amino acids can be encoded by several equivalent codons. The term "homology" and "sequence similarity" should have the same meaning for the purpose of this patent. Similarity parameters may be any generally acceptable parameter. For the purposes of this patent, percent similarity between two polymers such as nucleic acid molecules and polypeptides is preferably defined by Karlin and Altschul (11). The similarity algorithms of Karlin and Altschul are well known to those of skill in the art as exemplified by their adoption by the 40 National Center for Biological Information. For nucleic acid molecule sequence searching, one desirable set of parameters would M (score for a pair of matching residues) at 5; N (score for mismatching residues) at -4; W (word length) at 11. For proteins, it is well known that some amino acids 45 are similar and that substitution would be conservative. That is, for example, the replacement of an acidic amino acid with another acidic acid would be consider a conservative mismatch while the replacement of an acidic amino acid with a basic amino acid would be consider a more divergent mismatch. Preferably, the parameters for a desirable protein similarity determination are expressed in the sequence similarity matrix BLOSUM62 as described in Henikoff & Henikoff (12). Other similarity matrixes that are also preferred in the invention are PAM40, PAM120 and PAM250 as

The rapid synthesis of ADP-ribose polymers that occurs in response to DNA strand breaks is accompanied by very rapid polymer turnover, indicating that PARP and PARG activities are closely coordinated as cells respond to DNA damage. While PARP has been widely studied, information concerning structure and function relationships of PARG is much more limited. The present invention discloses the isolation of a cDNA encoding the bovine, human, murine and drosophila PARG and their deduced amino acid

The availability of PARP cDNA has allowed a number of molecular genetic approaches to study the function(s) of

25

30

35

ADP-ribose polymer metabolism and the availability of PARG cDNA should allow the design of additional molecular genetic approaches for studying this metabolism. For example, disruption of the gene encoding PARG in mice containing a normal PARP gene will allow the determination of whether other cellular enzymes can replace PARG in the turnover of ADP-ribose polymers and/or whether development of animals will occur in the absence of PARG. Alternatively, disruption of the PARG gene in mice containing a disrupted PARP gene may provide insights for the 10 coordinated function of PARP and PARG.

One embodiment of the invention is directed to a deoxyribonucleic acid (DNA) molecule that encodes a polypeptide having poly(ADP-ribose) glycohydrolase (PARG) activity. Preferably, the molecule is of mammalian origin, <sup>15</sup> such as, for example, of human origin.

In a preferred embodiment, a DNA molecule of the invention comprises a nucleotide sequence with at least about 70% sequence similarity with a sequence shown in a sequence shown in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 9. Higher degrees of sequence similarity, such as about 80%, about 90%, and about 100% are preferred. Most preferred is a DNA molecule comprising a nucleotide sequence substantially identical with any one of sequence shown in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 9. It is preferred that a DNA molecule of the present invention comprises at least about 1000 nucleotides and has a nucleotide sequence with at least 80% sequence similarity with a sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 9. Most preferably, the DNA molecule consist of a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 9.

For a DNA molecule of the present invention based on a human PARG gene it is preferred that the molecule comprises a nucleotide sequence that shows similarity to the sequence shown in SEQ ID NO: 3 from about residue 2113 to about residue 3105. More preferably, the sequence similarity is from about residue 1240 to about residue 3105. Still more preferably, the DNA molecule comprises a nucleotide sequence similarity to the coding sequence for the fulllength hPARG as shown in SEQ ID NO: 3 from about residue 175 to about residue 3105.

A DNA molecule of the present invention affords probes and primer molecules that can be used in hybridization assays and PCR amplification. An exemplary oligonucleotide is less than about 1000 residues in length and comprises a nucleotide sequence at least about 10 residues long 50 to ensure hybridization. Preferably, the at least about 10 residue region of the oligonucleotide is complementary to a sequence shown in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 9. Typically, the oligonucleotide will be a DNA molecule, which can be 55 labeled by any method as desired, for example, with a radiolabel, a fluorescence label, or chemi-luminescent label.

Another embodiment of the invention is directed to a nucleic acid molecule that hybridizes to in a nucleic acid blot (Southern blot, Northern blot) to a sequence of SEQ ID NO: 60 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or SEQ ID NO: 9 under stringent hybridization conditions. A nucleic acid blot may be made using techniques defined in Molecular Cloning, Second Edition, Sambrook et al., Cold Spring Harbor Press, Cold Spring Harbor, N.Y. DNA to be analyzed 65 may be separated in agarose or acrylamide gels. The DNA may be transferred to nylon or nitrocellulose membrane

using techniques known to those in the art. Stringent hybridization condition may be for example, prehybridizations 42° C. in 50% formamide, 0.25 M sodium phosphate buffer, pH 7.2, 0.25 M NaCl, 7% SDS, 1 mM EDTA for 10 hours, 100 ug denatured salmon sperm DNA, hybridization at 42° C. in 50% formamide, 0.25 M sodium phosphate buffer, 100 ug denatured salmon sperm DNA. pH 7.2, 0.25 M NaCl, 7% SDS, 1 mM EDTA, 1 ng/ml probe with a specific activity of  $10^9$  cpm/ug DNA, for 16 hours. The probe may comprise any contiguous sequence from SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or SEQ ID NO: 9. Preferably, said contiguous sequence is at least about 50 bases long, more preferably, the contiguous sequence is at least about 75 bases long, such as at least about 100 bases, at least about 200 bases long or at least about 300 bases long. The complete sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or SEQ ID NO: 9. Methods of labeling probes to with radioactive labels are known to those of skill in the art.

Method of washing after stringent hybridization are known. A stringent washing may comprise, for example, two washes at in 2× SSC, 0.1% SDS for 15 minutes each at room temperature; two washes in 0.2×SSC, 0.1% SDS for 15 minutes each at room temperature; and a final three washes in 0.2×SSC, 0.1% SDS for 15 minutes each at 60° C. The final wash may be increased in temperature for reduced background. For example, the final wash may be a final three washes in 0.2×SSC, 0.1% SDS for 15 minutes each at 65° C. or a final three washes in 0.2×SSC, 0.1% SDS for 15 minutes each at 68° C.

If a radioactive probe is used, hybridization may be monitored using known techniques such as autoradiogram or a two dimensional measurement of radioactivity.

An anti-sense oligonucleotide is also afforded by the present invention. The anti-sense molecule is typically less than about 1000 residues in length to ensure ease of synthesis, and hybridizes to an RNA molecule, e.g., messenger RNA, which has at least 70% sequence similarity with a sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID 40 NO: 5, SEQ ID NO: 7, SEQ ID NO: 9. Preferably, the anti-sense molecule is at least about 10 nucleotides in length to ensure hybridization with mRNA. Even more preferably, the anti-sense molecule may be at least about 15 nucleotides in length such as, for example, at least about 20 nucleotides 45 in length; at least about 30 nucleotides in length; at least about 50 nucleotides in length; at least about 75 nucleotides in length; at least about 100 nucleotides in length; at least about 150 nucleotides in length; at least about 200 nucleotides in length; at least about 500 nucleotides in length; at least about 1000 nucleotides in length; or at least about 1500 nucleotides in length. It is also preferred that the molecule has a ribozyme activity so that it can degrade the mRNA that it binds to.

An antisense oligonucleotide may be used therapeutically to inhibit translation of mRNA encoding PARG. Synthetic antisense oligonucleotides may be produced, for example, in a commercially available oligonucleotide synthesizer. This invention provides a means to therapeutically alter levels of expression of a human or other mammalian PARG by the use of a synthetic antisense oligonucleotide drug that inhibits translation of mRNA encoding PARG. Synthetic antisense oligonucleotides, or other antisense chemical structures designed to recognize and selectively bind to mRNA, are constructed to be complementary to portions of the nucleotide sequence shown in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7 and SEQ ID NO: 9. An antisense oligonucleotide may be designed to be stable in the

15

25

blood stream for administration to patients by injection, or in laboratory cell culture conditions, for administration to cells removed from the patient. The antisense may be designed to be capable of passing through cell membranes in order to enter the cytoplasm and nucleus of the cell by virtue of physical and chemical properties of the antisense oligonucleotide which render it capable of passing through cell membranes (e.g., by designing small, hydrophobic antisense oligonucleotide chemical structures) or by virtue of specific transport systems in the cell which recognize and transport the antisense oligonucleotide into the cell. In addition, the antisense oligonucleotide can be designed for administration only to certain selected cell populations by targeting the antisense oligonucleotide to be recognized by specific cellular uptake mechanisms which bind and take up the antisense oligonucleotide only within certain selected cell populations. For example, the antisense oligonucleotide may be designed to bind to transporter found only in a certain cell type, as discussed above. The antisense oligonucleotide may be designed to inactivate the PARG mRNA by (1) binding 20 to the PARG mRNA and thus inducing degradation of the mRNA by intrinsic cellular mechanisms such as RNase I digestion, (2) by inhibiting translation of the mRNA target by interfering with the binding of translation-regulating factors or of ribosomes, or (3) by inclusion of other chemical structures, such as ribozyme sequences or reactive chemical groups, which either degrade or chemically modify the target mRNA. Synthetic antisense oligonucleotide drugs have been shown to be capable of the properties described above when directed against mRNA targets (14). In addition,  $_{30}$ coupling of ribozymes to antisense oligonucleotides is a promising strategy for inactivating target mRNA(15). In this manner, an antisense oligonucleotide directed to PARG may serve as a therapy to reduce PARG expression in particular target cells of a patient and in any clinical condition that may 35 benefit from reduced expression of PARG.

It is known by those in the art that as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding PARG, some bearing minimal homology to the nucleotide sequences of any known and naturally 40 occurring, gene, may be produced. Thus, the invention contemplates a nucleic acid molecule that encodes a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO:6, SEQ ID NO: 8 and SEQ ID NO: 10. The 45 invention contemplates each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices that would encode the oligopeptides disclosed herein. These combinations are made in accordance with the standard triplet 50 Pichia pastoris, Hansela polymorpha, Kluyveromyces lactis, genetic code as applied to the nucleotide sequence of naturally occurring PARG and all such variants are to be considered as being specifically disclosed.

Although nucleic acid molecules which encode PARG and its variants preferably hybridizes under high stringency 55 localization or for extracellular export. conditions to the nucleotide sequence of the naturally occurring PARG gene under appropriate conditions of stringency, it may be advantageous to produce nucleotide sequences encoding PARG or its derivatives possessing a substantially different codon usage. Codons may be selected to increase 60 the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding PARG and its derivatives and 65 variants without altering the produced amino acid sequence include the production of RNA transcripts having more

desirable properties, such as greater half-life, than transcripts produced from the naturally occurring sequence.

In order to express a biologically active or immunologically active PARG, the nucleic acid molecule encoding PARG or functional equivalents, may be inserted into appropriate expression vector, such as, for example a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Thus, another aspect of the present invention is an expression vector comprising a regulatory sequence operatively linked to nucleic acid molecule comprising a nucleotide sequence disclosed herein. For example, an expression vector can contain a nucleotide sequence at least about 1000 base pairs in length, which has at least about 70%, about 80%, or higher, sequence similarity with a sequence shown in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 9.

Methods that are known to those skilled in the art may be used to construct expression vectors containing sequences encoding PARG and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination.

A variety of expression vector/host systems may be utilized to contain and express sequences encoding PARG. These include, for example, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus), insects infected with virus expression vectors (e.g., fall army worm infected with baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus; TMV) or with bacterial expression vectors (e.g., Ti or bacterial plasmids); or animal cell systems. The invention is not limited by the host cell employed.

Prokaryotic expression systems are commercially available from a number of suppliers worldwide. Prokaryotic expression vectors provide a convenient system to synthesize proteins. If it is desired to express a protein with characteristics such as immunogenic properties, 3D conformation, and other features exhibited by authentic PARG, the protein may be expressed in an eukaryotic protein expression system. The eukaryotic expression systems are numerous and include mammalian, amphibian, plant, insect, and yeast expression systems.

Yeast hosts that can be used for expression include Saccharomyces cerevisiae, Schizosaccharomyces pombe, and Yarrowia lipolytica. Yeast hosts offer the advantages of rapid growth on inexpensive minimal media and ease in large-scale production using bioreactors. Another advantage of yeast is the ability to direct expression to cytoplasmic

Most yeast vectors for protein expression are derivatives of the S. cerevisiae 2  $\mu$  (two micron) plasmid. Yeast vectors include pYES and pEST from Stratagene (La Jolla, Calif.). Constitutive gene expression by the yeast plasmid cassette can be mediated by well known promoters such as the glyceraldehyde-3-phosphate dehydrogenase promoter (TDH3); the triose phosphate isomerase promoter (TPI1); the phosphoglycerate isomerase promoter (PGK1); the alcohol dehydrogenase isozyme II (ADH2) gene promoter; GAL1 and GAL10 promoters; the metallothionein promoter from the CUP1 gene (induced by copper sulfate); and the PHO5 promoter (induced by phosphate limitation). Proper

15

20

25

30

35

40

60

termination of yeast transcripts is known to those in the art. Termination signals may include the MF-alpha-1, TPI1, CYC1, and PGK1 genes. These termination signals may be spliced onto the 3' end of the insert to provide proper termination.

Insect expression systems include baculovirus based vectors designed to express foreign proteins in a number of insect hosts and insect cell line hosts. Insect and insect cell lines may be of Drosophila melanogaster, Aedes albopictus, Spodoptera frugiperda, and Bombyx mori origin. Numerous expression systems comprising cells, vectors, hosts and the like can be purchased from a variety of commercial sources.

The control elements or regulatory sequences necessary for the proper expression of the insert, in this case PARG, may comprises promoters, enhancers (including both proximal and distal control elements) which interact with the host proteins to carry out transcription and translation. Such elements may vary in their strength and specificity and are known to those in the art. Depending on the vectors system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, the LacZ promoter may be used in a bacterial cell; the baculovirus polyhedrin promoter may be used in an insect cell; plant promoters such as heat shock promoters, and storage protein promoters, plant virus promoters and the like may be used in a plant cell. In a mammalian cell expression system, an SV40 promoter or EBV promoter may be used.

Methods and protocols for both prokaryotic and eukaryotic expression systems are generally known to those in the art. Further, the cells, vectors, growth medium may be purchased from commercial suppliers. The catalogs and product literature of commercial suppliers provide detailed protocols to enable the expression of proteins in prokaryotic and eukaryotic systems including bacterial, yeast, insect, insect cell, and mammalian cell systems. The product literature and catalogs of Clontech (Palo Alto, Calif.), Invitrogen (Carlsbad, Calif.), Life Technologies (Rockville, Md.), Novagen (Madison, Wis.), Plarmigen (San Diego, Calif.), Quantum Biotechnologies (Montreal, Quebec, Canada), and Stratagene (La Jolla, Calif.) are incorporated herein by reference.

A further aspect of the invention is isolated proteins and protein fragments having poly(ADP-ribose) glycohydrolase 45 (PARG) activity. Such a protein call comprise an amino acid sequence with sequence similarity of at least about 70%, about 80% or higher to a sequence shown SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 and SEQ ID NO: 10. For example, the full-length bovine PARG has a 50 molecular weight greater than about 100 kDa, thereby distinguishing it from previously known PARGs. The protein may be purified, for example, from cell lysates using the antibodies of the invention. The purification maybe through an antibody column.

PARG polypeptides are another aspect of the invention. Polypeptides of PARG may be used, for example, to generate antibodies in an immunogenic procedure. To be effective it is preferred that the polypeptides are at least about 6 amino acid residues in length, such as for example, at least about 10 amino acids in length, at least about 20 amino acids in length, at least about 30 amino acids in length, at least about 50 amino acids in length, at least about 75 amino acids in length, at least about 100 amino acids in length, at least about 150 amino acids in length, at least about 200 amino 65 PARG amino acids may be fused with those of another acids in length, or at least about 400 amino acids in length. In one embodiment, the polypeptide has a molecular weight

less than about 65 kDa and with at least about 80% sequence similarity with a sequence shown in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, and SEQ ID NO: 10. The polypeptide may consist of the sequence set forth in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 10.

The polypeptide of the invention may be conjugated to a larger molecule, such as, for example, keyhole lymphet hemocyanin (KLH), to increase the immunogenicity of the polypeptide. The increased immunogenicity of the polypeptide will, in turn, increase the yield of antibody. Preferably, the polypeptide has a molecular weight less than about 40 kDa and with at least about 90% sequence similarity with a sequence shown in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, and SEQ ID NO: 10. The polypeptide can also be used in a wide variety of assays, e.g., as a competitor of antigen in a liquid sample in an antibodybased assay. Therefore, it is preferred that the polypeptide has poly(ADP-ribose) glycohydrolase (PARG) activity. A particularly preferred polypeptide is of human origin and comprises an amino acid sequence substantially identical with SEQ ID NO: 4 from about residue 647 to about residue 977—the C terminus catalytic region of the enzyme. Longer sequences more inclusive of the natural molecule are of course also contemplated.

The invention also encompasses PARG variants and alleles. A preferred PARG variant is one having at least 80% and more preferably at least 90% amino acid similarity to the amino acid of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 and SEQ ID NO: 10 and which retains at least one biological, immunological or other functional characteristic or activity of PARG. A most preferred PARG variant is one having at least 95%, amino sequence similarity or identity to human PARG (SEQ ID NO: 3).

Antibodies to PARG may be generated using numerous established methods that are well known in the art. One example of such a method is described in the Examples. Generated antibodies may include, for example, polyclonal, monoclonal, chimeric, single chain, Fab fragments, Fab' fragments, Fab'(2) fragments, and fragments produced by a FAB expression library. Humanized antibodies and single chain antibodies may also be produced after the amino acid sequence of effective antibodies are determined.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others, may be immunized by injection with PARG or any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants maybe used to increase immunological response. Such adjuvants include, for example, Freund's mineral gels such as aluminum hydroxide, and surface-active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. 55 Among adjuvant used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to PARG have an amino acid sequence consisting of at least five amino acids and more preferably at least about 10 amino acids, such as for example about 20 amino acids or about 40 amino acids. It is also preferable that they are identical to a portion of the amino acid sequence of the natural PARG. Short stretches of protein such as keyhole limpet hemocyanin and antibodies may be produced against the chimeric molecule.

25

30

35

Antibodies may be produced by inducing in vivo production in the lymphocyte population of a living animal or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in published procedures (16).

Antibody fragments that contain specific binding sites for PARG may be generated. For example, such fragments include the F(ab')<sub>2</sub> fragment, Fab fragment, Fab' fragment which can be produced by enzymatic digestion of the antibody molecule. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse, W. D. (1989) Science 254, 1275-1281).

#### Therapeutic Methods

A method of preventing, treating, or ameliorating a disease condition in a patient, which disease state is affected by the level of PARG expression is also contemplated. This method entails administering a therapeutically effective amount of a poly(ADP-ribose) glycohydrolase (PARG) inhibitor or activator to the individual. Particularly, implicated disease states are neoplastic disorder, myocardial infarction, vascular stroke and neurodegenerative disorders.

In one embodiment, antisense oligonucleotides for PARG may be used alone or in combination with other chemotherapeutic agents to treat neoplastic disorder. The antisense oligo is designed to hybridize in vivo to messenger RNA expressed by the organism. The use of anti-sense molecules in a therapeutic setting is described, for example, by S. Agrawal, Antisense Therapeutics, Humana Press. Currently favored protocols call for the oligo to have ribozyme activity in an effort to degrade the mRNA. These methods are described, for example, in Therapeutic Application of Ribozymes, K. Scanlon, ed., Humana Press. Therefore, in one embodiment, an antagonist of PARG may be administered to a subject to prevent or treat neoplastic disorder.

PARG levels may be enhanced to suppress DNA repair and increase a cell's susceptibility to chemotherapy drugs. 40 Therefore, in another embodiment, an PARG enhancer is administered to a subject along with a chemotherapeutic drug as a treatment for neoplastic disorder.

Neoplastic disorders that can be treated by PARG elevation and chemotherapy include benign and malignant neo- 45 plasm such as, for example, adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, hyperplasia and hypertrophy. Neoplastic disorders may include, in particular, neoplastic disorders of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall 50 bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus. For the purposes of this invention, a neoplastic disorder is any new and abnormal growth; specifically a new 55 growth of tissue in which the growth is uncontrolled and progressive. Malignant cancer is a subset of neoplastic disorders which show a greater degree of anaplasia and have the properties of invasion and metastasis.

The synthesis of effective anti-sense inhibitors is known. 60 Numerous approaches have been previously described and generally involve altering the backbone of the polynucleotide to increase its stability in-vivo. Exemplary oligonucleotides and methods of synthesis are described in U.S. Pat. Nos. 5,661,134; 5,635,488; and 5,599,797 65 (phosphorothioate linkages), U.S. Pat. Nos. 5,587,469 and 5,459,255 (N-2 substituted purines), U.S. Pat. No. 5,539,083

(peptide nucleic acids) and U.S. Pat. Nos. 5,629,152; 5,623, 070; and 5,610,289 (miscellaneous approaches). The disclosures of each of these references are incorporated herein by reference.

Significantly, the present invention discloses a method of identifying an agent that inhibits or activates poly(ADPribose) glycohydrolase (PARG) activity. Such method comprises (i) providing a liquid medium that contains a polypeptide of the present invention; (ii) contacting the polypeptide 10with a candidate agent, in the presence of a reference compound having affinity for the polypeptide, under predetermined assay conditions; and (iii) determining the affinity of the candidate agent for the polypeptide relative to the reference compound, thereby determining the inhibition or <sup>15</sup> activation activity of the candidate agent relative to the reference compound. These determinations can be facilitated by immobilizing the polypeptide on a solid support. Alternatively, the polypeptide can be generated in vitro by culturing a cell transformed with a PARG gene under conditions effective to express the polypeptide.

Combination therapies are also afforded by the present invention in which a PARG inhibitor or activator is administered in combination with a chemotherapeutic or a "clotbusting" drug. The clot-busting drug may be, for example, tissue plasminogen activator (t-PA) or streptokinase.

In some cases it may be desired to overexpress PARG in the cells of an organism in order to achieve the correct PARP/PARG balance. In this context of gene therapy, it is desired to stably transfect target cells with a vector, such as, for example, a viral or a DNA (nucleic acid) vector, so that the desired gene is overexpressed. Gene therapy vector systems and protocols are well known and are described, for example, in the Internet Book of Gene Therapy (17) Antisense and ribozyme approaches to cancer gene therapy are described in chapters 7-9 of the Internet Book of Gene Therapy, and are incorporated herein by reference. Another reference is Gene Therapy Protocols, P. Robbins, ed., Humana Press. Furthermore, gene therapy methods have advanced greatly and are well documented in numerous issued US patents. Gene therapy may be practiced, for example, by substituting a nucleic acid molecule of the invention with the nucleic acid molecule described in the methods referred to in any issued US patents directed to Gene therapy (18).

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

#### **Diagnostic Methods**

Methods of genotyping an individual for a mutant PARG allele are also afforded by the present invention. A number of protocols are available for identifying a mutant allele as described herein once the nucleotide sequence encoding PARG is known. Some exemplary methods are restriction fragment length polymorphism (RFLP), allele-specific PCR (ASPCR) and single-strand conformation polymorphism (SSCP). Armed with this information, the genetic susceptibility of an individual to an above-mentioned disease condition can be assessed.

An allele-specific method for identifying point mutations by differential PCR amplication is described by (19). A non-electrophoretic method of genotyping with allelespecific PCR employs a dye specific for double-stranded DNA (20). A method of detecting mutations referred to as single-stranded conformation polymorphism (SSCP) is pres-

20

25

30

35

ently widely employed (21). A hybrid of SSCP and Sanger dideoxy sequencing, called dideoxy fingerprinting (ddF) has recently been described (22).

Other methods of identifying allelic mutations are known to the skilled artisan. Probably the most commonly used method of genotyping is restriction fragment length polymorphism (RFLP) (23), which is employs one or more restriction enzymes to identify mutant alleles occurring within a restriction site. This method has been used extensively in forensic applications and is employed commer-10 cially by such companies as Helix Biotech, Inc. Reliagene Technologies, Inc. and GenTest Laboratories, Inc. Accordingly, an instant mutant PARG allele can be detected by RFLP methods, optionally by one of these commercial entities. The above methods are most effective in the detec- 15 tion of homozygotes for the defective allele.

An RFLP method of identifying a mutant PARG allele in an individual entails: (i) obtaining genomic material from the individual; (ii) digesting the genomic material with a restriction enzyme having a recognition site inclusive of the mutant allele; (iii) fractionating the restriction fragments obtained from the digestion, e.g., by electrophoresis; and (iv) comparing the fractionation pattern with that obtained for a normal allele, thereby determining the presence or absence of the mutant allele.

An ASPCR method of identifying a mutant PARG allele in an individual entails: (i) hybridizing an oligonucleotide with genomic material from the individual; (ii) attempting to extend the oligonucleotide using PCR amplification; and (iii) determining the degree to which extension occurs, thereby determining the presence or absence of the mutant allele. In this method, it is preferred that the oligonucleotide hybridizes under predetermined hybridization conditions to a region immediately 5' of a predetermined mutation site in the PARG allele with the 3' terminus of the oligonucleotide complementary to an unmutated PARG allele. In these protocols, the PCR extension reaction is generally attempted at a temperature above about 50° C., more preferably above about 60° C.

A variety of protocols including ELISA, RIA and FACS for measuring PARG levels are known in the art and provide a basis for diagnosing altered or abnormal levels of PARG expression. Normal or standard values for PARG expression may be established by combining body fluids and tissue 45 biopsies from normal mammalian subjects, rupturing the cells or permeating the cells, combining the cells with antibody under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods but preferably by photometric 50 means. Quantities of PARG expressed in subject, control, and disease sample are compared to standard values to determine between normal, reduced or enhanced levels of PARG.

antibody immunoreactive with a polypeptide of the present invention. Preferably the antibodies are specifically immunoreactive with the polypeptides of this invention such as, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, and SEQ ID NO: 10. Frequently it is desired to label the 60 antibody, e.g., with a radiolabel, fluorescent or epitope label, to permit visualizing the antibody. Thus, antibodies immunoreactive with the PARG of this invention are afforded, which can be used to study features of PARG heterogeneity and possible modes of regulation. The high degree of sequence similarity between bovine PARC, human PARG and murine PARG permits eliciting antibodies to PARG of

one species, which are found to be cross-reactive with PARGs from other organisms. These antibodies are valuable in characterizing PARG in-vivo under defined physiological conditions in many different organisms.

Accordingly, a method of detecting a polypeptide having PARG activity, for example, a diagnostic assay, entails: (i) contacting the polypeptide with an aforementioned antibody of the invention; and (ii) determining whether the antibody immunoreacts with the polypeptide. Binding can be ascertained in an sandwich assay, as is well known, due to the ability of the antibodies to immunoreact with an epitope of PARG. Preferably, monoclonal antibodies, such as those prepared by the method of Kohler and Milstein (24) and labeled antigens effective in competing with the polypeptide, are employed. Exemplary assays are disclosed in U.S. Pat. No. 4,375,110, the disclosure of which is incorporated herein by reference.

The present invention includes immunoreactive fragments of a PARG enzyme. Immunoreactive fragments can be fragments that can elicit an immune response that recognizes a PARG enzyme. Alternatively, immunoreactive fragments can be fragments that are specifically bound by an antibody that specifically binds a PARG enzyme. Any of variety of methods may be employed in order to identify contiguous peptide fragments of a PARG enzyme that comprise immunoreactive sequences. PARG enzymes may be fractionated by proteases, cyanogen bromide, etc. and the resultant fragments assessed for their capacity to specifically bind anti-PARG antibodies.

In an alternative embodiment, one or more synthetic peptides may be prepared in order to locate contiguous amino acid sequences that are immunoreactive. The peptides may have a sequence that includes a series of contiguous amino acids that are identical to a series of contiguous amino acids of a PARG enzyme. The peptides may be of about six amino acids to about 500 amino acids in length. The peptide may also include sequences that are not identical to sequences of a PARG so long as it includes at least about six contiguous amino acids that are identical to about six contiguous amino acids of a PARG enzyme. In a preferred embodiment, the peptide will be about 50 amino acids in length. In other preferred embodiments the length of the peptide may be from about six amino acids to about 30 amino acids.

The peptides of the present invention may comprise amino acid sequences that elicit antibodies that specifically bind to the peptide or to a PARG enzyme. alternatively, the peptides may contain sequences that are specifically bound by anti-PARG antibodies. Peptides that are bound by anti-PARG antibodies may identified through the use of Epitope Scanning<sup>™</sup> strategy (Cambridge Research Biochemicals, Inc.). Thus, the linear sequence of amino acids of a particular PARG enzyme is used to construct a set of peptides of A still further aspect of the invention pertains to an 55 defined length which overlap other members of the set by one or more residues. The peptides may be any length; however, lengths of from about 6 to 25 amino acids are preferred. In selecting the length, a general consideration is that antibodies that recognize linear native epitopes constitute approximately 60-70% of the anti-protein antibody population (25).

> The number of overlapping amino acids will generally be more than half of the length of the peptides. That is, if the peptides are about 20 amino acids long, the overlap may be 65 11 or more amino acids long. In preferred embodiments, each peptide will be selected such that the number of overlapping amino acid residues in adjacent peptides is from

20

25

35

45

50

about (n-1) to (n-3), where "n" is the number of amino acids in the peptide. An overlap of (n-1) is particularly preferred. Thus, in a particularly preferred embodiment, a first peptide may have the amino acid sequence of residues 1-10 of a PARG enzyme, a second peptide may have the amino acid sequence of residues 2-11 of the same PARG enzyme, a third peptide may have the sequence of residues 3-12 of the same PARG enzyme and so on until the entire sequence of the PARG enzyme has been synthesized in fragments.

The peptides may be synthesized using any means known to those of skill in the art. In a preferred embodiment, the peptide will be synthesized using an automated synthesizer such as a multipin peptide synthesis system. Such systems or peptides synthesis services are commercially available from 15suitable providers known to those skilled in the art.

To identify suitable peptides, each peptide is introduced into a well of a microtiter plate, and assayed for its ability to bind to antibodies elicited by a PARG enzyme. Such assays may be conducted in various ways known to those skilled in the art. One suitable assay is conducted by immobilizing a peptide on the surface of a well and then contacting the peptide with a solution containing an anti-PARG antibody. After washing, the well is contacted with a labeled antibody that specifically binds to the anti-PARG antibody. Thus, the presence of label in the well indicates that the anti-PARG antibody bound to the immobilized peptide. Another preferred method of determining the ability of the peptide to be specifically recognized by anti-PARG antibodies is a competitive ELISA.

Once a particular peptide has been found to bind to anti-PARG antibodies, the peptide can be used to elicit monospecific antibodies. By immunizing an experimental animal with a single peptide containing a single antigenic determinant, the antibodies elicited will all specifically bind to the same antigenic determinant even though the antibodies are not monoclonal.

Where desired, the peptides can be modified to increase their immunogenicity. Thus, they may be modified to contain an amino-terminal and/or a carboxyl-terminal cysteine or lysine residue with or without spacer arms. The peptides may be conjugated to carriers such as bovine serum albumin, ovalbumin, human serum albumin, KLH (keyhole limpet hemocyanin) or tetanus toxoid. The use of human serum albumin is preferred over ovalbumin or bovine serum.

The peptides, alone or conjugated to a carrier, may be themselves capable of eliciting an antibody response when administered to an experimental animal. Alternatively, the peptides, alone or conjugated to a carrier, may be administered in conjunction with an adjuvant. Those skilled in the art will understand that a variety of materials may function as adjuvants. Examples of possible adjuvants include, but are not limited to, Freund's complete adjuvant, Freund's incomplete adjuvant, lipopolysaccharide (LPS) and the like. 55 Any material that increases the immune response to a fragment of a PARG enzyme may be used as an adjuvant.

The ability to produce large amounts of active PARG enzyme permits, for the first time, the large scale screening of chemical libraries for molecules capable of inhibiting or 60 activating PARG enzymatic activity. The screening may be conducted using any assay for PARG known to those skilled in the art. In a preferred embodiment, the screen may be conducted using the TLC based assay described by Ménard, et al. (26). A known amount of PARG will be incubated under standardized conditions with [32P]-poly(ADPR) in the presence of inhibitor or activator. After an appropriate period

of time, the reaction will be stopped and the reaction mixture separated on PEI-F cellulose TLC plates. The TLC plates may be developed in an appropriate solvent system such as methanol followed by 0.3N LiCl. The amount of ADPR released in the reaction will be quantified and the effect of the inhibitor or activator on enzymatic activity will be determined. Typical reaction conditions are 50 mM potassium phosphate (pH 7.5) at 37° C. in the presence of 25  $\mu$ M [<sup>32</sup>P]-poly(ADPR). The concentration of the inhibitor or activator can be varied as necessary to determine the  $K_i$ value of the inhibitor or activator according to standard procedures.

Another embodiment of the invention is directed to a method of altering the response of the cell to a genotoxic stress by modulating the concentration of ADPR polymers. As discussed above, the metabolism of ADPR polymers is critical in determining the fate of cells subjected to genotoxic stress. The modulation can be either an increase or a decrease in the concentration of the polymers. In one embodiment of the present invention, the concentration of ADPR polymers can be decreased by the use of a gene therapy vector expressing a high level of PARG. In another embodiment of the present invention, the concentration of polymers can be increased by inhibiting the enzymatic activity of the PARG enzyme by the addition of inhibitors or activators identified as described above. Alternatively, the concentration of ADPR polymers can be increased by interfering with the endogenous expression of PARG enzymes using antisense oligonucleotide technology.

Knowledge of the nucleotide sequence of the PARG gene permits the preparation of antisense therapeutics containing sequences complimentary to the mRNA of PARG gene. The preparation and delivery of antisense therapeutics is well known to those skilled in the art. For example, antisense therapeutics have been used to treat neoplastic disorder as exemplified by Smith, U.S. Pat. No. 5,248,671, specifically incorporated herein by reference. Additional examples of antisense therapeutics are provided by Miller, U.S. Pat. Nos. 4,511,713; and 4,757,055, specifically incorporated herein 40 by reference.

In the present invention, an oligonucleotide having a sequence complimentary to the mRNA of the PARG gene will be prepared. Such an oligonucleotide is said to be an antisense oligonucleotide with respect to the PARG gene. The oligonucleotide may be RNA or DNA or a may contain both RNA and DNA portions. The oligonucleotide may contain modified bonds so as to enhance the stability of the oligonucleotide and render it more resistant to the action of cellular nucleases. For example, the oligonucleotide may be constructed with phosphorothioate nucleotides, phosphonate nucleotides and other types of modified nucleotides known to those skilled in the art. The structure of the oligonucleotide maybe altered so as to include other types of bonds that do not naturally occur in oligonucleotides. For example, adjacent nucleosides might be joined using linear alkyl chains, peptide bonds or other types of structures. The only limitation is that the resulting oligonucleotide remains capable of hybridizing to the target PARG mRNA.

The antisense oligonucleotides may be delivered by any means customarily used in the art. For example, the oligonucleotide may be delivered in neutral liposomes, cationic liposomes or by ballistic high speed injection. Alternatively the DNA sequence encoding, the antisense oligonucleotide may be inserted into a gene vector and the vector may be 65 introduced into target cells. The vector may be any type of gene therapy vector known to those skilled in the art. Preferred embodiments include, plasmid vectors and viral

vectors. Viral vectors are seen to include those vectors customarily used for gene therapy applications including, but not limited to, retroviral vectors, vaccinia virus vectors, herpes virus vectors, adenovirus vectors and adenoassociated virus vectors. Upon introduction of the vector 5 into target cells, the vector will direct expression of a nucleic acid molecule comprising the appropriate sequence to hybridize with the mRNA encoding a PARG enzyme. In a preferred embodiment, introduction of the vector into the target cell will result in the production of an RNA molecule 10 that hybridizes with the mRNA of a PARG enzyme and also includes one or more additional RNA sequences capable of functioning as a ribozyme. The ribozyme portion of the molecule will cause the cleavage of the mRNA encoding the PARG enzyme thereby preventing the production of PARG. 15

Therapeutics of this type may be used to treat a wide variety of conditions. In one embodiment, an antisense therapeutic will be used to treat neoplastic disorder. In a preferred embodiment, an antisense therapeutic of the present invention will be delivered in combination with a <sup>20</sup> currently known chemotherapeutic agent. In general, chemotherapeutic agents function by disrupting the integrity of DNA in target cells. Since the recovery of a cell from such DNA disruption is highly dependent upon the normal ADPR polymer metabolism, the presence of the antisense thera-<sup>25</sup> peutic will have the effect of chemosensitizing the neoplastic cells by disturbing the ratio PARG and PARP.

In another preferred embodiment, the antisense oligonucleotides of the present invention may be used to treat a variety of conditions caused by genotoxic oxidative stress. Examples include cardiac disorders, neuronal disorders, reperfusion injury, neurotoxicity, Alzheimer's disease, Huntington's disease and Parkinson's disease. It has been shown that inhibition of ADPR polymer synthesis provides protection against cellular damage caused by nitric oxide injury. Zhang, et al,. U.S. Pat. No. 5,587,384, specifically incorporated herein by reference, teach that decreasing the amount of ADPR polymers formed can result in protection against nitric oxide induced neurotoxicity. As discussed above, decreasing the amount of ADPR polymers in the cell can be accomplished by the introduction of gene therapy vector expressing PARG, thus, the present invention can be used to treat neurodegenerative conditions resulting from oxidative stress.

#### CONCLUSION

The synthesis and rapid turnover of ADP-ribose polymers is an immediate cellular response to DNA damage. Reported here is the isolation and characterization of cDNAs encoding various poly(ADP-ribose) glycohydrolase (PARG) enzymes 50 responsible for ADP-ribose polymer turnover. PARG was isolated from bovine thymus, yielding a protein of approximately 59 kDa. Based on the sequence of oligopeptides derived from the enzyme, polymerase chain reaction products and partial cDNA clones were isolated and used to 55 construct a putative full-length cDNA. The cDNA of approximately 4.1 kb pairs predicts expression of a protein of approximately 111 kDa, nearly twice the size of the isolated protein. A single transcript of approximately 4.3 kb pairs is detected in bovine kidney poly(A)<sup>+</sup> RNA, consistent 60 with expression of a protein of 111 kDa. Expression of the cDNA in Escherichia coli results in an enzymatically active protein of 111 kDa and an active fragment of 59 kDa. Analysis of restriction endonuclease fragments from bovine DNA by Southern hybridization indicate that PARG is 65 encoded by a single copy gene. Taken together, the results indicate that previous reports of multiple PARGs can be

explained by proteolysis of an 111-kDa enzyme. The deduced amino acid sequence of the bovine PARG shares little or no sequence similarity with differing types of known proteins; however, it contains a putative bipartite nuclear location signal as would be predicted for a nuclear protein. The availability of cDNA clones for PARG should facilitate structure-function studies of the enzyme and its involvement in cellular responses to genomic damage.

Other embodiments and advantages of the invention are set forth, in part, in the description that follows and, in part, will be obvious from this description and may be learned from practice of the invention.

#### EXAMPLES

#### Example 1

#### Purification of Bovine PARG

PARG was purified from bovine thymus tissue (Pel-Freez, Rogers, Ak.) by modifications of previously published procedures (27). The enzyme was isolated up to the polyethylene glycol (PEG)-6,000 fractionation step as described previously (28). However, DNA-agarose and heparin-Sepharose chromatographic steps used previously were omitted, and the PEG-6,000 fraction was applied directly to an affinity matrix of poly(ADP-ribose)-dihydroxyboronyl-Sepharose (PADPR DHB-Sepharose). The active fractions eluted from PADPR DHB-Sepharose (25 ml) were pooled, 30 placed in dialysis tubing, concentrated against dry PEG-20, 000 to approximately 12 ml, and dialyzed against 2 liters of 20 mM potassium phosphate buffer, pH 8.0, 0.1% Triton X-100, 5 mM β-mercaptoethanol, 0.1 mM thioglycolic acid, 0.4 M KCl (buffer A). The sample was loaded onto a 35 1.0×11-cm Toyopearl AF-Red (Supelco) column, and PARG was eluted with an 80-ml linear gradient of 0.4-2 M KCl in buffer A. The active fractions, eluting at approximately 1.25 M KCl, were pooled, placed in dialysis tubing, concentrated against solid sucrose to approximately 9 ml, and dialyzed 40 against 20 mM potassium phosphate buffer, pH 7.2, 0.75 M KCl, 0.1% Triton X-100, 10% glycerol, 5 mM β-mercaptoethanol, 0.1 mM thioglycolic acid. PARG activity was determined as described by Ménard and Poirier (29), 45 and protein content was determined by the method of Bradford (30). The final preparation was quantified by SDS-PAGE (31) and Coomassie Blue staining to compare the intensity of the protein band with a known amount of bovine serum albumin (32).

The purification procedure for the bovine thymus PARG summarized in Table 1 is typical for results obtained from six separate preparations of the enzyme. Purification from 500 g of bovine thymus achieved approximately 50,000-fold purification and yielded approximately 20  $\mu$ g of purified protein. An aliquot of the purified enzyme was precipitated with trichloroacetic acid, washed with acetone, resuspended in SDS-PAGE sample buffer, separated on a 10% SDS-PAGE gel, and stained with Coomassie Blue. Analysis of the final preparation of SDS-PAGE revealed that more than 95% of the protein migrated at an apparent molecular mass of approximately 59 kDa (FIG. 2). In FIG. 2, an aliquot of the purified enzyme was precipitated by TCA, washed with acetone, resuspended in SDS-PAGE sample buffer, separated on a 10% SDS-PAGE gel and stained with Coomassie blue. The positions of molecular weight marker proteins are shown.

25

TABLE	1
-------	---

Purification of PARG from bovine thymus						
Step	Protein mg	Total activity units	Specific activity units/mg protein	Yield %	Puri- fication -fold	5
Crude extract	27,800	57,400	2.06	100	1.0	
Protamine sulfate	12,500	58,000	4.64	101	2.3	10
Ammonium sulfate	4,480	30,000	6.70	52	3.3	
CM-Sepharose	171	19,100	112	33	55	
PEG 6000	23.0	7,530	327	13	160	
PADPR-DHB-	1.30	6,730	5,180	12	2,500	
Sepharose Toyopearl AF-Red	0.023	2,260	98,300	4	48,000	15

#### Example 2

Peptide Sequencing Prior to proteolytic fragmentation, the purified bPARG  $(40 \,\mu g \text{ in } 100 \,\mu l \text{ of } 0.4 \text{ M} \text{ ammonium bicarbonate buffer, pH}$ 8.0, 8 M urea) was incubated in a final concentration of 2.2 mM dithiothreitol at 56° C. for 15 min. Iodoacetamide was added to a final concentration of 2.0 mM, and the sample was incubated at 25° C. for 15 min. After dilution with an equal volume of water, 1.5 units of immobolized L-1tosylamido-2-phenylethyl choloromethyl ketone-treated trypsin (Pierce Chemical, Rockford, Ill.) was added, and the 30 sample was incubated at 37° C. for 18 h with gentle rotary shaking. Finally, the mixture was subjected to centrifugation at 16,000×g for 5 min to separate the tryptic fragments from the immobolized trypsin. The tryptic fragments were adjusted to 0.05% in trifluoroacetic acid and separated on a 4.6 mm×25 cm, Microsorb MV, C4 reversed-phase HPLC column (Rainin) eluted with an 80-min linear gradient from 4 to 44% acetonitrile in 0.05% trifluoroacetic acid. Four oligopeptide fractions, with approximate elution times of 61, 63, 68, and 75 min, were selected for peptide sequence analysis the Edman degradation method. Amino acid sequence data of four oligopeptides, designated by their approximate HPLC elution times from the reversed-phase column, are shown in Table II.

TABLE II

Amino acid sequence of oligopeptides derived from bPARG					
Oligopeptide	Amino A	Acid Sequence	_		
10	20	30	SEQ ID NO:	5	
68 LFTEVLDHNE	CLIITGTEQY	SEYTGYAETY R	SEQ ID NO: 11		
63 AYCGFLRPGV	SSENLSAVAT	GNXGCGAFG	SEQ ID NO:		
61 FLINPELIVS	R		SEQ ID NO: 13	5	
75 IALXLPNIXT	QPIPLL		SEQ ID NO: 14		

#### Example 3

cDNA Cloning To obtain cDNA clones encoding bovine PARG, PCR amplification experiments were followed by the screening of two different bovine cDNA libraries. FIG. 3 depicts the alignment of the DNA sequences of two PCR products and eight  $\lambda$  gt11 cDNA clones used to identify the cDNA coding

for bovine PARG. The two PCR products and clones 1 and 2 were obtained from the bovine thymus cDNA library. Clones 3-8 were obtained from the bovine kidney cDNA library. The positions of restriction sites used in this study are shown, and the top diagram shows the consensus clone, denoting the relative location of the coding regions for oligopeptides, 75, 61, 68, and 63 as well as the open reading frame and non-coding regions. For each of the cDNA inserts characterized, the sequence of both strands was determined 10 by the dideoxynucleotide chain termination method using Sequenase<sup>™</sup> (U.S. Biochemical Corp., Cleveland, Ohio).

The first step leading to the isolation of cDNA clones was to synthesize two multi-degenerate 17-mer primers, GAY-CAYAAYGARTGYYT (SEQ ID NO: 15) and CKRTANG-TYTCNGCRTA (SEQ ID NO: 16) (where Y represents T/C, R is A/G, K is T/G, and N is A/T/C/G, based on two regions of the SEQ ID NO: 11; "DHNECL" (amino acids 7 to 12 of SEQ ID NO: 11) and "YAETYR" (amino acid 26 to amino acid 31 of SEQ ID NO: 11) (Table II). Using the multidegenerate primers and an oligo(dT)-primed bovine thymus cDNA \lagkt11 library BL1019b from Clontech (Palo Alto, Calif.), PCR amplification generated a 74-bp DNA fragment with a deduced amino acid sequence identical to the corresponding region of oligopeptide 68. Next, two specific 24-mer oligonucleotide primers, ATCATCACAGGTACT-GAGCAGTAC (SEQ ID NO: 17) and GCCTGTGTAT-TCACTGTACTGCTC (SEQ ID NO: 18), based on the sequence of this 74-bp DNA were used in combination with λgt11 forward and reverse primers to amplify PCR products 1 and 2 from the bovine thymus library. PCR product 12 contained 231 bp of sequence including the region encoding the N-terminal region of oligopeptide 68 (SEQ ID NO: 11) and the entire sequence of oligopeptide 61 (SEQ ID NO: 13). PCR product 2 contained 757 bp, which included a 35 sequence encoding the C-terminal region of oligopeptide 68 (SEQ ID NO: 11) and the entire sequence of oligopeptide 63 (SEQ ID NO: 12).

The sequence information obtained from PCR products 1 and 2 was used to isolate cDNA clones obtained by the screening of bovine thymus and bovine kidney cDNA librar-40 ies. A 518-bp EcoRI-HindIII fragment from PCR product 2 was used as a probe to screen approximately 1×10<sup>6</sup> independent clones from the bovine thymus library. Two positive cDNA clones (clones 1 and 2) were isolated, which over-45 lapped PCR products 1 and 2. However, attempts to obtain clones from the bovine thymus library that contained sequence 5' to clone 2 were unsuccessful. Thus, a 231-bp EcoRI-KpnI fragment from clone 2 was used as a probe to screen approximately  $5 \times 10^5$  independent clones of the 50 bovine kidney 5' stretch plus cDNA λgt11 library BL3001b (Clontech, Palo Alto, Calif.). Three positive cDNA clones (clones 3-5) were obtained, all of which contained sequence 5' to clone 2. Each of these clones also contained a sequence encoding oligopeptide 75. Clones 1-5 provided multiple 55 overlapping sequences in the 3'-terminal portion of a consensus cDNA, but additional clones were sought to obtain overlapping sequences for the 5'-terminal region. Thus, a 436-bp EcoRI-KpnI fragment located at the 5' end of clone 3 was used as a probe to screen approximately  $6 \times 10^5$ independent clones of the bovine kidney library. Clones 6-8 60 provided overlapping sequences for the 5'-terminal region. The full-length cDNA was constructed by ligating a 3.9-kb XbaI-NsiI fragment from pWL11 (clone 1 cDNA insert in pTZ18R (33)) and a 3.0-kb NsiI-XbaI fragment from 65 pWL13 (clone 4 cDNA insert in pTZ18R). The resulting plasmid, termed pWL30, contained the 4,070-bp full-length cDNA.

FIG. 3 shows an alignment of the DNA sequences of two PCR products and eight \lambda gt11 cDNA clones used to identify the cDNA coding for bovine PARG. The two PCR products and Clones 1 and 2 were obtained from the bovine thymus cDNA library. Clones 3 through 8 were obtained from the bovine kidney cDNA library. The position of restriction sites used in this study is shown and the top diagram shows the consensus clone, denoting the relative location of the coding regions for oligopeptides 75, 61, 68, and 63 as well as the open reading frame and non coding regions.

The nucleotide sequence of cDNA coding for bovine PARG is shown in the sequence listing as SEQ ID NO: 1. The deduced amino acid sequence of the enzyme is shown in the sequence listing as SEQ ID NO: 2. The four oligopeptides sequenced from purified enzyme is within SEQ ID NO: 15 2. They are IALCLPNICTQPIPLLK (amino acid 601 to 617, SEQ ID NO: 2); LINPELIVSR (amino acid 761 to 770, SEQ ID NO: 2); LFTEVLDHNECLIITGTEQYSEYTGYA-ETYR (amino acid 771 to 801, SEQ ID NO: 2) and AYCGFLRPGV PSENLSAVAT GNWGCGAFGGDAR 20 (amino acid 849 to 880, SEQ ID NO: 2). The combined nucleotide sequence of Clones 1 through 8 predicted a full-length cDNA clone of 4,070 bp containing 257 bp of 5'-non-coding sequence, a single open reading frame of 2,931 bp (beginning at the ATG at position 258 of SEQ ID 25 NO: 1) and a 3'-non-coding region of 882 bp. and the deduced amino acid sequence which predicts a protein of 977 amino acids and a molecular weight of 110.8 kDa.

#### Example 4

Analysis of the Sequence of Bovine PARG

The cDNA clone (SEQ ID NO: 1) has features typical of cDNAs that code for mammalian proteins. These include (i) an oligo A (putative poly(A)+) sequence at the 3'-end, (ii) a polyadenylation signal (AATAAA) 12 bp upstream from the 3'-untranslated region thought to play a role in selective mRNA degradation in mammalian cells (34), (iv) a single open reading frame, and (v) a nucleotide sequence around the first start codon commonly found at known sites of initiation of translation (35). The evidence that the cDNA clone constructed represents a full-length or nearly fulllength clone for PARG is shown by the observation that hybridization of poly(A)+ RNA from bovine kidney cells with the cDNA showed a single band of hybridization of hybridization conditions (set forth above) (FIG. 4).

The nucleotide sequence encoding bovine PARG indicates that PARG shares little or no sequence similarity with other known sequences. A search of sequence data banks has failed to reveal significant sequence similarity with any 50 sequences coding for known proteins. A strong sequence similarity has been observed with human and rat cDNA clones that likely represent partial clones for PARG from these species. Examination of protein sequence databases such as Genbank and SwissPro also has shown that the 55 deduced amino acid sequence of PARG lacks any sequence similarity with known proteins. However, the amino acid sequence shares a significant similarity with a protein sequence from Caenorhabditis elegans that may represent the PARG protein from this organism (36).

The deduced amino acid sequence of PARG has been examined for a number of structural motifs that can be predicted from the primary amino acid sequence. The expressed PARG protein was observed to be able to form dimers stable to SDS-PAGE conditions. In that regard, 65 mined. If PARG occurs as a larger protein, an interesting residues 871-907 show significant homologies to known leucine zipper dimerization sequences (37).

28

Another motif identified is a putative bipartite nuclear location signal (NLS) (38). It is interesting that PARP also contains a bipartite NLS (39). FIG. 5 compares deduced amino acid sequences in the NLS region of the bovine PARG, and regions of putative PARG sequences from human, mouse and C. elegans, with the NLS region of PARP from seven different organisms. Conserved residues are noted in bold and the amino acid distances are from the amino terminal methionine residue. Abbreviations and ref-10 erences for the sequences shown are as follows: bPARG, bovine PARG (SEQ ID NO: 19); hPARG, human PARG (SEQ ID NO. 20); mPARG, murine PARG (SEQ ID NO: 21); CePARG, Caenorhabditis elegans PARG (SEO ID NO: 22); hPARP, human PARP (SEQ ID NO: 23; 40); mPARP, murine PARP (SEQ ID NO: 24; 41); bPARP, bovine PARP (SEQ ID NO: 25, 42); aPARP, chicken PARP (SEQ ID NO: 26; 43); X1PARP, Xenopus laevis PARP (SEQ ID NO: 27; 44); DmPARP, Drosophila melanogaster PARP (SEQ ID NO: 28; 45); SpPARP, Sarcophaga peregrina PARP (SEQ ID NO: 29; 46). In FIG. 5, conserved residues are noted in boldface type, and the amino acid distances are from the amino-terminal methionine residue. Sequence alignment of putative bipartite nuclear localization signal of bovine, human and murine PARG compared to the nuclear localization signal of PARP from different organisms. The putative NLS of PARG fulfills the criteria for bipartite NLS in that it contains conserved acidic and basic amino acid residues at two different locations each within the region of sequence similarity to the NLS of PARP (47).

A surprising finding was that the bovine PARG cDNA clone codes for a protein of approximately 111 kDa, which is nearly twice the size of the PARG protein isolated from bovine thymus (FIG. 2). It indicates that PARG contains a protease sensitive site that, following proteolysis, yields a oligo A sequence, (iii) a sequence of ATTTA in the 35 protein fragment of approximately 59 kDa that still retains enzymatic activity. Several pieces of evidence favor this possibility. (i) Expression of the carboxyl terminal portion of the cDNA resulted in enzymatic activity (FIG. 6, bar 5). (ii) All of the oligopeptides sequenced were located in the carboxyl terminal half of the protein (FIG. 3, FIG. 6 and Table 2). (iii) The only protein, other than 59 kDa protein detected in the thymus preparation was approximately 111 kD (FIG. 2). (iv) The PARG activity expressed in bacteria was sensitive to proteolysis, yielding a protein of approxiapproximately the same size as the cDNA under stringent 45 mately 56 kD (FIG. 6). (v) The cleavage site in PARG is in the region of the putative NLS and the PARP NLS is located in a protease sensitive site (48). Taken together with the data suggesting that bovine PARG appears to be coded for by a single copy gene (FIG. 7), proteolysis seems likely to explain the presence of PARG activity of molecular weight of approximately 74 kDa and 59 kDa in bovine thymus preparations (49). Likewise, a similar mechanism could explain previous reports of a PARG of 74 kDa isolated from nuclear fractions of guinea pig liver and human placenta (50) and a PARG of 59 kDa isolated from postnuclear fractions of guinea pig liver (51).

> While proteolysis of a larger protein to yield smaller proteins retaining PARG activity seems likely to explain the size heterogeneity of PARG previously reported, it remains 60 to be determined if proteolysis normally occurs in vivo or whether it occurs during purification of the enzyme. While the results presented here show that a full-length protein can be expressed containing PARG activity (FIG. 8), the molecular size of PARG in vivo also remains to be deterpossibility is that the amino terminal region may be involved in the regulation of enzymatic activity.

## Example 5

Expression of bPARG in Escherichia coli

To determine whether the isolated cDNA encoded PARG, bPARG was express using two different bacterial expression systems, the pTrcHis Xpress System<sup>™</sup> (Invitrogen, Carlsbad, Calif.), in which the expressed protein contains a leader polyhistidine sequence, and the glutathione S-transferasae (GST) gene fusion system (Pharmacia Biotech Inc., Piscataway, N.J.). For expression in the pTrcHis fied and inserted into the pTrcHis expression plasmid. Constructs A and B contained the entire opening reading frame of 110.8 kDa, which together with the fusion partner predicted a protein of about 115 kDa. Construct B also contained the 3'-untranslated region of the clone. Construct 15 A, containing the cDNA sequence-3 to 2,946, was prepared by subcloning a 2.9kb XhoI-EcoRI DNA fragment amplified pWL30 WIN34 from with primers (GCTGCGGGTCTCGACGATGAGTGCGGGC) (SEQ ID NO: WIN15 30) and 20 (GCGTCTAGAATTCACTTGGCTCCTCAGGC) (SEQ ID No: 31). Construct B, containing the cDNA sequence-3 to 3,813, was prepared by subcloning a 2.8-kb XhoI-EcoRI DNA fragment amplified from pWL30 with primers WIN34 (SEO NO: 30) WIN33 25 ID and (CCGGAATTCGGGTTTTTTGTTAATGAAAATTTATTAAC) (SEQ ID NO: 32). Construct C, containing cDNA sequence 964-2,946, was prepared by subcloning a 2.0-kb DNA fragment amplified from pWL13 with primers WIN14 (TCAGAGCAGATGAACTCGAGCAGTCCAGG) (SEQ 30 ID NO: 33) and WIN15 (SEQ ID NO: 31). Since the isolated PARG of approximately 59 kDa contained enzymatic activity, construct C contained only the 75-kDa carboxylterminal region of the PARG, which predicted a fusion protein of approximately 79 kDa.

For expression experiments of bPARG as a GST fusion protein, an insert containing the cDNA sequence from position 1138 to 2946 was prepared by subcloning a 1.8-kb EcoRI-EcoRI fragment amplified from pWL30 with the oligonucleotide CCAATTTGAAGGAGGAATTCCCGC-CGCCACCATGAATGATGTGAATGC-CAAACGACCTGGA (SEQ ID NO: 34) and WIN15 (SEQ

ID NO: 31) as primers. The resulting DNA fragment was inserted into the EcoRI site of the pGEX-2T expression NM522 cells.

For expression experiments, bacterial cultures were grown at 37° C. in 1% Bacto-tryptone, 0.5% yeast extract, and 0.5% NaCl to a density of approximately 0.6 A<sub>600</sub>/ml and were induced with 1 mM isopropyl- $\beta$ -D-thiogalactoside 50 (IPTG). Cells were collected by centrifugation, and crude extracts were prepared by sonication  $(10 A_{600}/ml)$  in 10 mM sodium phosphate buffer, pH 7.2, 150 mM NaCl, 0.5 mg/ml lysozyme, 0.1 mg/ml phenylmethylsulfonyl fluoride, 1 mM EDTA, 0.7  $\mu$ g/ml pepstatin A, 0.5  $\mu$ g/ml leupeptin, and 1  $\mu$ g/ml aprotinin. Cell extracts were subjected to centrifugation, and the supernatant fraction was used for assay. PARG assay conditions were as described previously (52). Following, incubations, portions of reaction mixture were analyzed by thin layer chromatography or subjected to 60 kDa increased. anion exchange HPLC.

Using a thin layer chromatography assay that measures release of [<sup>32</sup>P]ADP-ribose from [<sup>32</sup>P]ADP-ribose polymers (53), PARG activity was detected in extracts from cells transformed by each of the constructs. FIG. 6 shows results 65 obtained with constructs B and C. Reaction mixtures contained approximately 15,000 cpm of [32P]ADP-ribose

polymers, and the cpm shown represent ADP-ribose released from the ADP-ribose polymers. Bar 1, a strain transformed by pTrcHis without an insert but induced with 1 mM IPTG for 5 h at 37° C. A strain containing construct B is shown without the addition of IPTG (bar 2) or after the addition of 1 mM IPTG for 1.5 h (bar 3) or 5 h (bar 4). A strain containing construct C 5 h after induction by IPTG is shown in the absence (bar 5) and presence (bar 6) of  $167 \,\mu m$ ADP-hydroxymethylpyrrolidine diol (54). No activity was Xpress system, three different DNA fragments were ampli- 10 detected in cells transformed with the empty vector, but activity was detectable without induction by IPTG, indicating a leaky lac promoter. The addition of IPTG resulted in a time-dependent increase of up to approximately 4.5-fold in enzymatic activity. FIG. 6 also shows that the enzymatic activity was strongly inhibited by the presence of ADPhydroxymethylpyrrolidine diol, a specific inhibitor of PARG (55).

In FIG. 9, material released from ADP-ribose polymers by anion exchange HPLC was analyzed. Extracts from a strain containing construct B were incubated with [<sup>32</sup>P]ADPribose polymers (56), and a portion was analyzed by anion exchange HPLC as described. The elution times for AMP, ADPR, and PR-AMP are indicated by arrows. The material analyzed was PARS expressed in E. coli. The results indicated that the material released from ADP-ribose polymers is exclusively ADP-ribose by strong anion exchange HPLC (FIG. 9), demonstrating that the cell extracts did not contain any other ADP-ribose polymer-degrading enzymes such as phosphodiesterase, which catalyzes the formation of AMP and phosphoribosyl-AMP (57).

Anion exchange HPLC utilized a Whatman Partisil SAX column equilibrated with 7 mM potassium phosphate buffer pH 4.0, at a flow rate of 1 ml/min. The sample was diluted in the same buffer, applied to the column, and eluted with a 35 30-min linear gradient from 7 mM potassium phosphate buffer, pH 4.0 to 250 mM potassium phosphate buffer, 0.5 M KCl, pH 4.0.

To determine the size of the expressed enzymatic activity, an activity gel assay (58) was used. Activity gel assays for 40 bPARG were done by casting polyacrylamide gels with automodified PARP containing [<sup>32</sup>P]ADP-ribose polymers as described previously (59). Following electrophoresis, PARG was renatured by incubating the gels at 25° C. in 5 volumes of 50 mM sodium phosphate buffer, pH 7.5, 50 mM vector, and the plasmid was used to transform E. coli 45 NaCl, 10% glycerol, 1% Triton X-100, 10 mM  $\beta$ -mercaptoethanol, changing the buffer every 3 h for a total of five changes. After an additional incubation at 37° C. for 3 h, gels were dried, and PARG activity was detected following autoradiography as a clear band on a black background. Cell extracts containing PARG fused to GST were examined for binding to glutathione-Sepharose 4B (GSH-Sepharose) (Pharmacia Biotech Inc.) according to the specifications of the manufacturer. No bands were produced from extracts from the IPTG-induced pTrcHisB vector that did not contain an insert. Extracts from cells transformed with a construct containing a PARG insect showed bands at approximately 115 and 59 kDa (FIG. 8). During storage at 4° C., cell extracts lost activity migrating at the higher molecular weight, while the activity at approximately 59

Expression of bPARG in the pTrcHisB expression vector did not result in detectable amounts of protein by staining the Coomassie Blue. Thus, another construction was designed to overexpress a 69-kDa carboxyl-terminal region of the PARG as a fusion with GST, which allows convenient protein purification by affinity chromatography on a GSH-Sepharose column. Two hours after induction with IPTG,

Northern Blot Analysis

strong expression of a protein migrating at approximately 90 kDa was observed. This protein bound to GSH-Sepharose and was eluted by GSH. The construct contained a thrombin cleavage site between the GST and the 69-kDa region of PARG, and the treatment of the material bound to GSH-Sepharose with thrombin resulted in the release of a protein that migrated at approximately 59 kDa. This result suggests that the protein purified from the bovine thymus may be larger than suggested by its migration on SDS-PAGE. The result of this experiment is presented in FIG. 10. Lane 1 10 shows extract from uninduced cells; lane 2 shows extract from cells induced with 1 mM IPTG for 2 hours; lane 3 shows proteins in extracts from cells shown in lane 2 that bound to GSH-Sepharose; lane 4 shows material released from GSH-Sepharose by treatment with thrombin.

In addition to the GST fusion construct described above, several other GST fusion proteins have been made. FIG. 11 shows the portions of the bovine PARG gene that have been expressed. The top line represents the structure of bovine PARG mRNA containing the open reading frame encoding 20 the 111 kDa PARG protein. The different parts of PARG that have been cloned in expression vectors are represented with the size of the resulting expressed recombinant proteins. The expression of the 65 kDa catalytic domain of PARG (starting at the amino acid MNDV) in pGEX-2T as a fusion protein 25 with glutathione-S-transferase (29 kDa) is detailed. Among the constructs, only the clone designed to express a protein of 69 kDa starting at amino acid +380 from the sequence of bovine PARG (bPARG<sub>MNDV</sub>) allowed high level expression as a fusion protein with glutathione-S transferase (GST). A 30 1.8 kb PCR EcoRI fragment encoding for the 65 kDa catalytic domain of PARG was cloned into the EcoRI site of pGEX-2T giving pGEX-2T-bPARG<sub>MNDV</sub>. This construction results in the expression of a fused polypeptide consisting of the sequence of GST. Amino acids derived from the 35 polylinker and thrombin site and the 65 kDa domain (FIG. 12).

In addition to various constructs designed to express PARG in E. coli, a recombinant baculovirus expressing a functional PARG has been constructed using the methodology of Summers and Smith as set out in U.S. Pat. No. 4,879,936 which is specifically incorporated herein by reference.

bPARG<sub>MNDV</sub> was cloned in baculovirus transfer vector pVL1393 using the EcoRI site. The recombinant vector was 45 constructed as follows. An insert containing the cDNA sequence from position 1138-2946 of bovine PARG was prepared by subcloning a 1.8 kb EcoRI fragment amplified from pWL30 using oligonucleotides CCAATTTGAAG-GAGGAATTCCCGCCGCCACCATGAAT-50 GATGTGAATGCCAAACGACCTGGA (SEQ ID NO: 34) and GCGTCTAGAATTCACTTGGCTCCTCAGGC (SEQ ID NO: 31, WIN15). The resulting fragment was inserted into the EcoRI site of the pVL1393 baculovirus transfer vector. The amplification introduced a Kozak consensus sequence (gaattcccgccgccaccATGAA SEQ ID NO: 35) at the start site of translation to enhance expression of the recombinant protein. The resulting recombinant plasmid was cotransfected with linearize Baculogold™ baculovirus DNA (Pharmingen, San Diego, Calif.) into SF9 cells according to the manufacturers instructions. Recombinant viruses isolated using standard techniques. Overexpression of the recombinant protein was confirmed by Western blot and the results displayed in FIG. 13 demonstrate that the 65 kDa domain expressed in E. coli contained enzymatic activity 65 (lane 2) migrating with the same apparent molecular weight as the enzyme purified from bovine thymus (lane 1).

Likewise, a construct expressing bPARG<sub>MNDV</sub> domain in SF9 insect cells infected with recombinant baculovirus showed activity (lane 4) migrating with the same apparent molecular weight.

#### Example 6

An surprising feature of the consensus full-length cDNA clone was that it predicted expression of a protein of approximately 111 kDa (FIG. 3, SEQ ID NO: 1, and SEQ ID NO: 2), while the enzymatically active PARG from thymus had a molecular weight of approximately 59 kDa (FIG. 2). To determine the size of the RNA transcript for PARG, total RNA and poly(A)+RNA were isolated from bovine kidney (MDBK) cells and annealed using Clone 4 as the hybridization probe.

Total cytoplasmic RNA and poly(A)+RNA were isolated from bovine kidney MDBK cells (ATCC #CCL22) using TRIzol reagent (Gibco/BRL) following the manufacturer's recommendations. After the RNA was fractionated, it was then transferred to nylon membranes and hybridized with Clone 4 (FIG. 3) radiolabeled by a random hexamer priming method (21). The results are presented in FIG. 4. Total RNA (5  $\mu$ g, lanes 1A and 1B) and poly(A)+RNA (4  $\mu$ g, lanes 2A and 2B) were separated on a denaturing agarose gel (60). Panel A shows the ethidium bromide stained gel and panel B shows the autoradiogram of a Northern blot analysis using a random primed, <sup>32</sup>P-labeled DNA probe constructed from Clone 4 (FIG. 3). A single transcript of approximately 4.3 kb was detected in the poly(A)+RNA (FIG. 4, lane 2). Thus, the transcript size was consistent with the expression of a 111 kDa PARG protein.

#### Example 7

Southern Blot Analysis of PARG Genomic Complexity

Previous studies have reported that PARG isolated from nuclear fractions had a molecular weight of approximately 75 kDa (61), while PARG isolated from whole cell homogenates or postnuclear supernatant fractions had a molecular weight of approximately 59 kDa (62). These results suggest that either two or more genes may code for PARG or that proteolysis generates lower molecular weight forms from higher molecular weight forms. The cDNA isolated encoded a protein considerably larger than any PARG proteins previously described, consistent with the possibility that the different forms of PARG are derived from a single form by proteolytic cleavage. To test the hypothesis that PARG is encoded by a single copy gene, the genomic complexity of the PARC gene was analyzed by a Southern hybridization experiment.

Total genomic DNA was prepared from bovine thymus tissue as described previously (63) and DNA (10  $\mu$ g) was digested with EcoRI, BglII, XbaI or PstI, fractionated on a 1% agarose gel, transferred to a nylon membrane (Hybond N+, Amersham), and hybridized using an 828 bp HindIII fragment of Clone 1 radiolabeled as described for clone 4 above (64). Pre-hybridizations and hybridizations were carried out at 42° C. in 50% formamide, 0.25 M sodium phosphate buffer, pH 7.2, 0.25 M NaCl, 7% SDS, 1 mM EDTA. The blot was annealed with a <sup>32</sup>P-labeled DNA probe 60 corresponding to the carboxyl terminal region of the PARG protein.

The results of the Southern blot analysis are presented in FIG. 7. Genomic DNA was digested with four different restriction enzymes, EcoRI (lane 1), BglII (lane 2), XbaI (lane 3) and PstI (lane 4), none of which cleave within the carboxyl terminal region of the PARG cDNA. Following electrophoresis, the restriction digests were subjected to

50

hybridization with a probe that corresponded to the carboxyl terminal region of the PARG cDNA. The analysis displayed in FIG. 7 shows that, in each restriction digest, the probe hybridized primarily with a single restriction fragment. The fainter signals likely reflect the presence of introns in the PARC gene. This result indicates that PARG is encoded by a single copy gene in the bovine genome.

#### Example 8

Isolation and Characterization of PARGs From Other Spe-10 cies

The isolation and characterization of bovine cDNA encoding poly(ADP-ribose) glycohydrolase (PARG) has been described above. Using the information provided by the sequencing of bovine PARG, various tools were used, including public sequence databases searches and screening of cDNA libraries using PARG specific probes, to clone and sequence the cDNA and determine the primary structure of PARG from human, mouse, Drosophila and Caernorhabditis elegans. Mammalian sequences newly obtained using this combined strategy show high sequence similarity to bovine PARG (bPARG), whereas the sequences of Drosophila and C. elegans only display significant homologies in the region responsible of the catalytic activity of the protein.

The strategy followed to obtain cDNAs coding for pro-25 teins with sequence similarity to bovine PARG is summarized in FIG. 14. dBEST, GenBank. SwissProt and PIR databases were searched for PARG like sequences at the nucleotide or amino acid level using the programs BLASTn, TBLASTn (Altschul et al., 1990) respectively, available at 30 the NIH site on the Worldwide Web, and also included in the sequence analysis package from the Genetic Computer Group, Inc. (GCG) (Madison, Wis.), version 9.1. Both programs perform pair-wise sequence comparisons on multiple nucleotide or amino acid sequences. PARG multiple 35 sequence comparisons obtained with these programs are very similar. Box-shading of the amino acids in the multisequence alignment was obtained using the program BOX-SHADE (K. Hofmann and M. D. Baron). The first step involved extensive searching for sequences with bPARG similarity in various databases. As a result of this search several partial nucleotide sequences sharing extensive homologies with bPARG cDNA were obtained from the dBEST database (65). These sequences were the result of random cloning and sequencing of partial cDNAs clones 45 obtained from mRNAs expressed in various tissues and organisms. Among them, partial cDNAs coding for PARG from human and mouse were available. One of these human clones was particularly interesting as its sequence (2500 bp long) overlapped the coding sequence of bovine PARG from aa470 to aa977 (Carboxy terminus end) and contained all the 3' untranslated region of the human PARG cDNA. This clone (No. 50859; GenBank accession number: H 17209) was requested and freely obtained from the IMAGE Consortium (in collaboration with Washington University 55 School of Medicine in St. Louis, Mo. and Merck & Co., info@image.llnl.gov). The sequence of the clone was then completed. This partial cDNA permitted design of a radiolabeled probe (fragment HindIII-KpnI of 677 bp) specific to human PARG (SEQ ID NO: 36).

#### Example 9

Cloning and Sequencing The cloning procedures used in this work generally known and are also described in details in the book, Molecular Cloning: A Laboratory Manual (Maniatis et al., 1982). 65 DNA sequencing was performed using the dideoxynucleotide method of Sanger (Sanger et al., 1977). Chemical

reagents were purchased from Sigma (St. Louis, Mo.). Restriction enzymes, T4 DNA ligase were from New England Biolabs, Inc. (Beverly, Mass.), T7 DNA polymerase Sequenase from US Biochemical (Cleveland, Ohio), Calf Intestine Phosphatase from Boehringer, Mannheim (Indianapolis, Ind.). The phagemid pTZ18/19R is from Pharmacia (Piscataway, N.J.). The labeled nucleotides  $\alpha$ -[<sup>35</sup>S]-dATP and  $\alpha$ -[<sup>32</sup>P]-dCTP were purchased from ICN (Costa Mesa, Calif.). Human thymus and murine liver 5'-stretch cDNA libraries cloned in the vector  $\lambda gt 10$  were from Clontech (Palo Alto, Calif.).

A single, isolated colony of C600Hfl E. coli strain was picked and grown in 5 ml of Luria-Bertani medium (LB)+10 mM MgSO<sub>4</sub>+0.2% maltose overnight at 37° C. in a shaker. The bovine library lysate was diluted 1:250,000 and incubated with the C600Hfl bacterial overnight culture and 1×lambda dilution buffer. Next, LB soft top agar+10 mM MgSO<sub>4</sub> was added, and the entire mixture was quickly poured onto 90 mm LB agar+10 mM MgSO<sub>4</sub> plates. The plates were cooled briefly at room temperature to allow the inoculum to soak into the agar before they were incubated at 37° C. for 6–7 hr. The number of clear plaques was counted to determine the titer.

Plaques containing the entire library that had been plated were transferred to nitrocellulose or nylon membranes. The filters were then washed in a 1.5 M NaCl/0.5 M NaOH solution to lyse the cells. This was followed by a 5 min wash in neutralizing solution (1.5 M NaCl/1 M Tris buffer pH 8). Finally, the filters were rinsed in 0.2×SSPE (30 mM NaCl/2 mM sodium phosphate buffer pH 7.2/0.2 mM EDTA) (Sambrook et al., 1992). The filters were then dried and baked in a 80° C. oven for 2 hr to fix the lysed plaques onto the filters.

Radioactive probes were prepared using a random hexamer priming method. Pre-hybridizations and hybridizations were carried out at 42° C. in 50% formamide, 0.25 M sodium phosphate buffer, pH 7.2, 0.25 M NaCl, 7% SDS, 1 mM EDTA.

#### Example 10

40 Specific Methods Used For Library Screening

All the cloning procedures used in obtaining the additional PARG cDNAs and determining their sequences were performed essentially as described for the bovine PARG cDNA and sequence. Human thymus and murine liver 5'-stretch cDNA libraries cloned in the vector  $\lambda gt 10$  were from Clontech (Palo Alto, Calif.).

Library plating and titering: A single, isolated colony of C600Hfl E. coli strain was picked and grown in 5 ml of Luria-Bertani medium (LB)+10 mM MgSO4+0.2% maltose overnight at 37° C. in a shaker. The library lysate was diluted 1:250000 and incubated with the C600Nfl bacterial overnight culture and 1×lambda dilution buffer. Next, LB soft top agar+10 mM MgSO4 was added, and the entire mixture was quickly poured onto 90 mm LB agar+10 mM MgSO4 plates. The plates were cooled briefly at room temperature to allow the inoculum to soak into the agar before they were incubated at 37° C. for 6–7 hr. The number of clear plaques was counted to determine the titer.

Plaque lifts: Plaques containing the entire library that 60 have been plated are transferred to nitrocellulose or nylon membranes. The filters are then washed in a 1.5 M NaCl/0.5 M NaOH solution to lyse the cells. This is followed by a 5 min wash in neutralizing solution (1.5 M NaCl/1 M Tris buffer pH 8). Finally, the filters are rinsed in 0.2×SSPE (30 mM NaCl/2 mM sodium phosphate buffer pH 7.2/0.2 mM EDTA) (66). The filters are then dried and baked in a 80° C. oven for 2 hr to fix the lysed plaques onto the filters.

15

25

30

35

40

Making a radioactive probe and Hybridizations: Radioactive probes were prepared using a random hexamer priming method. Pre-hybridizations and hybridizations were carried out at 42° C. in 50% formamide, 0.25 M sodium phosphate buffer, pH 7.2., 0.25 M NaCl, 7% SDS, 1 mM EDTA. This partial cDNA allowed to design a radiolabeled probe (fragment HindIII-KpnI of 750 bp long) specific to human PARG.

#### Example 11

Screening of a Human Thymus 5'-stretch cDNA Libraries Multiple screenings of a human thymus 5'-stretch cDNA library were performed to complete the cloning of human PARG cDNA. For each screening a new probe was designed and used to screen approximately one million recombinants of the library. During each round of screening, overlapping clones were isolated at high stringency conditions and subcloned into the EcoRI site of pTZ18/19R phagemid using standard techniques. The different positive clones (J5, C, E1, E2, M, M', M", P', P", Of, 02) were characterized by restriction analysis, subcloned into the appropriate restriction sites of pTZ18/19R as necessary and sequenced in both strand using the dideoxynucleotide method. The probe used to complete the cloning of the human cDNA library is shown is SEQ ID NO: 37. Finally, a full-length cDNA sequence was assembled which encodes the human PARG. The sequence of the cDNA encoding human PARG is presented in the sequence listing as SEQ ID NO: 3 and the amino acid sequence of human PARG is presented in the sequence listing as SEQ ID NO: 4.

The human PARG sequence shares extensive amino acid sequence homologies with bovine PARG with more than 89% identity. The sequence similarity is also high at the nucleotide level particularly in the region coding for the protein (174ATG-TGA3104). Surprisingly the 5'-untranslated region of the human sequence displays a completely different sequence with an extensive sequence similarity with highly repeated polymorphic DNA sequences found in the human genome such as Alu repetitive elements or variable number of tandem repeats (VNTR).

#### Example 12

Screening of Mouse Liver 5'-stretch cDNA Libraries

To isolate a PARG cDNA from the mouse liver cDNA library, a probe was designed from the human cDNA clone sequences revealed that PARG was highly conserved between these two species, suggesting that it might also be conserved in the mouse. Based on the restriction map of the human cDNA clone, a region in the human clone was selected, located where the active site of the protein is 50 encoded, that exhibited near identity to its counterpart in the bovine clone. This region, consisting of approximately 800 bases, was excised from the entire human clone by digestion with the restriction endonuclease, HindIII, then purified by agarose gel separation and radiolabeled by random priming.

This probe was used to screen a mouse liver 5'-stretch cDNA library. One clone consistently hybridized with the probe. After two rounds of screening to ensure the purity of the clone the 2.5 kb insert was subcloned into the plasmid pTZ19R and sequenced. Comparison with the sequence of 60 bovine and human PARG showed that this clone had the partial sequence that has extensive similarities to the two other mammalian sequences covering almost entirely the coding region from nucleotide-10 to a few nucleotides from the end of the coding region. A second screen was 65 performed to obtain the missing part of the cDNA using a radioactive probe specifically designed to hybridize with the

region the most 3'of the previous clone to increase the chance to get the missing part of the cDNA.

With this new probe, the same mouse liver cDNA library was screened to obtain a second clone, containing an insert that was about 3 kb. This clone was purified, subcloned arid sequenced. The sequence showed that this second clone starts at amino acids 634, extends toward the stop codon to approximately 900 nucleotides into the 3'non-coding region.

A search of the dBEST database turned up one significant match to a 400 bp fragment cloned from mouse muscularis. 10 This fragment had an exact match to the very tail end of the second clone and exceeded it by 34 bases. This extra extension contained the oligo A sequence as well as the polyadenylation signal. Because there was an exact match, the cDNA sequence was completed using this information coming from the database. The complete cDNA sequence of murine PARG is presented in the Sequence Listing as SEQ ID NO: 5 and SEQ ID NO: 6.

#### Example 13

Obtaining the Drosophila PARG cDNA

20 Among the clones obtained from DNA databases searches were several clones from the Drosophila genome sequencing project (European Drosophila Genome Sequencing Consortium) as well as the Drosophila expression sequence TAG sequencing project (67). The EST clone was requested from the University of California Berkeley and obtained. Because the sequence published in the dBEST database was only partial, its sequence was completed in our laboratory and compared to a genomic sequence, part of the distal X chromosome of Drosophila melanogaster submitted by Murphy et al., August 1997 which presumably contains the gene of Drosophila PARG. The 768 aa shares less homologies with only 40% identity (48% similarity) mainly located in the catalytic domain of the protein. The domain organization of the protein is also very different with an unknown domain of 20 kDa located Carboxy terminus of the highly conserved active domain. (See FIG. 15). The sequence of the cDNA encoding the Drosophila PARG is presented in the Sequence Listing, as SEQ ID NO: 7 and the amino acid sequence of the Drosophila PARG is presented in the Sequence Listing as SEQ ID NO: 8.

#### Example 14

Obtaining the C. elegans PARG Sequence

This sequence has been obtained by searching the Gencoding for PARG. Analysis of the bovine and human 45 Bank database with the mammalian PARG protein sequence. A sequence with PARG similarity was found in the cosmid F20C5 (Accession number: Z68161, SEQ ID NO: 38) derived from the C. elegans genomic DNA (68). The overall sequence conservation (726aa, MW 83129 Da) with the other PARG sequences is as follows: 32% similarity and 22% identity with the mammalian PARG and 39% similarity and 30% identity with the Drosophila PARG. The sequence is presented in the Sequence Listing as SEQ ID NO: 38 (Genbank accession number CEF20C5). SEQ ID NO: 38 contains 12 exons as follows: exon 1 from 3591 to 3635; exon 2 from 3681 to 4121; exon 3 from 5065 to 5235; exon 4 from 5930 to 6152; exon 5 from 6200 to 6267; exon 6 from 7246 to 7338; exon 7 from 7386 to 7553; exon 8 from 7738 to 7853; exon 9 from 8153 to 8435; exon 10 from 8487 to: 8610; exon 11 from 8662 to 8952; and exon 12 from 9383 to: 9540. The coding sequence of the CePARG protein, which is publicly available from Accession number: Z68161, is referred to in the Sequence Listing as SEQ ID NO: 9. Its corresponding amino acid sequence is referred to in the Sequence Listing as SEQ ID NO: 10. The amino acid sequence of the C. elegans PARG is presented on the alignment (FIG. 16)

20

25

30

#### Example 15

Cloning and Overproduction of the Carboxyl-terminus 69 kDa Domain of Bovine PARG (bPARG) in E. coli

As described, above, bovine PARG is encoded by a messenger of 4 kb predicting a protein of 110 kDa, almost twice the size of the purified enzyme (65 kDa). It is also demonstrated that bPARG can be expressed in E. coli as an active enzyme either as a 110 kDa or a 65 kDa protein. This result combined with other evidence implies that the active site of PARG is located in the carboxyl-terminal part of the protein. FIG. 11 is a schematic representation of the different clones we have expressed in bacteria. Among them, only the clone designed to express a protein of 69 kDa starting at the amino acid+380 from the sequence of bovine PARG (bPARG<sub>MNDV</sub>) allowed high level expression as a fusion protein with glutathione-S transferase (GST).

The heterologous expression of bPARG<sub>MNDV</sub> was conducted as represented in FIG. 12. The 1.8 kb cDNA encoding the 69 kDa carboxyl-terminal part of bovine PARG was amplified by PCR and cloned in the EcoRI site of pGEX-2T vector (Pharmacia) in fusion with GST giving the pGEX-2T-bPARG<sub>MNDV</sub> plasmid. E. coli NM522 cells transformed with the pGEX-2T-bPARG<sub>MNDV</sub> were induced by addition of IPTG, resulting in expression of a 90 kDa fusion protein. The fusion protein can be conveniently purified using Glutathione-Sepharose and the  $bPARG_{MNDV}$  can be released by treatment with thrombin while the GST protein remains bound to the beads of GSH-Sepharose. In this manner milligram amounts of protein can be routinely obtained.

#### Example 16

Characterization of the Purified 65 kDa Domain and the Generation of Antibodies

The purified bPARG<sub>MNDV</sub> was characterized by activity gel assays (69) by casting polyacrylamide gels with auto-modified PARP containing [<sup>32</sup>P]ADP-ribose polymers. The 35 results demonstrate that the 65 kDa domain expressed in E. coli contained enzymatic activity migrating with the same apparent molecular weight as the enzyme purified from bovine thymus. Likewise, a construction expressing bPARG<sub>MNDV</sub> domain in SF9 insect cells infected with recombinant baculovirus showed activity migrating with the same apparent molecular weight.

The availability of PARG cDNA allows the development of new molecular tools to study this enzyme in its cellular context. Until this work, it was not possible to obtain PARG 45 in sufficient quantities to produce antibodies against the protein. The antibody raised against bovine PARG is able to recognize PARG from other organisms and, thus, will be valuable in characterizing PARG in vivo under defined physiological conditions in many different organisms.

Antibodies against bPARG<sub>MNDV</sub> overexpressed in E. coli were raised in rabbits using the procedure described by Vaitukaitis (70). Specific high affinity antibodies are generated by administration of small doses of immunogens intradermally over a wide anatomic area of the animal. Rabbits 55 were immunized by three injections of 10–50  $\mu$ g of the Mr 65,000 protein band excised from a preparative SDS polyacrylamide gel. Titer and affinity of sera harvested weekly were followed by conventional methods. Peak affinity was attained in 8 to 10 weeks after primary immunization. For 60 each animal, a preimmune serum was retained as a control.

FIG. 17 shows a Western blot experiment demonstrating the specificity of the resulting PARG anti-serum against the purified bPARG from thymus (lane 1), SF9 protein extract expressing 65 kDa-bPARG<sub>MNDV</sub> in recombinant baculovirus 65 (lane 2), recombinant 65 kDa-PARG<sub>MNDV</sub> purified by treatment with thrombin from GSH-Sepharose (lane 3), and an E.

coli crude extract expressing the fusion protein GST-65 kDa-PARG<sub>MNDV</sub> (lane 4). The pre-immune serum did not show reactivity against any of these fractions even at a low dilution (1/250).

Antibodies directed against the 45 kDa-terminal have also been generated using the same strategy used to generate antibodies against the catalytic domain. This involved the overexpression of the 45 kDa protein domain in E. coli in a construct designed for easy purification, followed by injec-10 tion of the purified protein into rabbits. The heterologous expression of PARG45 was conducted by cloning a part (1.1 kb) of the coding region of the cDNA, generated by PCR amplification of the region located between the ATG(267) codon and nucleotide 1400 in the bovine sequence, into the Eco RI site of the bacterial expression vector pGEX-2T (Pharmacia) in fusion with glutathione-S-transferase. E. coli NM522 cells transformed with this construct were induced by addition of IPTG, resulting in expression of a 72 kDa fusion protein. The fusion protein was purified using glutathione Sepharose and the PARG45 was released by treatment with thrombin, while the GST protein remained bound to the GSH Sepharose beads. In this manner milligram amounts of protein were obtained. Antibodies against PARG45 overexpressed in E. coli were raised in rabbits using the procedure described (71). Specific high affinity antibodies were generated by administration of small doses of immunogens subcutaneously over a wide area of the animal. Rabbits were immunized by three injections of 10-50  $\mu$ g of the 45 kDa protein band excised from a preparative SDS-polyacrylamide gel. Titer and affinity of sera harvested weekly were followed by conventional methods. Peak affinity was attained in 8 to 10 weeks after primary immunization. For each animal, a preimmune serum was retained as a control.

#### Example 17

Conservation of PARG in Tissues and Organisms

Tissue and cell extracts from different origins were homogenized in a cold hypotonic lysis buffer containing a cocktail of protease inhibitors and sonicated. SDS and 40  $\beta$ -mercaptoethanol were added to insure inactivation of any remaining active proteases. Thirty  $\mu g$  of protein from each extract was analyzed by Western-blot using the anti-PARG antibody (FIG. 18). In all of the fractions from bovine tissues, PARG was observed as a major band at 65 KDa. However, less intense, discrete proteins of higher molecular weight were also detected. These proteins may correspond to different forms of PARG; the band of highest molecular weight (about 115 kDa) found in thymus extract likely corresponds to the full-length of PARG (111 kDa) as 50 deduced from the cDNA. Multiple species were detected in cell extracts from mouse fibroblasts, rat PC 12 cells, and SF9 insect cells. This result shows that the sequence of PARG is well conserved phylogenetically. Moreover, the conservation includes multiple molecular forms of the protein.

#### Example 18

Regulation of the Expression of PARG

In the metabolism of ADP-ribose polymers, the activities of PARP and PARG are closely related. Soon after polymer has been synthesized by PARP following DNA damage, it is extensively degraded by PARG. The net result is that the polymer has a very short half life. The close relationship between the two proteins suggests a possible mode of regulation in which PARG expression depends on the presence of PARP. In order to test if the presence or the absence of PARP influences the expression of PARG, a Western Blot experiment was performed with cell extracts from mouse fibroblasts of different PARP genotypes (72).

Cell extract (30  $\mu$ g) from mouse cells with PARP +/+, PARP +/-and PARP-/-genotypes were separated by SDS-PAGE, transferred to a membrane and probed with the antibodies indicated. The results are shown in FIG. 19. In FIG. 19, purified PARG (50 ng) from bovine thymus (lane 1), 30  $\mu$ g of protein of a total extract from PARG recombinant baculovirus infected SF9 cells (lane 2), 150 ng of 10 purified recombinant PARG produced in the bacteria (lane 3) and 30  $\mu$ g of protein of a crude extract from *E. coli* NM522 transformed with pGEX-2T-bPARG<sub>MNDV</sub>2 h after induction by IPTG (lane 4) were separated on a 0.1% SDS-12% polyacrylamide gel, then transferred on nitrocellulose, and incubated with a 1/5000 dilution of the rabbit polyclonal 15 antiserum raised against the 65 kDa domain of bPARG. Proteins were revealed by immunofluorescence with the ECL detection kit (Amersham) and autoradiography. Panel A is a western blot of PARP in cells of varying PARP genotype showing the results of the analysis using anti-  $^{\rm 20}$ PARP antibodies. The amount of PARP expressed varies as expected dependant upon the genotype of the cell line with the PARP-/-cell line producing no detectable amount of PARP. Panel B is western blot of PARG from various tissues using an anti-PARG antibody. It shows that the level of  $^{25}$ PARP is variable. The amount of PARG present in the cell extracts was not dependent upon the PARG genotype of the cell. Further support for this view is provided by the results of the PARG activity assay presented in panel C. The specific activity of PARG detected in the extracts showed no 30 significant difference among the three genotypes.

### Example 19

Preparation PARG Gene Ablation (Knockout) Animals

One embodiment of the present invention is experimental 35 analyzed by PCR and Southern blot. animals with targeted mutations in the PARG gene. These animals may be constructed using standard techniques and the cDNA sequence of the PARG. In the following example, a mouse containing a targeted mutation in the PARG gene is constructed. Those skilled in the art will readily appreciate 40 that other experimental animals, including but not limited to rats, guinea pigs, hamsters and the like, may be constructed using similar techniques. The construction of animals with disrupted genes may be accomplished using standard techcells lines, construction kits, and protocols for knockout mice are available from commercial suppliers such as Stratagene (Stratagene 1999 catalog, La Jolla, Calif.). Commercial services such as Lexicon Genetics (The Woodlands, Tex.) and Chrysalis DNX Transgenic Sciences (Princeton, 50 N.J.) also offer complete ES cell knockout mice production services.

A genomic clone of the murine PARG enzyme may be isolated from a genomic library by screening with a probe derived from the cDNA sequence of PARG. A mouse 129/SV genomic library (Stratagene) containing mouse genomic sequences in  $\lambda$  phage was screened using a 2.49 kb fragment of the mouse PARG cDNA as a probe. A partial restriction map of one positive clone thus isolated, R1, is provided in FIG. 20. The R1 clone contains the genomic 60 sequence corresponding to the 5'-most end of the murine cDNA. The clone was subcloned into pBluescript as three fragments. The plasmid containing the 5'-end contained a 2.8 kb NotI-EcoRI fragment and was designated p2.8R. The fragment containing the central portion contained a 3.5 kb 65 and illustration. It should be appreciated that certain obvious EcoRI fragment and was designated p3.5R. The plasmid containing the 3'-end of the gene contained a 7,0 kb EcoRI-

NotI fragment and was designated 7.0R. Sequencing the resulting plasmids revealed that p2.9R contained no sequences corresponding to the cDNA, p3.5R contains a 1.5 kb promoter region and/or untranslated region and exon 1 coding for 72 amino acids including the initiation ATG codon and p7.0R contains at least 4 additional exons. Gene targeting vectors may be constructed using both p3.5R and p7.0R.

A gene targeting vector may contain one or more selection genes flanked by genomic sequences. The targeting vector is introduced into the genome by homologous recombination resulting in the incorporation of the selection gene into the genome of the cell. The mouse PARG gene was targeted using a "conditional" inactivation procedure outlined in FIG. 21. This approach allows the production of viable animals even if the disrupted gene results in a lethal phenotype since the gene is not disrupted until a second "conditional" recombination event is induced.

A lox-P sequence may be inserted into the first intron. A cassette expressing the neomycin resistance gene (neo) and the thymidine kinase gene (TK) flanked by two additional lox-P sites may be placed in intron 2. In the presence of Cre recombinase, recombination will occur between two lox-P sites thereby deleting the genomic sequences present between the sites. A MCI-DTA cassette is ligated at the 3'-end of the vector to reduce random integration of the vector into the genome.

The targeting vector may be introduced into embryonic stem cells by any method known to those skilled in the art such as transfection, lipofection or electroporation. In a preferred embodiment, the targeting vector will be introduced into embryonic stem cells by electroporation. After homologous recombination, cells containing the neo gene will be selected for using G418. Selected cells will then be

To generate mutant alleles of PARG, the positive embryonic stem cell clones identified will be transfected with a plasmid expressing Cre recombinase. The action of Cre recombinase will result in three different mutant alleles. Mutant allele I contains a deletion in exon 2 but still maintains the selection genes neo and TK. Mutant allele II contains the genomic sequence for exon 2 flanked by two lox-P sites (exon 2 is said to be "floxed") and does not contain the selection genes. Mutant allele III has a deletion niques such as those described by Moreadith (73). Further, 45 of the genomic sequences and does not contain the selection genes.

> Mice containing each of the three mutant alleles may be constructed by microinjecting embryonic stem cells containing the mutant allele into blastocytes resulting in the production of chimeric and mutant mice. Mice homozygous in mutant allele I or III will be null mutants in that they will be unable to express a functional PARG enzyme due to the loss of required genomic sequences. In the absence of Cre recombinase, mice containing mutant allele II will express a wild type protein. In the presence of the Cre recombinase, the PARG will lose exon 2, thus producing an inactive protein. To inactivate the gene, these mice will be bred to mice expressing Cre recombinase under the control of a tissue specific promoter. This will result in mice expressing PARG in some tissues and not expressing PARG in others. Mice homozygous in mutant allele II, will be valuable for evaluating the role of PARG in specific tissues.

> Although the present invention has been described with reference to certain examples for purposes of clarification improvements and modifications can be practiced within the scope of the appended claims and their equivalents. Other

50

65

embodiments and uses of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein.

All U.S. Patents GenBank sequence listings, and other references noted herein for whatever reason are specifically incorporated by reference. The specification and examples should be considered exemplary only with the true scope and spirit of the invention indicated by the following claims.

- 1. Miwa, M. et al. (1971) J. Biol. Chem. 246, 6362-6364; Ueda, K. et al. (1972) Biochem. Biophys. Res. Commun. 10 46, 516-523
- 2. Oka, J. et al. (1984) J. Biol. Chem. 259, 986-995.
- 3. Gaal, J. et al. (1987) Trends in Biol. Sci., 12, 129.
- 4. Nudka, N. et al. (1980) Eur. J. Biochem. 105, 525-530; Jacobson, E. et al. (1985) Carcinogenesis 6, 715-718; K 15 üpper, J. et al. (1990) J. Biol. Chem. 265, 18721-18724; Ding, R. et al. (1992) J. Biol. Chem. 267, 12804-12812.
- 5. Jacobson, E. et al. (1985) in ADP-ribosylation of Proteins (Althaus, F. R., Hilz, H., and Shall, S., eds) pp. 277-283, Springer-Verlag, Berlin; Lubet, R. et al. (1986) Carcino- 20 genesis 7, 71-75; Kasid, U. et al. (1986) Carcinogenesis 7, 327–330.
- 6. Berger, N. (1985) Radiat. Res. 101, 4-15.
- 7. Kaufmann, S. et al. (1993) Cancer Res. 53,3976-3985; Lazebnik, Y. et al. (1994) Nature :371, 346-347.
- 8. de Murcia, G. et al. (1994) Trends Biochem. Sci. 19, 172 - 176.
- 9. BioWorld Today, Apr. 29, 1994, p. 3.
- 10. Thomassin, H. et al. (1990) Nucleic Acids Res. 18, 4691-4694.
- 11. Karlin, Samuel and Stephen F. Altschul (1993). Proc. Natl. Acad. Sci. USA 90:5873-7
- 12. Henikoff and Henikoff Proc. Natl. Acad. Sci. USA 89:10915-19, 1992
- 13. Altschul, Stephen F. (1991). J. Mol. Biol. 219:555-65. 35
- 14. Cohen, J. S., 1989; Weintraub, H. M., 1990
- 15. N. Sarver et al., 1990
- 16. Orlandi, R. et al., (1989) Proc. Natl. Acad. Sci. 86, 3833-3837; Winter, G et al., (1991) Nature 349, 293-299
- www.appleton-lange.com.
- 18. e.g., at least, but not limited to U.S. Pat. Nos. 5,797,870, 5,804,383, 5,670,161, 5,645,829, 5,741,486, 5,836,905, 5,843,069, 5,827,216, 5,871,464, 5,702,384, 5,810,888, 5,787,900, 5,752,515, 5,674,192, 5,658,955, 5,656,465, 45 59. Brochu, G. et al. (1994) Anal. Biochem. 218, 265–272. 5,547,932, 5,873,904 5,792,651, 5,772,888, 5,641,750, 5,641,749, and 5,626,561
- 19. Kaltenbock, B. et al. (1998) Biotechniques, 24, 202-206.
- 20. Moran, P. et al. (1998) Biotechniques, 24, 206-212.
- 21. Orita, M. et al. (1989) PNAS USA, 86, 2766-2770.
- 22. Liu, Q. et al. (1998) Biotechniques, 24, 140-147.
- 23. Proceeding from the Sixth International Symposium on Human Identification 1995 (ISBN 1-882274-55-5).
- 24. Kohler and Milstein, Nature, 256:495-497 (1975).
- 25. Geysen, et al. (1984) Proc. Natl. Acad. Sci. USA 55 81:3998-4002.
- 26. Ménard, et al. (1987) Biochem. Cell Biol. 65, 668-673.
- 27. Hatakeyama, K. et al. (1986) J. Biol. Chem. 261, 14902-14911.
- 28. Thomassin, H. et al. (1990) Nucleic Acids Res. 18, 60 4691-4694.
- 29. Ménard, L. et al. (1987) Biochem. Cell Biol. 65, 668-673.
- 30. Bradford, M. (1976) Anal. Biochem. 72, 248-254.
- 31. Laemmli, U. (1970) Nature 227, 680-685.
- 32. Althaus, F. et al. (1987) Molecular Biology, Biochemistry and Biophysics, Vol. 37, Springer-Verlag, Berlin.

- 33. Mead, D. et al. (1986) Protein Eng. 1, 67-74.
- 34. Shaw, et al. (1986) Cell 46, 659-667.
- 35. Kozak (1987) Nucleic Acids Res. 15, 8125-8148.
- 36. Wilson, et al. (1994) Nature (London) 368, 32-38.
- 37. Brendel, et al. (1992) Proc. Natl. Acad. Sci. USA 89, 2002-2006.
- 38. Robbins, et al. (1991) Cell 64, 615-623.
- 39. Schreiber, et al. (1992) EMBO J. 11, 3263-3269.
- 40. Uchida, K. et al. (1987) Biochem. Biophys. Res. Commun. 148,617-622; Cherney, B. et al. (1987) Proc. Natl. Acad. Sci. U.S.A. 84, 8370-8374; Kurosaki, T. et al. (1987) J. Biol. Chem. 262, 15990-15997.
- 41. Huppi, K. et al. (1989) Nucleic Acids Res. 17, 3387-3401.
- 42. Saito, I. et al. (1990) Gene (Amst.) 90, 249-254.
- 43. Ittel, M.-E. et al. (1991) Gene (Amst.) 102, 157-164.
- 44. Saulier-Le Drean, B. (1992) Poly(ADP-ribose) Polymerase in Xenopus lae-vis, Ph.D. thesis, Université De Rennes, France.
- 45. Uchida, K. et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 3481-3485.
- 46. Masutani, M. et al. (1994) Eur. J. Biochem. 220, 607-614.
- 25 47. Schreiber, et al. (1992) EMBO J. 11, 3263-3269.
  - 48. Lazebnik, et al. (1994) Nature (London) 371, 346-347. 49. Brochu, et al. (1994) Biochem. Biophys. Acta 1219, 342-350.
  - 50. Tanuma, et al. (1986) J. Biol. Chem. 261, 965-969; Uchida, et al. (1993) J. Biol. Chem. 268, 3194-3200.
  - 51. Maruta, et al. (1991) Biochemistry 30, 5907-5912.
  - 52. Ménard, L. et al. (1987) Biochem. Cell Biol. 65, 668-673.
  - 53. Ménard, L. et al. (1987) Biochem. Cell Biol. 65, 668-673.
  - 54. Slama, J. et al. (1995) J. Med. Chem. 38, 389-393; Slama, J. et al. (1995) J. Med. Chem. 38, 4332-4336.
  - 55. Slama, J. et al. (1995) J. Med. Chem. 38, 389-393; Slama, J. et al. (1995) J. Med. Chem. 38, 4332-4336.
- 17. R. Sobol and K. Scanlon eds., available at 40 56. Ménard, L. et al. (1987) Biochem. Cell Biol. 65, 668-673.
  - 57. Althaus, F. et al. (1987) Molecular Biology, Biochemistry and Biophysics, Vol. 37, Springer-Verlag, Berlin.
  - 58. Brochu, G. et al. (1994) Anal. Biochem. 218, 265-272.

  - 60. Moreadith, et al. (1997) J. Mol. Med. 75, 208-216.
  - 61. Tanuma, et al. (1986) J. Biol. Chem. 261, 965-969 and Uchida, et al. (1993) J. Biol. Chem. 268, 3194-3200.
  - 62. Hatakeyama, et al. (1986) J. Biol. Chem. 261, 14902-14911; Thomassin, et al. (1990) Nucleic Acids Res. 18, 4691-4694; and Maruta, et al. (1991) Biochemistry 30, 5907-5912.
  - 63. Sambrook, et al. (1992) MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory Cold Spring harbor, N.Y.
  - 64. Feinberg, et al. (1983) Anal. Biochem. 132, 6-13.
  - 65. Boguski, 1995
  - 66. Sambrook, et al. (1992) MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory Cold Spring Harbor, N.Y.
  - 67. BDGP/HHMI Drosophila EST Project, University of California Berkeley, EST@fruitfly.berkeley.edu
  - 68. Nematode Sequencing Project, Sanger Centre, Hinzton, Cambridge CB101RQ, England and Department of Genetics, Washington University, St. Louis, Mo. 63110, USA. E-mail: jes@sanger.ac.uk
  - 69. Brochu G. et al. (1994) Anal. Biochem. 218, 265-272.

70. Vaitukaitis (1981) Methods in Enzymology 73, 46–52.71. Vaitukaitis (1981) Methods in Enzymology 73, 46–52.

44

72. Wang, et al. (1995) Genes & Dev. 9, 509–520.
73. Moreadith, et al. (1997) J. Mol. Med. 75, 208–216.

	SEQUENCE LIS	TING						
<160> NUMBER OF SEQ ID NO	os: 38							
<pre>&lt;210&gt; SEQ ID NO 1 &lt;211&gt; LENGTH: 4070 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Bos tauru &lt;220&gt; FEATURE:</pre>	18							
<400> SEQUENCE: 1								
accggaaagt gaacgaagcc cga	aatcagaa cggctcatcc	tgaggctggt a	gggtgccgg	60				
tggaagaggg aaggcaggcg tct	aggatagg gcctggttcg	ggaggctgtc a	gagcaggag	120				
ctgcagaagc agtcagcggc aga	aggggggca tggtgccggg	aggcaccgag g	aggggggcgc	180				
agtccgtccc tcccagggtt agt	-gaatgag gctctacgcc	cgggctggcc c	ggagactca	240				
gtgctgcggg tcccagcatg agt	cgcgggcc ccggctgtga	gccctgcacc a	agcgacccc	300				
gctgggacgc cgctgcaact tct	ccgccgg ccgcctcgga	cgcccggagc t	tccccggca	360				
ggcagaggcg cgtcctcgat tco	caaggacg ctccggtgca	gttcagggtc c	cgccgtcct	420				
cgtcaggctg cgccctgggc cg	Jgcgggac agcaccgagg	cagegeeace t	ctcttgttt	480				
tcaaacagaa gactataacc agt	tggatgg acactaaagg	aatcaagaca g	ttgaatcag	540				
aaagtttgca tagtaaagaa aac	caacaata caagagaaga	atccatgatg a	gttctgtac	600				
aaaaagataa cttttatcaa cat	aacatgg aaaaattaga	aaatgtttct c	agctaggtt	660				
ttgataagtc accagttgaa aaa	aggtacac agtatttgaa	gcagcatcag a	ctgcggcta	720				
tgtgtaagtg gcagaatgaa ggo	gccacact cagaacggct	tttggaaagt g	aacctccag	780				
cggtaactct ggtaccagag cao	yttcagta atgctaatgt	cgatcagtcg t	ccccaaagg	840				
atgatcacag tgacacaaat agt	cgaggaga gtagagataa	tcagcagttt t	tgacacatg	900				
taaagcttgc gaatgcaaag cao	yacgatgg aagatgaaca	gggcagagaa g	ccagaagcc	960				
accagaagtg tggcaaggct tgo	ccatcctg cagaagcctg	tgcagggtgt c	agcaggagg	1020				
agacagacgt ggtgtccgag ago	ecccttgt cggacactgg	ctctgaggat g	ttggtactg	1080				
gactgaaaaa tgccaacaga tto	gaatagac aagaaagtag	tctaggaaat t	ctcctccat	1140				
ttgagaaaga aagtgaacct gag	ytcaccaa tggatgtaga	taattccaaa a	atagttgtc	1200				
aggattcaga agcagatgaa gaq	gacaagtc caggttttga	tgaacaggaa g	atagcagtt	1260				
ctgctcaaac agcaaataaa cct	tcaaggt tccaaccaag	agaagctgac a	ctgagttga	1320				
ggaagcggtc ctctgctaag gga	aggtgaga ttcgattaca	tttccaattt g	aaggaggag	1380				
agagtcgagc tggaatgaat gat	gtgaatg ccaaacgacc	tggaagtact t	ctagcctga	1440				
atgtagagtg cagaaattct aag	gcaacatg ggagaaagga	ttctaaaatc a	cagatcatt	1500				
tcatgagagt gcccaaagca gag	ggacaaaa gaaaagaaca	atgtgaaatg a	aacatcaaa	1560				
gaacagaaag gaagatccct aaa	atacattc cacctcacct	ttctccagat a	agaaatggc	1620				
ttggaactcc tattgaggag ato	yaggagaa tgccaaggtg	tgggatccgg c	tgcctccct	1680				
tgagaccatc tgccaatcac aca	agtgacta ttcgggtaga	tcttttgcga a	taggagaag	1740				
ttoctaaacc tttoccaaca cat	tttaaag atttgtggga	caacaagcat g	ttaagatgc	1800				
cttgttcaga acaaaacttg tac	ccctgtgg aagatgagaa	tggtgagcga g	ctgcaggca	1860				

## -continued

gccggtggga	actcattcag	actgcacttc	tcaacaggct	cactcggccc	c agaacctga	1920
aggatgctat	tctgaagtac	aatgtggcat	attctaagaa	atgggacttt	a cagctttga	1980
ttgatttctg	ggataaggta	ctagaagaag	cagaagctca	acacttgtat	c agtccatct	2040
tgcctgatat	ggtgaaaatt	gcactctgtc	tgccaaatat	ttgtacccag	c caataccac	2100
tcctgaaaca	gaagatgaat	cattccatca	caatgtcaca	ggaacagatt	g ccagtcttt	2160
tagctaatgc	tttcttctgc	acgtttccac	gacgcaatgc	caagatgaaa	t cagagtatt	2220
ccagttatcc	agatattaac	ttcaatcggt	tgtttgaagg	acgttcatca	a ggaaaccag	2280
agaagcttaa	aacgctcttc	tgctacttta	gaagagtcac	agagaaaaaa	c ccactgggt	2340
tggtgacatt	cacaagacag	agtcttgaag	attttccaga	gtgggaaaga	t gtgaaaaac	2400
tcctgactcg	actgcatgtc	acttacgaag	gtaccataga	aggaaacggc	c agggcatgc	2460
tacaggtgga	ttttgcaaac	cgtttcgttg	gaggtggtgt	aaccagtgca	g gacttgtgc	2520
aagaagaaat	ccgcttttta	atcaaccctg	agttgattgt	ttcacggctc	t tcactgagg	2580
tgctggatca	caatgaatgt	cttatcatca	caggtactga	gcagtacagt	g aatacacag	2640
gctatgccga	aacataccgc	tgggcccgga	gccatgaaga	caggagcgaa	a gggacgact	2700
ggcagaggcg	cacgactgag	atcgtcgcca	tcgacgccct	ccacttcaga	c gctacctcg	2760
accagtttgt	gcccgagaag	atcagacggg	agcttaacaa	ggcttactgt	g gatttcttc	2820
gtcctggagt	ttcttcagag	aacctgtctg	cagtggctac	aggaaactgg	g gctgtggtg	2880
cctttggggg	tgatgctaga	ctaaaagcct	taatacagat	cctggcagct	g ctgtagctg	2940
agcgagacgt	ggtttatttc	acctttgggg	actcagaact	gatgagagac	a tttacagca	3000
tgcatacatt	cctcactgag	aggaaactga	ctgttggaga	agtatataag	c tgctgctac	3060
gatattacaa	tgaagaatgc	agaaactgct	ccacccccgg	accagacatc	a agctttatc	3120
cattcatata	ccatgcagtt	gagtcctgta	cacagaccac	caaccagccg	g gacaaagga	3180
cgggggcctg	aggagccaag	tgactagacg	ctccccactt	gtgtaacaag	a aggtgtgac	3240
gtgtgaactg	acatgatatc	catgtgtata	taatccgcgt	ttgtaggcaa	g gatgcagtc	3300
ccttccgccc	atgcagctgt	cagtacatct	gcgcctcctc	catcccgact	t acatagact	3360
gagacatact	ttgtttcttt	ttttttctat	ttcagccctg	attcttttat	t tttctttct	3420
tttgcccatc	agacttcttg	tgaaatttca	tcagagtttg	tgctcagcct	g gcaggtgtc	3480
ttttttgatg	cctaaatata	caaatcacct	ctgcagctag	cagatgccac	g gaaggtggt	3540
ggaaccctag	gagctgtaac	tgagtctgct	gcagatctcc	ctctgagcct	c tcaccccta	3600
ccctattatc	attgtggtgg	tggaggtttt	ttgatttttg	aaataagagt	t gggtttgtt	3660
aaataataca	gatctcctag	gttaagagtt	ttatatttaa	gaatactttt	c aaaaagtta	3720
ttttgagata	tcacctttat	ttgtaatggt	aatttgcctg	tcccttttcc	c ctgatcaat	3780
ttgtattgac	tgtttttgga	aattgaccca	aatgaaagga	aatatgagaa	t aagagtttc	3840
ccaaatggtg	tttaaaaaca	aacaggttca	agacacgcga	aggacctcgt	t tcctgggat	3900
ttttttttt	tttcttttt	tgaattagga	ttattgtttg	ttccttggtg	c ttgagacat	3960
attcatataa	ccaaagttta	ggaactggga	acttcgtggt	gatttgtaca	t attgaagtt	4020
tctctggtac	tcaaaggtta	tgtagttaat	aaattttcat	taacaaaaaa		4070

<210> SEQ ID NO 2 <211> LENGTH: 977 <212> TYPE: PRT <213> ORGANISM: Bos taurus

			-concinaca	
<220> FEATURE:				
<400> SEQUENCE:	2			
Met Ser Ala Gly 1	7 Pro Gly Cys 5	s Glu Pro Cys 10	s T hr Lys Arg Pro Arg Trp 15	
Asp Ala Ala Ala 20	a Thr Ser Pro	o Pro Ala Ala 25	a S er Asp Ala Arg Ser Phe 30	
Pro Gly Arg Glr 35	n Arg Arg Val	Leu Asp Ser 40	r L ys Asp Ala Pro Val Gln 45	
Phe Arg Val Pro 50	) Pro Ser Ser 55	: Ser Gly Cys	s A la Leu Gly Arg Ala Gly 60	
Gln His Arg Gly 65	y Ser Ala Thr 70	: Ser Leu Val	l P he Lys Gln Lys Thr Ile 75 80	
Thr Ser Trp Met	Asp Thr Lys 85	s Gly Ile Lys 90	s T hr Val Glu Ser Glu Ser 95	
Leu His Ser Lys 100		n Asn Thr Arg 105	g G lu Glu Ser Met Met Ser 110	
Ser Val Gln Lys 115	s Asp Asn Phe	e Tyr Gln His 120	s A sn Met Glu Lys Leu Glu 125	
Asn Val Ser Glr 130	n Leu Gly Phe 135		r P ro Val Glu Lys Gly Thr 140	
Gln Tyr Leu Lys 145	s Gln His Glr 150	n Thr Ala Ala	a M et Cys Lys Trp Gln Asn 155 160	
Glu Gl <b>y</b> Pro His	Ser Glu Arc 165	g Leu Leu Glu 170	u S er Glu Pro Pro Ala Val ) 175	
Thr Leu Val Pro 180		e Ser Asn Ala 185	a A sn Val Asp Gln Ser Ser 190	
Pro Lys Asp Asp 195	) His Ser Asp	o Thr Asn Ser 200	r G lu Glu Ser Arg Asp Asn 205	
Gln Gln Phe Leu 210	n Thr His Val 215		a A sn Ala Lys Gln Thr Met 220	
Glu Asp Glu Glr 225	n Gly Arg Glu 230	ı Ala Arg Ser	r H is Gln Lys Cys Gly Lys 235 240	
Ala Cys His Pro	Ala Glu Ala 245	a Cys Ala Gly 250	y C ys Gln Gln Glu Glu Thr 255	
Asp Val Val Sen 260		b Leu Ser Asp 265	o T hr Gly Ser Glu Asp Val 270	
Gly Thr Gly Leu 275	l Lys Asn Ala	a Asn Arg Leu 280	ı A sn Arg Gln Glu Ser Ser 285	
Leu Gly Asn Ser 290	Pro Pro Phe 295	-	ı S er Glu Pro Glu Ser Pro 300	
Met Asp Val Asp 305	Asn Ser Lys 310	s Asn Ser Cys	s G ln Asp Ser Glu Ala Asp 315 320	
Glu Glu Thr Sei	Pro Gly Phe 325	e Asp Glu Gln 330	n G lu Asp Ser Ser Ser Ala ) 335	
Gln Thr Ala Asr 340	-	r Arg Phe Gln 345	n P ro Arg Glu Ala Asp Thr 350	
Glu Leu Arg Lys 355	arg Ser Ser	Ala Lys Gly 360	y G ly Glu Ile Arg Leu His 365	
Phe Gln Phe Glu 370	n Gly Gly Glu 375		a G ly Met Asn Asp Val Asn 380	
Ala Lys Arg Pro 385	Gly Ser Thr 390	r Ser Ser Leu	ı A sn Val Glu Cys Arg Asn 395 400	

-continued

Ser	Lys	Gln	His	Gly 405	Arg	Lys	Asp	Ser	L <b>y</b> s 410	Ι	le	Thr	Asp		Phe 415	Met
Arg	Val	Pro	L <b>y</b> s 420	Ala	Glu	Asp	Lys	Arg 425	Lys	G	lu	Gln		Glu 430	Met	Lys
His	Gln	Arg 435	Thr	Glu	Arg	Lys	Ile 440	Pro	Lys	т	yr		Pro 445	Pro	His	Leu
Ser	Pro 450	Asp	Lys	Lys	Trp	Leu 455	Gly	Thr	Pro	I		Glu 160	Glu	Met	Arg	Arg
Met 465	Pro	Arg	Сув	Gly	Ile 470	Arg	Leu	Pro	Pro		eu 75	Arg	Pro	Ser	Ala	Asn 480
His	Thr	Val	Thr	Ile 485	Arg	Val	Asp	Leu	Leu 490	A	rg	Ile	Gly		Val 495	Pro
Lys	Pro	Phe	Pro 500	Thr	His	Phe	Lys	<b>A</b> sp 505	Leu	т	rp	Asp		Lys 510	His	Val
Lys	Met	Pro 515	Сув	Ser	Glu	Gln	Asn 520	Leu	Tyr	Ρ	ro		Glu 525	Asp	Glu	Asn
Gly	Glu 530	Arg	Ala	Ala	Gly	Ser 535	Arg	Trp	Glu	L		Ile 540	Gln	Thr	Ala	Leu
Leu 545	Asn	Arg	Leu	Thr	Arg 550	Pro	Gln	Asn	Leu		<b>ys</b> 55	Asp	Ala	Ile	Leu	L <b>y</b> s 560
Tyr	Asn	Val	Ala	T <b>y</b> r 565	Ser	Lys	Lys	Trp	Asp 570	Ρ	he	Thr	Ala		Ile 575	Asp
Phe	Trp	Asp	Lys 580	Val	Leu	Glu	Glu	Ala 585	Glu	A	la	Gln		Leu 590	Tyr	Gln
Ser	Ile	Leu 595	Pro	Asp	Met	Val	L <b>y</b> s 600	Ile	Ala	L	eu		Leu 505	Pro	Asn	Ile
Сув	Thr 610	Gln	Pro	Ile	Pro	Leu 615	Leu	Lys	Gln	L		Met 20	Asn	His	Ser	Ile
Thr 625	Met	Ser	Gln	Glu	Gln 630	Ile	Ala	Ser	Leu		eu 35	Ala	Asn	Ala	Phe	Phe 540
Сув	Thr	Phe	Pro	Arg 645	Arg	Asn	Ala	Lys	Met 650	L	уs	Ser	Glu		Ser 655	Ser
Tyr	Pro	Asp	Ile 660	Asn	Phe	Asn	Arg	Leu 665	Phe	G	lu	Gly		Ser 670	Ser	Arg
Lys	Pro	Glu 675	Lys	Leu	Lys	Thr	Leu 680	Phe	Cys	т	yr		Arg 585	Arg	Val	Thr
Glu	Lys 690	Lys	Pro	Thr	Gly	Leu 695	Val	Thr	Phe	т	-	Arg 700	Gln	Ser	Leu	Glu
Asp 705	Phe	Pro	Glu	Trp	Glu 710	Arg	Cys	Glu	Lys		eu 15	Leu	Thr	Arg	Leu	His 720
Val	Thr	Tyr	Glu	Gly 725	Thr	Ile	Glu	Gly	Asn 730	G	ly	Gln	Gly		Leu 735	Gln
Val	Asp	Phe	Ala 740	Asn	Arg	Phe	Val	Gly 745	Gly	G	ly	Val		Ser 750	Ala	Gly
Leu	Val	Gln 755	Glu	Glu	Ile	Arg	Phe 760	Leu	Ile	A	sn		Glu 765	Leu	Ile	Val
Ser	Arg 770	Leu	Phe	Thr	Glu	Val 775	Leu	Asp	His	A		Glu 780	Суз	Leu	Ile	Ile
Thr 785	Gly	Thr	Glu	Gln	T <b>y</b> r 790	Ser	Glu	Tyr	Thr		1y 95	Tyr	Ala	Glu	Thr	Т <b>у</b> г 300
Arg	Trp	Ala	Arg	Ser 805	His	Glu	Asp	Arg	Ser 810	G	lu	Arg	Asp		Trp 815	Gln
Arg	Arg	Thr	Thr	Glu	Ile	Val	Ala	Ile	Asp	A	la	Leu	His	Phe	Arg	Arg

-continued	
820 825 830	
Tyr Leu Asp Gln Phe Val Pro Glu Lys Ile A rg Arg Glu Leu Asn Lys 835 840 845	
Ala Tyr Cys Gly Phe Leu Arg Pro Gly Val S er Ser Glu Asn Leu Ser 850 855 860	
Ala Val Ala Thr Gly Asn Trp Gly Cys Gly A la Phe Gly Gly Asp Ala 865 870 875 880	
Arg Leu Lys Ala Leu Ile Gln Ile Leu Ala A la Ala Val Ala Glu Arg 885 890 895	
Asp Val Val Tyr Phe Thr Phe Gly Asp Ser G lu Leu Met Arg Asp Ile 900 905 910	
Tyr Ser Met His Thr Phe Leu Thr Glu Arg L ys Leu Thr Val Gly Glu 915 920 925	
Val Tyr Lys Leu Leu Arg Tyr Tyr Asn G lu Glu Cys Arg Asn Cys 930 935 940	
Ser Thr Pro Gly Pro Asp Ile Lys Leu Tyr P ro Phe Ile Tyr His Ala 945 950 955 960	
Val Glu Ser Cys Thr Gln Thr Thr Asn Gln P ro Gly Gln Arg Thr Gly 965 970 975	
Ala	
<210> SEQ ID NO 3 <211> LENGTH: 4069 <212> TYPE: DNA <213> ORGANISM: Homo sapiens	
<220> FEATURE:	
<400> SEQUENCE: 3	
ggcgtctggg aagtgaggag cgtctctgcc tggcagaggc tgcaatctct g cactttggg	60
gggccaaggc aggcgctgag aaggacgcgc agtccatctc tctcaggtta g tgaaatgag	120
gctctccgcg gggccggccc ggggacagtg cgctgctggt cccagcatga a tgcgggccc	180
cggctgtgaa ccctgcacca aagcgacccg ctgggggggcc gctacaactt c gccggctgc	240
ttcggacgcc cggagctttc cgagcaggca gaggcgcgtc ctcgacccca a ggacgctca	300
cgtgcagttc agggtcccac cgtcctcgcc agcctgcgtc ccagggcagg c gggacagca	360
cagaggcagc gccacctcgc ttgttttcaa acaaaagact attaccagtt g gatggacac	420
taaaggaatc aagacagcgg aatcagaaag tttggatagt aaagaaaaca a caatacaag	480
aatagaatcc atgatgagtt ctgtacaaaa agataacttt taccaacata a tgtagaaaa	540
attagtaaat gtttctcagc taagtcttga taagtcactc actgaaaaaa g tacacagta	600
tttgaaccag catcagactg cagcaatgtg taagtggcaa aatgaaggga a acacacgga	660
gcagcttttg gaaagtgaac ctcaaacagt aaccctggta ccagagcagt t tagtaatgc	720
taacattgat cggtcacctc aaaatgatga tcacagtgac acagatagtg a agagaatag	780
agacaatcaa cagtttctca caactgtaaa gcttgcaaat gcaaagcaga c tacggaaga	840
tgaacacgcc agagaagcca aaagccacca gaagtgcagc aagtcttgcc a tcctgggga	900
agactgtgca agttgtcagc aagatgagat agacgtggtg ccaaagagtc c attgtcaga	960
tgttggctct gaggatgttg gtactgggtc aaaaaatgac aacaaattga t tagacaaga	1020
aagttgccta ggaaattctc ctccatttga gaaggaaagt gaacccgaat c accgatgga	1080
tgtggataat tctaaaaata gttgtcaaga ctcagaagca gatgaggaga c aagtccagg	1140
ttttgatgaa caagaagatg gtagtteete eeaacagea aataaaeett e aaggtteea	1200

agcaagagac	gctgacattg	aatttaggaa	acggtactct	actaagggcg	g	tgaagttag	1260
attacatttc	caatttgaag	gaggagagag	tcgcactgga	atgaatgatt	t	aaatgctaa	1320
actacctgga	aatatttcta	gcctgaatgt	agaatgcaga	aattctaagc	a	acatggaaa	1380
aaaggattct	aaaatcacag	atcatttgat	gagactgccc	aaagcagagg	a	cagaagaaa	1440
agaacagtgg	gaaaccaaac	atcaaagaac	agaaaggaag	atccctaaat	a	cgttccacc	1500
tcacctttct	ccagataaga	agtggcttgg	aactcccatt	gaggagatga	g	aagaatgcc	1560
tcggtgtggg	atccggctgc	ctctcttgag	accatctgcc	aatcacacag	t	aactattcg	1620
ggtagatctt	ttgcgagcag	gagaagttcc	taaacctttt	ccaacacatt	a	taaagattt	1680
gtgggataac	aagcatgtta	aaatgccttg	ttcagaacaa	aatttgtacc	С	agtggaaga	1740
tgagaatggt	gagcgaactg	cggggagccg	gtgggagctc	attcagactg	С	acttctcaa	1800
caaatttaca	cgaccccaaa	acttgaagga	tgctattctg	aaatacaatg	t	ggcatattc	1860
taagaaatgg	gactttacag	ctttgatcga	tttctgggat	aaggtacttg	a	agaagcaga	1920
agctcaacat	ttatatcagt	ccatcttgcc	tgatatggtg	aaaattgcac	t	ctgtctgcc	1980
aaatatttgc	acccagccaa	taccactcct	gaaacagaag	atgaatcatt	с	catcacaat	2040
gtcgcaggaa	cagattgcca	gtcttttagc	taatgctttc	ttctgcacat	t	tccacgacg	2100
aaatgctaag	atgaaatcgg	agtattctag	ttacccagac	attaacttca	a	tcgattgtt	2160
tgagggacgt	tcatcaagga	aaccggagaa	acttaaaacg	ctcttctgct	a	ctttagaag	2220
agtcacagag	aaaaaccta	ctgggttggt	gacatttaca	agacagagtc	t	tgaagattt	2280
tccagaatgg	gaaagatgtg	aaaaaccctt	gacacgattg	catgtcactt	a	cgaaggtac	2340
catagaagaa	aatggccaag	gcatgctaca	ggtggatttt	gcaaatcgtt	t	tgttggagg	2400
tggtgtaacc	agtgcaggac	ttgtgcaaga	agaaatccgc	ttttaatca	a	tcctgagtt	2460
gattatttca	cggctcttca	ctgaggtgct	ggatcacaat	gaatgtctaa	t	tatcacagg	2520
tactgagcag	tacagtgaat	acacaggcta	tgctgagaca	tatcgttggt	С	ccggagcca	2580
cgaagatggg	agtgaaaggg	acgactgcga	gcggcgctgc	actgagatcg	t	tgccatcga	2640
tgctcttcac	ttcagacgct	acctcgatca	gtttgtgcct	gagaaaatga	g	acgcgagct	2700
gaacaaggct	tactgtggat	ttctccgtcc	tggagtttct	tcagagaatc	t	ttctgcagt	2760
ggccacagga	aactggggct	gtggtgcctt	tgggggtgat	gccaggttaa	a	agccttaat	2820
acagatattg	gcagctgctg	cagctgagcg	agatgtggtt	tatttcacct	t	tggggactc	2880
agaattgatg	agagacattt	acagcatgca	cattttcctt	actgaaagga	a	actcactgt	2940
tggagatgtg	tataagctgt	tgctacgata	ctacaatgaa	gaatgcagaa	a	ctgttccac	3000
ccctggacca	gacatcaagc	tttatccatt	catataccat	gctgtcgagt	с	ctgtgcaga	3060
gaccgctgac	cattcagggc	aaaggacagg	gacctgagga	gccgagcgaa	t	agcatctcc	3120
tcccacctcc	caccagagac	gtcctgtttg	agctgtcagg	tgtaatatat	g	aattgactt	3180
aagttaatat	aaatgtgtac	ataatccaca	tttgtagtca	aggacgcaat	с	tcttccaca	3240
catgtgcagt	tgtcagttgg	tacatctaaa	ctccctccat	cctgactcac	g	tggacttag	3300
atatgttttg	tttctatttt	cttctatttc	agtttttcat	tctttgatgt	t	tatttcttt	3360
tgtccatcag	atctcttgtg	aaatcccatg	gaaggttgtg	ctcagctgtc	g	ggtctcttt	3420
cttcctgccc	atatattata	ccagttgctt	ctgcagcccg	cagatgccca	g	cgatgccca	3480
ggaaacaagt	tgaaatccca	ggaatctctt	taactgattt	tgctaaaaat	с	tccctgtga	3540

						-c	ont	inu	ed			 
gccttccact	caactctt	aa tatgc	ttgca tt	gttta	aagt ·	tttta	aatt	c t	gaaa	attaa	3600	
taattagggt	tttttca	ta tgtgti	tgcat aa	itgcaa	aacc -	tccta	ıggtt	a a	aata	gtttc	3660	
tttatttaag	atagaata	at ttcca	gaaat to	rtacti	ttg a	aggta	tcat	tt	ttat	ctgta	3720	
atggtttgtc	tgtctttt	tt cctct	gatca gt	attt	ttt a	atacc	agtt	t t	ggag	Jactgc	3780	
ctgagatgaa	aggaaatg	tg gaataa	aaagg ag	gttt	cct (	gatgt	ggtg	rt a	aaga	aaaca	3840	
gattccaaga	gaattgaa	ga ttttt	tttgt tt	cctt	ggta (	ctttt	ttct	t t	ttaa	attag	3900	
gactaatgtt	tcttttgt	gg tgctt	gaggc at	attca	atat a	aacca	aagt	t t	gaga	actgg	3960	
gaacttcatg	ctgatttg <sup>.</sup>	ta catati	tgaag tt	tctct	ggt a	attca	aagg	t t	atat	agtga	4020	
atgaattttc	attaataa	at cactt	tgtca ga	aaaaa	aaaa a	aaaaa	aaaa	L			4069	
<210> SEQ I <211> LENGT <212> TYPE: <213> ORGAN <220> FEATU	H: 976 PRT ISM: Homo RE:	o sapiens	5									
<400> SEQUE		Clu Gue	Clu Dra	0	п	Tera	<b>N</b> 1-	Пhw	7.000	<b>11</b> 1070		
Met Asn Ala 1	GIY Pro 5	сту суз	GIU Pro	10 C <b>y</b> s	ı nr	цув	нıа		Arg 15	ттр		
Gly Ala Ala	Thr Thr 20	Ser Pro	Ala Ala 25	. Ser	A sp	Ala	-	Ser 0	Phe	Pro		
Ser Arg Gln 35	Arg Arg	Val Leu	Asp Pro 40	Lys	A sp		His 5	Val	Gln	Phe		
Arg Val Pro 50	Pro Ser	Ser Pro 55	Ala Cys	s Val		Gly 60	Gln	Ala	Gly	Gln		
His Arg Gly 65	Ser Ala	Thr Ser 70	Leu Val	. Phe	L <b>y</b> s 75	Gln	Lys	Thr		Thr 80		
Ser Trp Met	Asp Thr 85	Lys Gly	Ile Lys	Thr 90	A la	Glu	Ser		Ser 95	Leu		
Asp Ser Lys	Glu Asn 100	Asn Asn	Thr Arg 105		G lu	Ser		Met 10	Ser	Ser		
Val Gln Lys 115		Phe Tyr	Gln His 120	Asn	V al		L <b>y</b> s 25	Leu	Val	Asn		
Val Ser Gln 130	Leu Ser	Leu Asp 135	Lys Ser	Leu		Glu 140	Lys	Ser	Thr	Gln		
Tyr Leu Asn 145	Gln His	Gln Thr 150	Ala Ala	Met	C <b>y</b> s 155	Lys	Trp	Gln		Glu .60		
Gly Lys His	Thr Glu 165	Gln Leu	Leu Glu	1 Ser 170	G lu	Pro	Gln		Val 175	Thr		
Leu Val Pro	Glu Gln 180	Phe Ser	Asn Ala 185		I le	Asp	-	Ser 90	Pro	Gln		
Asn Asp Asp 195		Asp Thr	Asp Ser 200	Glu	G lu		Arg 05	Asp	Asn	Gln		
Gln Phe Leu 210	Thr Thr	Val Lys 215	Leu Ala	. Asn		L <b>y</b> s 220	Gln	Thr	Thr	Glu		
Asp Glu His 225	Ala Arg	Glu Ala 230	Lys Ser	His	G ln 235	Lys	Сув	Ser	-	Ser 240		
Cys His Pro	Gly Glu 245	Азр Суз	Ala Ser	сув 250	G ln	Gln	Asp		Ile 255	Asp		
Val Val Pro	Lys Ser 260	Pro Leu	Ser Asp 265		G ly	Ser		Asp 70	Val	Gly		
Thr Gly Ser	Lys Asn	Asp Asn	Lys Leu	ı Ile	A rg	Gln	Glu	Ser	Cys	Leu		

		275					280					2	285			
Gly	Asn 290		Pro	Pro	Phe	Glu 295		Glu	Ser	G				Ser	Pro	Met
Asp 305	Val	Asp	Asn	Ser	L <b>y</b> s 310	Asn	Ser	Сув	Gln	A 31		Ser	Glu	Ala	-	Glu 320
Glu	Thr	Ser	Pro	Gly 325	Phe	Asp	Glu	Gln	Glu 330	A	sp	Gly	Ser		Ser 335	Gln
Thr	Ala	Asn	L <b>y</b> s 340	Pro	Ser	Arg	Phe	Gln 345	Ala	A	rg	Asp		Asp 350	Ile	Glu
Phe	Arg	L <b>y</b> s 355	Arg	Tyr	Ser	Thr	L <b>y</b> s 360	Gly	Gly	G	lu		Arg 865	Leu	His	Phe
Gln	Phe 370	Glu	Gly	Gly	Glu	Ser 375	Arg	Thr	Gly	М		Asn 80	Asp	Leu	Asn	Ala
L <b>y</b> s 385	Leu	Pro	Gly	Asn	Ile 390	Ser	Ser	Leu	Asn	V 39		Glu	Сув	Arg		Ser 400
Lys	Gln	His	Gly	L <b>y</b> s 405	Lys	Asp	Ser	Lys	Ile 410	т	hr	Asp	His		Met 415	Arg
Leu	Pro	Lys	Ala 420	Glu	Asp	Arg	Arg	L <b>y</b> s 425	Glu	G	ln	Trp		Thr 430	Lys	His
Gln	Arg	Thr 435	Glu	Arg	Lys	Ile	Pro 440	Lys	Tyr	v	al		Pro 145	His	Leu	Ser
Pro	Asp 450	Lys	Lys	Trp	Leu	Gly 455	Thr	Pro	Ile	G		Glu 60	Met	Arg	Arg	Met
Pro 465	Arg	Cys	Gly	Ile	Arg 470	Leu	Pro	Leu	Leu	A 47		Pro	Ser	Ala		His 480
Thr	Val	Thr	Ile	Arg 485	Val	Asp	Leu	Leu	Arg 490	A	la	Gly	Glu		Pro 495	Lys
Pro	Phe	Pro	Thr 500	His	Tyr	Lys	Asp	Leu 505	Trp	A	sp	Asn		His 510	Val	Lys
Met	Pro	C <b>ys</b> 515	Ser	Glu	Gln	Asn	Leu 520	Tyr	Pro	v	al		Asp 25	Glu	Asn	Gly
Glu	Arg 530	Thr	Ala	Gly	Ser	Arg 535	Trp	Glu	Leu	I		Gln 40	Thr	Ala	Leu	Leu
Asn 545	Lys	Phe	Thr	Arg	Pro 550	Gln	Asn	Leu	Lys	А 55		Ala	Ile	Leu		<b>Tyr</b> 560
Asn	Val	Ala	Tyr	Ser 565	Lys	Lys	Trp	Asp	Phe 570	т	hr	Ala	Leu		<b>A</b> sp 575	Phe
Trp	Asp	Lys	Val 580	Leu	Glu	Glu	Ala	Glu 585	Ala	G	ln	His		<b>Ty</b> r 590	Gln	Ser
Ile	Leu	Pro 595	Asp	Met	Val	Lys	Ile 600	Ala	Leu	С	уs		Pro 505	Asn	Ile	Сув
Thr	Gln 610	Pro	Ile	Pro	Leu	Leu 615	Lys	Gln	Lys	М		Asn 20	His	Ser	Ile	Thr
Met 625	Ser	Gln	Glu	Gln	Ile 630	Ala	Ser	Leu	Leu	A 63		Asn	Ala	Phe		С <b>у</b> в 540
Thr	Phe	Pro	Arg	Arg 645	Asn	Ala	Lys	Met	L <b>y</b> s 650	s	er	Glu	Tyr		Ser 655	Tyr
Pro	Asp	Ile	Asn 660	Phe	Asn	Arg	Leu	Phe 665	Glu	G	ly	Arg		Ser 570	Arg	Lys
Pro	Glu	Lys 675	Leu	Lys	Thr	Leu	Phe 680	Сув	Tyr	Ρ	he		Arg 85	Val	Thr	Glu
Lys	Lys 690	Pro	Thr	Gly	Leu	Val 695	Thr	Phe	Thr	A		Gln 00	Ser	Leu	Glu	Asp

Phe Pro Glu Trp Glu Arg Cys Glu Lys Pro L eu Thr Arg Leu His Val 705 710 715 720									
Thr Tyr Glu Gly Thr Ile Glu Glu Asn Gly G ln Gly Met Leu Gln Val 725 730 735									
Asp Phe Ala Asn Arg Phe Val Gly Gly Gly V al Thr Ser Ala Gly Leu 740 745 750									
Val Gln Glu Glu Ile Arg Phe Leu Ile Asn P ro Glu Leu Ile Ile Ser 755 760 765									
Arg Leu Phe Thr Glu Val Leu Asp His Asn G lu Cys Leu Ile Ile Thr 770 775 780									
Gly Thr Glu Gln Tyr Ser Glu Tyr Thr Gly T yr Ala Glu Thr Tyr Arg 785 790 795 800									
Trp Ser Arg Ser His Glu Asp Gly Ser Glu A rg Asp Asp Cys Glu Arg 805 810 815									
Arg Cys Thr Glu Ile Val Ala Ile Asp Ala L eu His Phe Arg Arg Tyr 820 825 830									
Leu Asp Gln Phe Val Pro Glu Lys Met Arg A rg Glu Leu Asn Lys Ala 835 840 845									
Tyr Cys Gly Phe Leu Arg Pro Gly Val Ser S er Glu Asn Leu Ser Ala 850 855 860									
Val Ala Thr Gly Asn Trp Gly Cys Gly Ala P he Gly Gly Asp Ala Arg 865 870 875 880									
Leu Lys Ala Leu Ile Gln Ile Leu Ala Ala A la Ala Ala Glu Arg Asp 885 890 895									
Val Val Tyr Phe Thr Phe Gly Asp Ser Glu L eu Met Arg Asp Ile Tyr 900 905 910									
Ser Met His Ile Phe Leu Thr Glu Arg Lys L eu Thr Val Gly Asp Val 915 920 925									
Tyr Lys Leu Leu Arg Tyr Tyr Asn Glu G lu Cys Arg Asn Cys Ser 930 935 940									
Thr Pro Gly Pro Asp Ile Lys Leu Tyr Pro P he Ile Tyr His Ala Val 945 950 955 960									
Glu Ser Cys Ala Glu Thr Ala Asp His Ser G ly Gln Arg Thr Gly Thr 965 970 975									
<210> SEQ ID NO 5 <211> LENGTH: 3814 <212> TYPE: DNA <213> ORGANISM: Mus musculus <220> FEATURE:									
<400> SEQUENCE: 5									
gggggactgt gtgctgcggg tcccagcatg agtgcgggcc ccggctggga g ccctgcacg									
aaagegeget ggggegeege tggaacttet gegeegaetg eeteggaete e eggagette									
cctggcaggc agaggcgtgt tctcgacccc aaggacgctc ccgtccagtt c agggtccct									
ccgtcctcgc cagcctgcgt ctcggggcgg gcgggaccgc acagaggcaa c gccacctcg									
tttgttttca aacaaaagac tattactact tggatggata ctaaaggacc c aagacagct									
gaatcagaaa gtaaagaaaa caacaataca agaattgact ccatgatgag t tctgtgcag									
aaagataact tttacccaca taaggtggaa aaattggaaa atgttcctca g ctaaatctt									
gataaatcac ccacagaaaa gagttcacag tatttgaacc aacagcagac t gcgagtgtg									
tgcaagtggc agaatgaagg gaagcatgca gaacagcttt tggcaagtga g cctcccgcg									

gggactccgc	taccaaagca	gettagtaat	gctaacattg	gtcagtcacc c	cacactgat	600
				agcagtttct t		660
aaacttgcaa	atacaaagcc	aacagtagga	gatgggcagg	ccagaagcaa c	tgtaagtgc	720
agtggatctc	gccagtctgt	gaaagactgt	acaggctgtc	aacaggagga g	gtggatgtg	780
ctaccagaga	gtcctttgtc	agatgttggt	gccgaggaca	ttggaactgg a	ccaaaaaat	840
gacaacaaat	tgactggaca	agaaagcagc	ctaggtgatt	cgcctccatt t	gagaaagaa	900
agtgagcctg	agtcaccaat	ggatgtagac	aactcgagaa	acagttgtca a	gattcagaa	960
gcagatgaag	aaacaagtcc	agtctttgat	gagcaagatg	atcgttcctc c	caaacagca	1020
aataaacttt	caagttgcca	agcaagagaa	gctgatggcg	atcttaggaa a	cggtatttg	1080
actaagggaa	gtgaagttag	attgcatttc	caatttgaag	gagaaaataa t	gctgggacc	1140
agtgacttaa	atgccaagcc	atctggaaac	tcttctagcc	ttaatgtaga g	tgtagaagt	1200
tccaagcagc	atggaaaaag	ggattctaaa	attacagatc	atttcatgag a	atttccaag	1260
tcagaggaca	gaagaaaaga	acaatgtgaa	gtcagacatc	aaagaacaga a	aggaagatt	1320
ccaaaataca	tcccacctaa	cctccctcca	gagaagaagt	ggctgggaac t	cctattgag	1380
gaaatgagaa	aaatgcctcg	gtgtgggatc	catttgcctt	ccttaagacc a	tctgcaagt	1440
cacacagtga	ctgttcgggt	agaccttctg	agagcaggag	aggttccgaa a	ccttttcca	1500
acacattaca	aagatttgtg	ggataacaaa	catgtgaaaa	tgeettgtte g	gaacaaaac	1560
ttgtaccctg	tggaagatga	gaatggtgag	cgaactgcag	ggagtaggtg g	gagctcatt	1620
cagactgcac	ttctcaacaa	attcacacga	ccccagaact	tgaaggatgc g	attctgaaa	1680
tacaatgtgg	catattctaa	gaaatgggac	tttacagctt	tggttgattt c	tgggataag	1740
gtacttgaag	aagcagaggc	ccaacattta	tatcagtcca	ttttacctga c	atggtgaaa	1800
attgcactct	gtctgccaaa	tatttgcacc	cagccaatac	cactcctgaa a	cagaagatg	1860
aatcattctg	tcacgatgtc	acaggaacag	atcgccagtc	ttttagctaa t	gctttcttc	1920
tgcacatttc	cccgacggaa	tgccaagatg	aaatcggagt	attctagtta c	ccagacatt	1980
aacttcaatc	ggttgtttga	aggacgttca	tcaaggaaac	cagaaaaact g	aaaacactc	2040
ttctgctact	ttcgaagagt	cacagagaaa	aaacctacag	gattggtgac a	. tttacaaga	2100
cagagtcttg	aagattttcc	agaatgggaa	aggtgtgaaa	agcctctgac a	cgcttacac	2160
gtcacttacg	agggtaccat	agaaggcaac	ggccgaggca	tgctacaggt g	gattttgca	2220
aatcgttttg	ttggaggtgg	tgtgactggt	gcgggacttg	tacaagaaga a	atcagattt	2280
ttaatcaatc	ctgaattgat	tgtttcacgg	ctgttcactg	aggtgctgga t	cacaatgag	2340
tgtcttatta	tcacaggtac	tgaacagtac	agtgaataca	caggctatgc t	gaaacttat	2400
cgttgggccc	gaagccatga	agatgggagt	gaaaaggacg	attggcagcg g	cgctgcacg	2460
gagatcgttg	ccattgacgc	acttcacttc	agacgctacc	tcgatcagtt t	gtgcctgag	2520
aaagtgagac	gtgagcttaa	caaggcttac	tgcggattcc	tccgtcctgg a	gtteettet	2580
gaaaatcttt	ctgcagtggc	cacgggaaac	tggggctgtg	gtgcctttgg g	ggtgacgct	2640
agattaaaag	ccttaataca	gatcctggca	gctgctgcgg	ctgaacgtga c	gtggtttat	2700
ttcacctttg	gggactcaga	gttgatgaga	gacatttaca	gcatgcacac t	ttccttacc	2760
gagaggaagc	tggatgttgg	aaaagtgtac	aagttattgc	ttagatacta c	aatgaagaa	2820
tgcagaaact	gttccacccc	tggaccagac	atcaagcttt	atccattcat a	taccatgct	2880
gttgagtcaa	gtgcagagac	cactgacatg	ccaggacaga	aggcaggcac c	tgaggaaca	2940

agtgactagg acctcctctc aaagagacat cctatttgaa atgtggggtg t gatgtctga	3000
attgactgaa tctgatctaa gtgtgtatat aatccacatt tgtaatcaag g atgcagtct	3060
cttctgcata tgcagttgtt tcttgttcat cctggtggac atgcctttag a catggcttc	3120
ttcaattttt cttctccttc agtctttatt ctttgatttt ttttttccaa c ttgatttct	3180
tgggaaaact caagaaaggt tgcactcagc ttctagatct ttctcttcct g tctgtgtgt	3240
tgtccagact gctttggtgg ctagcagata ccatcacact tggaggaagt t acaaatcca	3300
gaaatctgag tttgctgcag atttacctgt gagcttctca ctcccaaccc t tgttaggct	3360
tgtgttgtct acattttcaa ttttggaagt tgaagttttt cttatgttac t taatgctag	3420
tatettttag getaaaacta ttttetattt aaggeagaet aattteeagt t tetettttg	3480
aaacatcatc cctataagta acggtttttt tcgtcctttt ttccccagcg c tattttaga	3540
agctggccaa gaggaaagaa aatgtagaat aaaaggattt tcctcggatg c tataaagaa 🔅	3600
gccaggttca agagcgttgg ggtttttgtt tttttcaaga cttgtttttc c tttgcagct	3660
agggtgagtg cttgttctgt ggtgctgagg gcatagtcct gtaaccaaag g tctttgctg	3720
gagacttgat gctgatttgt acatatggaa gtttctctgg caggaaatat t agagttaat	3780
aaatttcatt aataaatcat ttgtcagaaa aaaa 33	314
<210> SEQ ID NO 6 <211> LENGTH: 968 <212> TYPE: PRT <213> ORGANISM: Mus musculus <220> FEATURE:	
<400> SEQUENCE: 6	
Met Ser Ala Gly Pro Gly Trp Glu Pro Cys T hr Lys Ala Arg Trp Gly 1 5 10 15	
Ala Ala Gly Thr Ser Ala Pro Thr Ala Ser A sp Ser Arg Ser Phe Pro 20 25 30	
Gly Arg Gln Arg Arg Val Leu Asp Pro Lys A sp Ala Pro Val Gln Phe 35 40 45	
Arg Val Pro Pro Ser Ser Pro Ala Cys Val S er Gly Arg Ala Gly Pro 50 55 60	
His Arg Gly Asn Ala Thr Ser Phe Val Phe L ys Gln Lys Thr Ile Thr 65 70 75 80	
Thr Trp Met Asp Thr Lys Gly Pro Lys Thr A la Glu Ser Glu Ser Lys 85 90 95	
Glu Asn Asn Thr Arg Ile Asp Ser Met M et Ser Ser Val Gln Lys 100 105 110	
Asp Asn Phe Tyr Pro His Lys Val Glu Lys L eu Glu Asn Val Pro Gln 115 120 125	
Leu Asn Leu Asp Lys Ser Pro Thr Glu Lys S er Ser Gln Tyr Leu Asn 130 135 140	
Gln Gln Gln Thr Ala Ser Val Cys Lys Trp G ln Asn Glu Gly Lys His 145 150 155 160	
Ala Glu Gln Leu Leu Ala Ser Glu Pro Pro A la Gly Thr Pro Leu Pro 165 170 175	
Lys Gln Leu Ser Asn Ala Asn Ile Gly Gln S er Pro His Thr Asp Asp 180 185 190	
His Ser Asp Thr Asp His Glu Glu Asp Arg A sp Asn Gln Gln Phe Leu 195 200 205	

-continued

Thr Pro Ile Lys Leu Ala Asn Thr Lys Pro T hr Val Gly Asp Gly	. Cln
210 215 220	GIII
Ala Arg Ser Asn Cys Lys Cys Ser Gly Ser A rg Gln Ser Val Lys225230235	Asp 240
Cys Thr Gly Cys Gln Gln Glu Glu Val Asp V al Leu Pro Glu Ser 245 250 255	Pro
Leu Ser Asp Val Gly Ala Glu Asp Ile Gly T hr Gly Pro Lys Asm 260 265 270	Asp
Asn Lys Leu Thr Gly Gln Glu Ser Ser Leu G ly Asp Ser Pro Pro 275 280 285	) Phe
Glu Lys Glu Ser Glu Pro Glu Ser Pro Met A sp Val Asp Asn Ser 290 295 300	Arg
Asn Ser Cys Gln Asp Ser Glu Ala Asp Glu G lu Thr Ser Pro Val 305 310 315	. Phe 320
Asp Glu Gln Asp Asp Arg Ser Ser Gln Thr A la Asn Lys Leu Ser 325 330 335	Ser
Cys Gln Ala Arg Glu Ala Asp Gly Asp Leu A rg Lys Arg Tyr Leu 340 345 350	1 Thr
Lys Gly Ser Glu Val Arg Leu His Phe Gln P he Glu Gly Glu Asn 355 360 365	Asn
Ala Gly Thr Ser Asp Leu Asn Ala Lys Pro S er Gly Asn Ser Ser 370 375 380	Ser
Leu Asn Val Glu Cys Arg Ser Ser Lys Gln H is Gly Lys Arg Asp 385 390 395	Ser 400
Lys Ile Thr Asp His Phe Met Arg Ile Ser L ys Ser Glu Asp Arg 405 410 415	Arg
Lys Glu Gln Cys Glu Val Arg His Gln Arg T hr Glu Arg Lys Ile 420 425 430	e Pro
Lys Tyr Ile Pro Pro Asn Leu Pro Pro Glu L ys Lys Trp Leu Gly 435 440 445	Thr
Pro Ile Glu Glu Met Arg Lys Met Pro Arg C ys Gly Ile His Leu 450 455 460	Pro
Ser Leu Arg Pro Ser Ala Ser His Thr Val T hr Val Arg Val Asg 465 470 475	6 Leu 480
Leu Arg Ala Gly Glu Val Pro Lys Pro Phe P ro Thr His Tyr Lys 485 490 495	Asp
Leu Trp Asp Asn Lys His Val Lys Met Pro C ys Ser Glu Gln Asn 500 505 510	Leu
Tyr Pro Val Glu Asp Glu Asn Gly Glu Arg T hr Ala Gly Ser Arg 515 520 525	Trp
Glu Leu Ile Gln Thr Ala Leu Leu Asn Lys P he Thr Arg Pro Gln 530 535 540	Asn
Leu Lys Asp Ala Ile Leu Lys Tyr Asn Val A la Tyr Ser Lys Lys 545 550 555	Trp 560
Asp Phe Thr Ala Leu Val Asp Phe Trp Asp L ys Val Leu Glu Glu 565 570 575	Ala
Glu Ala Gln His Leu Tyr Gln Ser Ile Leu P ro Asp Met Val Lys 580 585 590	Ile
Ala Leu Cys Leu Pro Asn Ile Cys Thr Gln P ro Ile Pro Leu Leu 595 600 605	Lys
Gln Lys Met Asn His Ser Val Thr Met Ser G ln Glu Gln Ile Ala 610 615 620	Ser
Leu Leu Ala Asn Ala Phe Phe Cys Thr Phe P ro Arg Arg Asn Ala	Lys

-continued

	-concinued									
625 630	635 640									
Met Lys Ser Glu Tyr Ser Ser Tyr Pro Asp 645 650										
Phe Glu Gly Arg Ser Ser Arg Lys Pro Glu	1 L ys Leu Lys Thr Leu Phe									
660 665	670									
Cys Tyr Phe Arg Arg Val Thr Glu Lys Lys	P ro Thr Gly Leu Val Thr									
675 680	685									
Phe Thr Arg Gln Ser Leu Glu Asp Phe Pro	o G lu Trp Glu Arg Cys Glu									
690 695	700									
Lys Pro Leu Thr Arg Leu His Val Thr Tyr	r G lu Gly Thr Ile Glu Gly									
705 710	715 720									
Asn Gly Arg Gly Met Leu Gln Val Asp Phe 725 730										
Gly Gly Val Thr Gly Ala Gly Leu Val Gln	n G lu Glu Ile Arg Phe Leu									
740 745	750									
Ile Asn Pro Glu Leu Ile Val Ser Arg Leu	ı P he Thr Glu Val Leu Asp									
755 760	765									
His Asn Glu Cys Leu Ile Ile Thr Gly Thr	r G lu Gln Tyr Ser Glu Tyr									
770 775	780									
Thr Gly Tyr Ala Glu Thr Tyr Arg Trp Ala	a A rg Ser His Glu Asp Gl <b>y</b>									
785 790	795 800									
Ser Glu Lys Asp Asp Trp Gln Arg Arg Cys 805 810										
Asp Ala Leu His Phe Arg Arg Tyr Leu Asp	G ln Phe Val Pro Glu Lys									
820 825	830									
Val Arg Arg Glu Leu Asn Lys Ala Tyr Cys	G ly Phe Leu Arg Pro Gly									
835 840	845									
Val Pro Ser Glu Asn Leu Ser Ala Val Ala	a T hr Gly Asn Trp Gly Cys									
850 855	860									
Gly Ala Phe Gly Gly Asp Ala Arg Leu Lys	A la Leu Ile Gln Ile Leu									
865 870	875 880									
Ala Ala Ala Ala Glu Arg Asp Val Val 885 890										
Ser Glu Leu Met Arg Asp Ile Tyr Ser Met	: H is Thr Phe Leu Thr Glu									
900 905	910									
Arg Lys Leu Asp Val Gly Lys Val Tyr Lys	s L eu Leu Leu Arg Tyr Tyr									
915 920	925									
Asn Glu Glu Cys Arg Asn Cys Ser Thr Pro	G ly Pro Asp Ile Lys Leu									
930 935	940									
Tyr Pro Phe Ile Tyr His Ala Val Glu Ser	S er Ala Glu Thr Thr Asp									
945 950	955 960									
Met Pro Gly Gln Lys Ala Gly Thr 965										
<210> SEQ ID NO 7 <211> LENGTH: 2781 <212> TYPE: DNA <213> ORGANISM: Drosophila melanogaster <220> FEATURE:										
<400> SEQUENCE: 7										
tcgaagtgtg tggtatttat aaagtgcgat attcat	togaagtgtg tggtatttat aaagtgogat attoatoaca gotatogoto a tooccaaaa									
caccggtatg caagaattca ggtcacactt gatttttccg atattccaaa a ggtttacca										
atctacggca aatcgccgca gagcaagtgc atccgt	atctacggca aatcgccgca gagcaagtgc atccgtgctg accaatcgac t cggcaaggc									

tttgtgctta aa	ctgcgcca	qqatqtcqaa	qtcqccqqat	qqcqqqattt	с	cgaaataga	240
aacggaggag ga							300
catggaggct at							360
tgccggcaat ct							420
ctacaaatca cc	gggaaagt	gggactccga	gcatgtgcgt	ctgccctgtg	с	gcccgagtc	480
gaaatatccg ag	ggagaatc	cggatggcag	caccaccatc	gattttcgct	g	ggaaatgat	540
cgaacgagcc ct	tctgcagc	ccataaagac	gtgtgaggaa	ctgcaggcgg	с	gataatatc	600
atataatacc ac	ctataggg	atcagtggca	ctttcgtgcc	cttcatcaac	t	tctcgacga	660
ggaactggac ga	gagcgaaa	cacgggtttt	cttcgaggat	ctattgccgc	g	cattatccg	720
attggcattg cg	gctaccgg	acttgattca	atcgccagtt	ccgctgctca	a	gcaccacaa	780
gaacgcctca tt	gagcctga	gccaacagca	gatctcctgc	ctgttggcca	a	tgccttctt	840
gtgcacgttt cc	ccgaagaa	acaccctcaa	gaggaagtcc	gagtacagca	с	ttttccaga	900
catcaacttt aa	caggcttt	accaatcgac	gggaccggca	gttctggaga	a	gcttaaatg	960
cattatgcac ta	ttttcgtc	gcgtgtgtcc	cacagagcgg	gatgccagca	a	tgtgcccac	1020
cggtgtggta ac	ctttgttc	gtcggagcgg	attgccggaa	catctgatcg	a	ctggagcca	1080
aagtgcggcg cc	gttgggtg	atgtgccatt	gcacgtggat	gccgagggaa	с	aatcgagga	1140
tgagggcatt gg	actgctgc	aagtagactt	tgccaacaaa	tatttgggtg	g	cggtgtctt	1200
gggacatggc tg	cgttcagg	aggagatacg	ctttgttatc	tgtccggagc	t	attggtggg	1260
taaactcttt ac	ggagtgtc	tgcgaccatt	cgaggccctg	gtgatgttgg	g	cgccgaaag	1320
gtatagtaac ta	tacgggat	atgccggaag	cttcgagtgg	tccggcaact	t	tgaggattc	1380
aacgccaaga ga	tagctcag	gtcgtcgaca	aacggccatt	gtggcaatcg	a	tgccctaca	1440
ttttgcccag tc	acatcatc	aatatcgcga	ggatctcatg	gaaagggagc	t	gaacaaggc	1500
gtacattgga tt	tgttcact	ggatggtgac	gccgccaccg	ggtgtggcaa	с	tggtaactg	1560
gggttgcggc gc	attcggcg	gtgactccta	tctgaaagcc	ctgctgcaac	t	tatggtctg	1620
cgcccagttg gg	cagacctt	tggcctacta	tacctttgga	aatgtggagt	t	tagggatga	1680
ttttcatgaa at	gtggctgt	tgtttcgaaa	tgacgggact	acggtgcagc	a	gctttggag	1740
tattttaagg tc	gtacagta	ggcttattaa	ggagaagagc	tccaaggagc	с	gcgtgagaa	1800
taaggcatcc aa	aaagaagc	tatatgattt	tattaaagag	gaacttaaga	a	ggtcagaga	1860
tgtgcccgga ga	gggagcat	ccgccgaagc	tggaagctct	agagtagctg	g	attaggcga	1920
aggaaaatca ga	aacatcag	cgaaatcctc	gccagaactc	aacaagcaac	с	cgcccgacc	1980
gcaaatcacc at	aacgcaac	aaagtaccga	tctattgccc	gcgcaattat	С	gcaagataa	2040
ctctaattct tc	ggaagatc	aggcccttct	tatgctgtcg	gacgatgagg	a	ggccaatgc	2100
catgatggag gc	cgctagtc	tggaggctaa	aagcagcgta	gaaataagca	a	cagcagcac	2160
aacgtccaaa ac	gagcagta	cagccacgaa	atcaatgggt	tcaggtggcc	g	ccagttgag	2220
tctgctcgag at	gctggaca	cccattatga	aaagggttcg	gcctcgaaga	g	gccacgaaa	2280
atcacccaac tg	cagcaagg	ctgagggttc	agcaaagagt	cgtaaggaga	t	cgatgtgac	2340
cgacaaggac ga	aaaggacg	atattgttga	ctaggtgata	ttgcactaca	g	gattgttac	2400
tgcccccaaa aa	ttgaagag	gtataaaatg	tattgtagat	aactttaagg	a	catatttag	2460
ggcattttaa ag	taggatca	ttgtaagtcg	aataaagtga	aattttttt	t	tttttaat	2520

#### -continued

tatactattc taatctgcaa agacaatttt actgttaaat ttgtataaca t tcgaattaa 2580 ttaatataat ttgttatatc atgcaaatct agcttttatt atgcgaaatt t gtagttaaa 2640 2700 agaacatcaa caacaacaac cacgaaaaaa aagcgaatat atatttqttt g ttcgtatat 2760 2781 atatatatat ctaaqcaqat c <210> SEQ ID NO 8 <211> LENGTH: 768 <212> TYPE: PRT <213> ORGANISM: Drosophila melanogaster <220> FEATURE: <400> SEQUENCE: 8 Met Gln Glu Phe Arg Ser His Leu Ile Phe P ro Ile Phe Gln Lys Val 10 Tyr Gln Ser Thr Ala Asn Arg Arg Arg Ala S er Ala Ser Val Leu Thr 20 25 30 Asn Arg Leu Gly Lys Ala Leu Cys Leu Asn C ys Ala Arg Met Ser Lys 35 40 45 Ser Pro Asp Gly Gly Ile Ser Glu Ile Glu T hr Glu Glu Glu Pro Glu 50 55 60 Asn Leu Ala Asn Ser Leu Asp Asp Ser Trp A rg Gly Val Ser Met Glu 65 70 75 80 Ala Ile His Arg Asn Arg Gln Pro Phe Glu L eu Glu Asn Leu Pro Pro 85 90 95 Val Thr Ala Gly Asn Leu His Arg Val Met T yr Gln Leu Pro Ile Arg 100 105 110 Glu Thr Pro Pro Arg Pro Tyr Lys Ser Pro G ly Lys Trp Asp Ser Glu 120 125 His Val Arg Leu Pro Cys Ala Pro Glu Ser L ys Tyr Pro Arg Glu Asn 135 140 130 Pro Asp Gly Ser Thr Thr Ile Asp Phe Arg T rp Glu Met Ile Glu Arg 145 150 155 160 150 155 145 Ala Leu Leu Gln Pro Ile Lys Thr Cys Glu G lu Leu Gln Ala Ala Ile 165 170 175 Ile Ser Tyr Asn Thr Thr Tyr Arg Asp Gln T rp His Phe Arg Ala Leu 185 180 190 His Gln Leu Leu Asp Glu Glu Leu Asp Glu S er Glu Thr Arg Val Phe 195 200 205 Phe Glu Asp Leu Leu Pro Arg Ile Ile Arg L eu Ala Leu Arg Leu Pro 215 220 210 Asp Leu Ile Gln Ser Pro Val Pro Leu Leu Lys His His Lys Asn Ala225230235240 Ser Leu Ser Leu Ser Gln Gln Gln Ile Ser C ys Leu Leu Ala Asn Ala 245 250 255 Phe Leu Cys Thr Phe Pro  $\operatorname{Arg}$  Arg Asn Thr L eu Lys  $\operatorname{Arg}$  Lys Ser Glu 265 260 Tyr Ser Thr Phe Pro Asp Ile Asn Phe Asn A rg Leu Tyr Gln Ser Thr 275 280 285 Gly Pro Ala Val Leu Glu Lys Leu Lys Cys I le Met His Tyr Phe Arg 290 295 300 Arg Val Cys Pro Thr Glu Arg Asp Ala Ser A sn Val Pro Thr Gly Val 305 310 315 320

-continued

Val Thr Phe Val Arg Arg Ser Gly Leu Pro G lu His Leu Ile Asp Trp 325 330 335	
Ser Gln Ser Ala Ala Pro Leu Gly Asp Val P ro Leu His Val Asp Ala 340 345 350	
Glu Gly Thr Ile Glu Asp Glu Gly Ile Gly L eu Leu Gln Val Asp Phe 355 360 365	
Ala Asn Lys Tyr Leu Gly Gly Gly Val Leu G ly His Gly Cys Val Gln 370 375 380	
Glu Glu Ile Arg Phe Val Ile Cys Pro Glu L eu Leu Val Gly Lys Leu385390395400	
Phe Thr Glu Cys Leu Arg Pro Phe Glu Ala L eu Val Met Leu Gly Ala 405 410 415	
Glu Arg Tyr Ser Asn Tyr Thr Gly Tyr Ala G ly Ser Phe Glu Trp Ser 420 425 430	
Gly Asn Phe Glu Asp Ser Thr Pro Arg Asp S er Ser Gly Arg Arg Gln 435 440 445	
Thr Ala Ile Val Ala Ile Asp Ala Leu His P he Ala Gln Ser His His 450 455 460	
Gln Tyr Arg Glu Asp Leu Met Glu Arg Glu L eu Asn Lys Ala Tyr Ile 465 470 475 480	
Gly Phe Val His Trp Met Val Thr Pro Pro P ro Gly Val Ala Thr Gly 485 490 495	
Asn Trp Gly Cys Gly Ala Phe Gly Gly Asp S er Tyr Leu Lys Ala Leu 500 505 510	
Leu Gln Leu Met Val Cys Ala Gln Leu Gly A rg Pro Leu Ala Tyr Tyr 515 520 525	
Thr Phe Gly Asn Val Glu Phe Arg Asp Asp P he His Glu Met Trp Leu 530 535 540	
Leu Phe Arg Asn Asp Gly Thr Thr Val Gln G ln Leu Trp Ser Ile Leu545550550555560	
Arg Ser Tyr Ser Arg Leu Ile Lys Glu Lys S er Ser Lys Glu Pro Arg 565 570 575	
Glu Asn Lys Ala Ser Lys Lys Lys Leu Tyr A sp Phe Ile Lys Glu Glu 580 585 590	
Leu Lys Lys Val Arg Asp Val Pro Gly Glu G ly Ala Ser Ala Glu Ala 595 600 605	
Gly Ser Ser Arg Val Ala Gly Leu Gly Glu G ly Lys Ser Glu Thr Ser 610 615 620	
Ala Lys Ser Ser Pro Glu Leu Asn Lys Gln P ro Ala Arg Pro Gln Ile625630635640	
Thr Ile Thr Gln Gln Ser Thr Asp Leu Leu P ro Ala Gln Leu Ser Gln 645 650 655	
Asp Asn Ser Asn Ser Ser Glu Asp Gln Ala L eu Leu Met Leu Ser Asp 660 665 670	
Asp Glu Glu Ala Asn Ala Met Met Glu Ala A la Ser Leu Glu Ala Lys 675 680 685	
Ser Ser Val Glu Ile Ser Asn Ser Ser Thr T hr Ser Lys Thr Ser Ser 690 695 700	
Thr Ala Thr Lys Ser Met Gly Ser Gly Gly A rg Gln Leu Ser Leu705710715720	
Glu Met Leu Asp Thr His Tyr Glu Lys Gly S er Ala Ser Lys Arg Pro 725 730 735	
Arg Lys Ser Pro Asn Cys Ser Lys Ala Glu G ly Ser Ala Lys Ser Arg	

#### -continued

		-contin	ued		
740	745	750			
L <b>y</b> s Glu Ile Asp Val T 755	hr Asp Lys Asp Glu 760	1 L ys Asp Asp Ile 765	e Val Asp		
<210> SEQ ID NO 9 <211> LENGTH: 2181 <212> TYPE: DNA <213> ORGANISM: Caeno <220> FEATURE:	rhabditis elegans				
<400> SEQUENCE: 9					
atgagcaaga agtttatcga	actgggtgat cctgto	cactc aagacgagaa a	a gactacgaa	60	
gactatgtcg gagttggttt	cgcgcatcaa gtccco	gacaa tgaaaaggcg d	g aagttgaca	120	
gaacatggaa atactacaga	atcaaaagaa gatcc	cgaag agccaaaaag (	c cgtgacgta	180	
tttgtctcct cgcagtcaag	tgatgagagt caagaa	agatt cggctgaaaa <sup>.</sup>	t ccggagatc	240	
gctaaagaag tgtcagaaaa	ttgtgaaaat ctgaca	agaaa ctctcaaaat <sup>.</sup>	t tctaatatt	300	
gagagtttgg acaatgttac	tgaaagatct gaacad	cactc ttgataatca o	c aaaagtact	360	
gaaccaatgg aagaagatgt	aaacaacaag tccaat	attg acgttgcgat -	t aattctgac	420	
gaggatgatg aacttgttct	ggaagagaat aataaa	agaaa tgagggatgg a	a gaacaagta	480	
caacagttgt cacaggattt	attcgctgat gatcaa	agagc taattgaata <sup>-</sup>	t ccaggaatt	540	
atgaaagaca ctacaactca	actggatata acaga	tctg aagtggagac -	t gctcaaaaa	600	
atggaaatga ttgaagaaac	tgaagcagat tcgaca	atttg taggcgagga -	t tcaaaagct	660	
acgaaaactg tgaggacatc	cagttcaagt ttcct	gtcaa ctgtttcaac a	a tgcgaagcc	720	
cctgcaaaag gacgagcaag	aatgtatcaa aaagag	gttgg aaaagcatgt (	g attgcattt	780	
actgagggaa atctcacact	acaaccagat ttgaad	caaag ttgatcccga (	c agaaactat	840	
cgatattgta caattccgaa	ctttccagct tcccaa	aggaa aacttcgaga a	a gataatcga	900	
tatggcccaa aaatcgtttt	gcctcaaaga tggcga	agaat ttgattcgag (	g ggccgtaga	960	
agagactcat atttctattt	caaacgtaag ctcgat	tggat atttgaaatg (	c tacaaaaca	1020	
actggatatt ttatgtttgt	tggacttttg cacaad	catgt gggaatttga (	c ccagacatc	1080	
acatataaac tgccagcact	ggaaatgtat tacaaa	agaga tgtcggaact -	t gttggtaga	1140	
gaagaggttt tggaaaaatt	tgcacgagtt gcccgo	catcg caaaaactgc -	t gaagatatt	1200	
ctgccagagc gaatttatcg	tcttgttggt gacgto	cgaat cagctacctt (	g agccacaag	1260	
caatgtgctg cacttgttgc	gagaatgttt tttgco	ccgac cggacagtcc -	t ttcagtttc	1320	
tgccgaattc tctcgtctga	taaatctatt tgtgtg	ggaga aacttaaatt (	c ctgttcact	1380	
tatttcgaca aaatgtcaat	ggatccaccg gatgg	cgccg tcagttttag a	a cttacaaaa	1440	
atggataaag atacgttcaa	cgaagagtgg aaagat	aaaa aattacgttc -	t cttcctgaa	1500	
gttgaattct ttgatgaaat	gcttattgaa gacaca	agctc tctgtacaca a	a gttgatttt	1560	
gcgaacgaac atcttggtgg	cggagtttta aatca	.gggt ctgttcagga (	g gagatccgt	1620	
ttcttgatgt gtccagaaat	gatggttgga atgttg	yttgt gcgagaaaat o	g aaacaactg	1680	
gaagcgattt caattgttgg	agcttacgtt ttcag	tett atactggtta -	t ggtcatact	1740	
ctaaaatggg cagaacttca	accaaatcat tctcg	ccaga atacaaacga a	a tttcgagat	1800	
cgttttggac gtcttcgggt	agaaactatt gcaato	cgatg caattctgtt (	c aaaggatca	1860	
aaattagatt gtcagacgga	gcagttaaac aaagca	aaata tcattaggga a	a atgaagaaa	1920	
gcatctatcg gattcatgag	ccagggaccg aaatto	cacaa atattccaat ·	t gttactgga	1980	

# -continued

tggtggggat gtggagcatt taatggggac aagccactga agttcataat c caagtaatt	2040
gctgccggag tcgctgatcg tccacttcat ttctgttcat ttggagaacc c gagcttgcc	2100
gcaaagtgca agaaaattat agaacgaatg aaacagaagg acgtaacact t ggtaagtca	2160
tgtttttcaa tcttcagttg a	2181
<210> SEQ ID NO 10 <211> LENGTH: 726 <212> TYPE: PRT <213> ORGANISM: Caenorhabditis elegans <220> FEATURE:	
<400> SEQUENCE: 10	
Met Ser Lys Lys Phe Ile Glu Leu Gly Asp P ro Val Thr Gln Asp Glu 1 5 10 15	
Lys Asp Tyr Glu Asp Tyr Val Gly Val Gly P he Ala His Gln Val Pro 20 25 30	
Thr Met Lys Arg Arg Lys Leu Thr Glu His G ly Asn Thr Thr Glu Ser 35 40 45	
Lys Glu Asp Pro Glu Glu Pro Lys Ser Arg A sp Val Phe Val Ser Ser 50 55 60	
Gln Ser Ser Asp Glu Ser Gln Glu Asp Ser A la Glu Asn Pro Glu Ile 65 70 75 80	
Ala Lys Glu Val Ser Glu Asn Cys Glu Asn L eu Thr Glu Thr Leu Lys 85 90 95	
Ile Ser Asn Ile Glu Ser Leu Asp Asn Val T hr Glu Arg Ser Glu His 100 105 110	
Thr Leu Asp Asn His Lys Ser Thr Glu Pro M et Glu Glu Asp Val Asn 115 120 125	
Asn Lys Ser Asn Ile Asp Val Ala Ile Asn S er Asp Glu Asp Asp Glu 130 135 140	
Leu Val Leu Glu Glu Asn Asn Lys Glu Met A rg Asp Gly Glu Gln Val 145 150 155 160	
Gln Gln Leu Ser Gln Asp Leu Phe Ala Asp A sp Gln Glu Leu Ile Glu 165 170 175	
Tyr Pro Gly Ile Met Lys Asp Thr Thr Thr G ln Leu Asp Ile Thr Asp 180 185 190	
Ser Glu Val Glu Thr Ala Gln Lys Met Glu M et Ile Glu Glu Thr Glu 195 200 205	
Ala Asp Ser Thr Phe Val Gly Glu Asp Ser L ys Ala Thr Lys Thr Val 210 215 220	
Arg Thr Ser Ser Ser Ser Phe Leu Ser Thr V al Ser Thr Cys Glu Ala225230235240	
Pro Ala Lys Gly Arg Ala Arg Met Tyr Gln L ys Glu Leu Glu Lys His 245 250 255	
Val Ile Ala Phe Thr Glu Gly Asn Leu Thr L eu Gln Pro Asp Leu Asn 260 265 270	
Lys Val Asp Pro Asp Arg Asn Tyr Arg Tyr C ys Thr Ile Pro Asn Phe 275 280 285	
Pro Ala Ser Gln Gly Lys Leu Arg Glu Asp A sn Arg Tyr Gly Pro Lys 290 295 300	
Ile Val Leu Pro Gln Arg Trp Arg Glu Phe A sp Ser Arg Gly Arg Arg305310315320	
Arg Asp Ser Tyr Phe Tyr Phe Lys Arg Lys L eu Asp Gly Tyr Leu Lys	

-continued

	325	330	335
Cys Tyr Lys Th		Phe Met Phe V	al Gly Leu Leu His Asn
34		345	350
Met Trp Glu Ph	e Asp Pro Asp	Ile Thr T <b>y</b> r L	ys Leu Pro Ala Leu Glu
355		360	365
Met Tyr Tyr Ly	s Glu Met Ser	Glu Leu Val G	l <b>y</b> Arg Glu Glu Val Leu
370	375		380
Glu Lys Phe Al	a Arg Val Ala	Arg Ile Ala L	ys Thr Ala Glu Asp Ile
385	390	39	5
Leu Pro Glu Ar	g Ile Tyr Arg	Leu Val Gly A	sp Val Glu Ser Ala Thr
	405	410	415
Leu Ser His Ly	-	Ala Leu Val A	la Arg Met Phe Phe Ala
42		425	430
Arg Pro Asp Se	r Pro Phe Ser	Phe Cys Arg I	le Leu Ser Ser Asp Lys
435		440	445
Ser Ile Cys Va	l Glu Lys Leu	Lys Phe Leu P	he Thr Tyr Phe Asp Lys
450	455		460
Met Ser Met As	p Pro Pro Asp	Gly Ala Val S	er Phe Arg Leu Thr Lys
465	470	47	5
Met Asp Lys As	p Thr Phe Asn	Glu Glu Trp L	ys Asp Lys Lys Leu Arg
	485	490	495
Ser Leu Pro Gl <sup>.</sup>		Phe Asp Glu M	et Leu Ile Glu Asp Thr
50		505	510
Ala Leu Cys Th	r Gln Val Asp	Phe Ala Asn G	lu His Leu Gl <b>y</b> Gl <b>y</b> Gly
515		520	525
Val Leu Asn Hi	s Gly Ser Val	Gln Glu Glu I	le Arg Phe Leu Met Cys
530	535		540
Pro Glu Met Me	t Val Gly Met	Leu Leu Cys G	lu Lys Met Lys Gln Leu
545	550	55	5
Glu Ala Ile Se	r Ile Val Gly	Ala Tyr Val P	he Ser Ser Tyr Thr Gly
	565	570	575
Tyr Gly His Th		Ala Glu Leu G	ln Pro Asn His Ser Arg
58		585	590
Gln Asn Thr As:	n Glu Phe Arg	Asp Arg Phe G	ly Arg Leu Arg Val Glu
595		600	605
Thr Ile Ala Il	e Asp Ala Ile	Leu Phe Lys G	ly Ser Lys Leu Asp Cys
610	615		620
Gln Thr Glu Gl:	n Leu Asn Lys	Ala Asn Ile I	le Arg Glu Met Lys Lys
625	630	63	5 640
Ala Ser Ile Gl	y Phe Met Ser	Gln Gly Pro L	ys Phe Thr Asn Ile Pro
	645	650	655
Ile Val Thr Gl		Cys Gly Ala P 665	he Asn Gly Asp Lys Pro 670
Leu Lys Phe Il	e Ile Gln Val	Ile Ala Ala G	l <b>y Val Ala Asp Arg Pro</b>
675		680	685
Leu His Phe Cy	s Ser Phe Gly	Glu Pro Glu L	eu Ala Ala Lys Cys Lys
690	695		700
Lys Ile Ile Gl <sup>.</sup>	u Arg Met Lys	Gln Lys Asp V	al Thr Leu Gl <b>y</b> Lys Ser
705	710	71	5
Cys Phe Ser Il	e Phe Ser 725		

<210> SEQ ID NO 11

-continued

<211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Bos taurus <220> FEATURE: <400> SEQUENCE: 11 Leu Phe Thr Glu Val Leu Asp His Asn Glu C ys Leu Ile Ile Thr Gly 1 5 10 15 Thr Glu Gln Tyr Ser Glu Tyr Thr Gly Tyr A la Glu Thr Tyr Arg 20 25 30 <210> SEQ ID NO 12 <211> LENGTH: 29 <212> TYPE: PRT <213> ORGANISM: Bos taurus <220> FEATURE: <400> SEOUENCE: 12 Ala Tyr Cys Gly Phe Leu Arg Pro Gly Val S er Ser Glu Asn Leu Ser 1 5 10 15 Ala Val Ala Thr Gly Asn Xaa Gly Cys Gly A la Phe Gly 20 25 20 <210> SEQ ID NO 13 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Bos taurus <220> FEATURE: <400> SEQUENCE: 13 Phe Leu Ile Asn Pro Glu Leu Ile Val Ser A rq 5 10 1 <210> SEQ ID NO 14 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Bos taurus <220> FEATURE: <400> SEQUENCE: 14 Ile Ala Leu Xaa Leu Pro Asn Ile Xaa Thr G ln Pro Ile Pro Leu Leu 5 10 1 15 <210> SEQ ID NO 15 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Bos taurus <220> FEATURE: <400> SEQUENCE: 15 gaycayaayg artgyyt <210> SEQ ID NO 16 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Bos taurus <220> FEATURE: <400> SEQUENCE: 16 ckrtangtyt cngcrta <210> SEQ ID NO 17 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Bos taurus

82

17

-continued <220> FEATURE: <400> SEQUENCE: 17 atcatcacag gtactgagca gtac 24 <210> SEQ ID NO 18 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Bos taurus <220> FEATURE: <400> SEQUENCE: 18 gcctgtgtat tcactgtact gctc 24 <210> SEQ ID NO 19 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Bos taurus <220> FEATURE: <400> SEQUENCE: 19 Glu Asp Lys Arg Lys Glu Gln Cys Glu Met L ys His Gln Arg Thr Glu 1 10 15 Arg Lys Ile Pro Lys Tyr Ile Pro Pro His 20 25 <210> SEQ ID NO 20 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <400> SEQUENCE: 20 Glu Asp Arg Arg Lys Glu Gln Trp Glu Thr L ys His Gln Arg Thr Glu 1 5 10 15 Arg Lys Ile Pro Lys Tyr Val Pro Pro His 20 25 <210> SEQ ID NO 21 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Mus Musculus <220> FEATURE: <400> SEQUENCE: 21 Glu Asp Arg Arg Lys Glu Gln Cys Glu Val A rg His Gln Arg Thr Glu 5 10 15 1 Arg Lys Ile Pro Lys Tyr Ile Pro Pro Asn 20 25 <210> SEQ ID NO 22 <211> LENGTH: 32 <212> TYPE: PRT <213> ORGANISM: Caenorhabotitis elegans <220> FEATURE: <400> SEQUENCE: 22 His Gln Val Pro Thr Met Lys Arg Arg Lys L eu Thr Glu His Gly Asn 5 10 15 1 Thr Thr Glu Ser Leu Leu Lys Glu Asp P ro Pro Glu Pro Lys Ser 2.0 25 30

<210> SEQ ID NO 23

-continued

<211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <400> SEQUENCE: 23 Glu Gly Lys Arg Lys Gly Asp Glu Val Asp G ly Val Asp Glu Val Ala 1 5 10 15 Lys Lys Lys Ser Lys Lys Glu Lys Asp Lys 20 25 <210> SEQ ID NO 24 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Mus musculus <220> FEATURE: <400> SEOUENCE: 24 Glu Gly Lys Arg Lys Gly Asp Glu Val Asp G ly Thr Asp Glu Val Ala 1 10 15 Lys Lys Lys Ser Arg Lys Glu Thr Asp Lys 20 25 <210> SEQ ID NO 25 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Bos taurus <220> FEATURE: <400> SEQUENCE: 25 Glu Gly Lys Arg Lys Gly Asp Glu Val Asp G ly Ile Asp Glu Val Thr 10 15 1 5 Lys Lys Lys Ser Lys Lys Glu Lys Asp Lys 20 25 <210> SEQ ID NO 26 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Galus galus <220> FEATURE: <400> SEQUENCE: 26 Glu Gly Lys Arg Lys Gly Glu Glu Val Asp G ly Asn Val Val Ala Lys 5 10 15 1 Lys Lys Ser Arg Lys Glu Lys Glu Lys 20 25 <210> SEQ ID NO 27 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Xenopus laevis <220> FEATURE: <400> SEQUENCE: 27 Glu Gly Lys Arg Lys Ala Asp Glu Val Asp G ly His Ser Ala Ala Thr 1 10 15 Lys Lys Lys Ile Lys Lys Glu Lys Glu Lys 20 25 <210> SEQ ID NO 28 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Drosophila melanoguster <220> FEATURE:

-continued

<400> SEQUENCE: 28 Glu Glu Leu Pro Asp Thr Lys Arg Ala Lys M et Glu Leu Ser Asp Thr 1 10 15 5 Asn Glu Glu Gly Glu Lys Lys Gln Arg 20 25 <210> SEQ ID NO 29 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Sarcophaga peregrina <220> FEATURE: <400> SEQUENCE: 29 Glu Gly Val Ser Ser Ala Lys Lys Ala Lys I le Glu Lys Ile Asp Glu 1 5 10 15 Glu Asp Ala Ala Ser Ile Lys Glu Leu Thr G lu Lys Ile Lys Lys 20 25 30 <210> SEQ ID NO 30 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Bos taurus <220> FEATURE: <400> SEQUENCE: 30 28 gctgcgggtc tcgacgatga gtgcgggc <210> SEQ ID NO 31 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: Bos taurus <220> FEATURE: <400> SEQUENCE: 31 gcgtctagaa ttcacttggc tcctcaggc 29 <210> SEQ ID NO 32 <211> LENGTH: 38 <212> TYPE: DNA <213> ORGANISM: Bos taurus <220> FEATURE: <400> SEQUENCE: 32 ccggaattcg ggttttttgt taatgaaaat ttattaac 38 <210> SEQ ID NO 33 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: Bos taurus <220> FEATURE: <400> SEQUENCE: 33 tcagagcaga tgaactcgag cagtccagg 29 <210> SEQ ID NO 34 <211> LENGTH: 61 <212> TYPE: DNA <213> ORGANISM: Bos taurus <220> FEATURE: <400> SEQUENCE: 34 ccaatttqaa qqaqqaattc ccqccqccac catqaatqat qtqaatqcca a acqacctqq 60

-continued

61 a <210> SEQ ID NO 35 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: Kozak consensus sequence <223> OTHER INFORMATION: Synthesized by oligonucle otide synthesizer <400> SEQUENCE: 35 22 gaatteeege egecaceatg aa <210> SEQ ID NO 36 <211> LENGTH: 674 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <400> SEOUENCE: 36 agaagaaaat ggccaaggca tgctacaggt ggattttgca aatcgttttg t tggaggtgg 60 tgtaaccagt gcaggacttg tgcaagaaga aatccgcttt ttaatcaatc c tgagttgat 120 tatttcacgg ctcttcactg aggtgctgga tcacaatgaa tgtctaatta t cacaggtac 180 tgagcagtac agtgaataca caggctatgc tgagacatat cgttggtccc g gagccacga 240 agatgggagt gaaagggacg actgcgagcg gcgctgcact gagatcgttg c catcgatgc 300 360 tcttcacttc agacgctacc tcgatcagtt tgtgcctgag aaaatgagac g cgagctgaa caaggettac tgtggatttc tccgtcctgg agtttcttca gagaatettt c tgcagtggc 420 480 cacaggaaac tggggctgtg gtgcctttgg gggtgatgcc aggttaaaag c cttaataca gatattggca gctgctgcag ctgagcgaga tgtggtttat ttcacctttg g ggactcaga 540 attgatgaga gacatttaca gcatgcacat tttccttact gaaaggaaac t cactgttgg 600 agatgtgtat aagctgttgc tacgatacta caatgaagaa tgcagaaact g ttccacccc 660 tggaccagac atca 674 <210> SEO ID NO 37 <211> LENGTH: 200 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <400> SEQUENCE: 37 aaaaatagtt gtcaagactc agaagcagat gaggagacaa gtccaggttt t gatgaacaa 60 gaagatggta gttcctccca aacagcaaat aaaccttcaa ggttccaagc a agagacgct 120 gacattgaat ttaggaaacg gtactctact aagggcggtg aagttagatt a catttccaa 180 200 tttgaaggag gagagagtcg <210> SEQ ID NO 38 <211> LENGTH: 29793 <212> TYPE: DNA <213> ORGANISM: Caenorhabaditis elegans <220> FEATURE: <400> SEQUENCE: 38 gatetegaag taaaaaetea egeagaaaga geteeteete ettageatg a gaateeaae 60 tttgtaatga taacactggc aacatcaaca gtttgagaga aagcacgtgc t tgggcttca 120 180 caagettqtc caataqaagc atccatcaca aaaacaacat tatctqqtqt a actqcqttq

gaaacttgga g	catttcttc	gaaaagtgaa	gcttcttgct	tgtgacgacc	t	gatgtatca	240
acaatgatga t	ttcgaaccc	ttcttgctgc	aaaacaaata	ttattaaacc	a	ttttctgt	300
gataaattac c	gtgaatttt	tctactcctt	cggcggcaat	tttacgggg	t	caatttcag	360
agtatgatcc a	tagaaggga	atacgagctt	ttgtggcatt	ttgctttaat	t	gatcaaaag	420
ctccagcacg g	aatgtatcg	gcacagatca	gacatgtttt	ccatcctttt	С	tttggtagt	480
aatacgccat c	tgaacttga	aaagtgttga	aaagttgttg	gaagtttact	a	attaaaaaa	540
tataatgttt g	atggtgtgt	gagctttcta	ttgtaattca	tggaacgaac	с	ttggtacaa	600
gtcgtagttt t	accggaacc	ttgaagacca	acaaacatga	aaacgttgcg	a	cgtcctttt	660
gttggtgtga a	aggagttac	accaggatcc	acaagcttca	gcagttcatt	g	aatactgtc	720
ttctgaatgt a	ccgacgttt	gtttgctcct	ccgacgatct	cttcgaaatt	a	atcgctttt	780
ctgaaaatat t	tattaaatt	taaatcttaa	atagcgtaaa	aatttacttc	a	cgttgtcct	840
taagttgctt t	acaagacga	atatgaacat	cagattcaat	aagagctgta	с	agacttctt	900
tcagcatcaa a	tccagctcc	ccctcattga	taacggtgct	ctgaccgagc	t	ttccgatcg	960
catttcggat t	ttccgcccc	aaatcggcca	aaaccatttt	gaactgaaat	t	tgaaatgct	1020
ttaatttgtt t	aagcataga	attaaacgcg	ttttaaatcg	agagcaccat	a	aaaacagtt	1080
tggagaaaaa t	cgataattc	ttgtaggaga	ttcagtccct	gtggttttct	t	cggcttcct	1140
aatcattttt t	gacgacata	gtggtatttc	acaataggtt	ttttcaagac	a	caacagatt	1200
tttcacaaag a	gtagagaag	aaatggaaaa	ctgtagattt	cttctcgaag	a	gccgagaaa	1260
ggcaaggtat t	ggaagttta	aaaaggtaat	gtttctttat	tctttttca	a	aacaataat	1320
aaatggaaaa t	atatattta	tagataacaa	tttcagacag	ttaaaatcac	g	tgaaaaatt	1380
caaatttcaa c	acaaaaatt	gacgagtgga	accccgttgt	tgcgccttga	a	gagtaacgc	1440
ttgcgcgttt g	acgatttta	ttgacgcgtt	tctggtgcat	gcgggaaatt	t	tttattttc	1500
aacttttttc c	tgtttgttt	atccttttt	aattgaattc	tcatgatttg	a	aagctttga	1560
aaaatattat t	ttgctcaaa	aacatgcgtt	ttgtaaaaca	ttgattagat	t	caaggcaat	1620
taatggattt t	tgcacgttc	caaaaaaag	gaaattcatt	ttttgaaaat	t	ttgataatt	1680
taataatgaa a	aatgttcca	tagatttatt	caatgccatc	cttctctata	a	tctcgaact	1740
tccgcatcct t	caactgtgg	tagaggtatt	tgcaatacca	tatagtcgta	a	taataaact	1800
ttagtgaaca a	atccaagac	atcagctctt	gagtaaatga	atgatttata	a	aaactgctg	1860
attttctcgt a	ggaagaaag	agaatcagct	aataatccgt	cgttgtctat	t	ctgtcaggc	1920
cgcttaaatg t	taaaaaata	aaaacgtttt	aagctaattt	tgtatgtcta	g	aaactctaa	1980
ctcacaagca t	ttctgcata	cgccggatta	gttggttttg	caaaaagcga	g	taatctaca	2040
aaagtgaatt t	ttgattcat	ctcttccatt	tcacaaaacc	aattttgtgg	t	acgtatttc	2100
atatgatctt c	atccacttt	tttagttttt	gaatgtattt	gtgtgagttg	t	gtccagatt	2160
tgaataagat a	acatctcag	atccaacttg	caattgaagc	aagaacgatc	t	tctctgaaa	2220
ttttatatga c	cttaaactt	tatacttttg	tagtttcgtc	gatatctgat	С	gttcagttg	2280
tataggtatg t	acatctcta	ggtttatgtg	ctacacgaaa	atataatttg	t	tttacctaa	2340
cacacgcatc c	ataaaatga	tctacaaatc	gttcaattgg	atcctgtctt	g	gaaataata	2400
atttccaatt c	gtaaagttt	gcattcaact	cattttctcg	tttcaaatcg	t	cgatatccg	2460
caaaatatgt t	agtgaatca	ctatcacaca	ctctgaaaag	cacaatattc	а	tatttcgta	2520
gttaataatg a	acctcacga	ttcatcatta	aatttctctt	ggagcccgca	t	aatacttgc	2580

tgcccaatta	aagtatcagt	ttcacagatt	gcagttctat	catttccgat	a	gcctcaaat	2640
aagatttaat	cttaagcgag	tgttctgatc	aatttaaata	tttgatactc	a	ccgcaagtt	2700
tcttcgaaac	ttgttcgaaa	gctggaattt	tagaatatcc	ttcaaaactt	t	tttcctcgc	2760
cctcatcaag	ccataataag	ttttgatcag	caatatattc	gaataaatta	g	tctctgata	2820
aatctcgtat	cacaatcttt	ttttctactc	taaagaatac	aattttgata	a	gaatgataa	2880
taattataat	tataatagtt	cgtcgctgag	ttgatgaaga	ccacataatt	a	gtttaatgg	2940
caagctatgc	aacttgttga	atactaatag	gacttagcaa	atcttatctt	g	aaccttttt	3000
cattcgaaag	aaaaatgaga	tcgaatctcg	ttcaaactgt	ggagtagtca	g	ttaagaaac	3060
ttgtttctag	tttgtgagga	gacactggag	aacgtgaaag	tattacccat	a	cgcaatatt	3120
tttgcggcga	aaaatacggt	acccggtctc	gacacgacag	ttttaaaac	t	tgtaaatag	3180
gtatgtaaaa	gaaaacttta	attttaaacg	tgttgtttcg	gaattttcat	с	gttttgtca	3240
tagttattct	acaaataatt	atttatgaaa	aaaaactaa	aatataacta	t	aataacacc	3300
tgaatattaa	caaatcgatc	gaaaaaaaac	tatgaaaaaa	atggatgaaa	a	ttccgcagc	3360
aacgagagtt	tgaaatttca	gtattcttta	aaggcttacc	gatttcaata	a	atagtgaca	3420
ctgaaaattg	tagttttaaa	actagttggt	tagtatcatc	aaatattcaa	t	ccttcaaaa	3480
attcctcaat	attaacgtat	tttctctaat	tgtcttcatt	atctaaaaaa	a	agttgcaat	3540
atattttcc	aggcagaaat	agactttcac	aaaacacatc	gacacttcga	a	tgagcaaga	3600
agtttatcga	actgggtgat	cctgtcactc	aagacgttag	ttatagtttt	t	attacttga	3660
acattatcat	cttttacag	gagaaagact	acgaagacta	tgtcggagtt	g	gtttcgcgc	3720
atcaagtccc	gacaatgaaa	aggcggaagt	tgacagaaca	tggaaatact	a	cagaatcaa	3780
aagaagatcc	tgaagagcca	aaaagccgtg	acgtatttgt	ctcctcgcag	t	caagtgatg	3840
agagtcaaga	agattcggct	gaaaatccgg	agatcgctaa	agaagtgtca	g	aaaattgtg	3900
aaaatctgac	agaaactctc	aaaatttcta	atattgagag	tttggacaat	g	ttactgaaa	3960
gatctgaaca	cactcttgat	aatcacaaaa	gtactgaacc	aatggaagaa	g	atgtaaaca	4020
acaagtccaa	tattgacgtt	gcgattaatt	ctgacgagga	tgatgaactt	g	ttctggaag	4080
agaataataa	agaaatgagg	gatggagaac	aagtacaaca	ggtcaggaaa	t	tttacaagt	4140
gaatgaaata	agttaatcac	caaaatgaat	aaggacattt	cccatcagaa	a	ggtcttctg	4200
aattttaggt	gtaatgttaa	tttttgctg	tagtttttcc	cattgtttga	a	atttttgcc	4260
aaaattagtt	attgcatacc	cttcatgttt	ttgaagattg	tttaggaatg	a	gaaaacatt	4320
ttggacgctt	ttattattag	gacaccaaac	actttttgtt	gaaaaaacag	с	tcgtttaaa	4380
aaaagctttt	tccaaaaaat	ctgacgcaag	gcttgtgaat	tttcgttttc	с	cctgatttt	4440
taaaatttct	cctaaagttt	tttgctaata	tttttcgcta	tcgcgtaatt	t	actagtgaa	4500
tcaacaaaaa	atttttttt	tttcatagat	tttttataag	ttttgaaaa	с	atagattta	4560
aaacttaaac	ttaaattttg	acaaggcgag	aggaaaaaat	taaaattgc	t	gaacattca	4620
gatgccggtt	accttatttt	tggttcaaaa	atcccaatat	tacgcgtctg	g	gttatagtc	4680
atttgccttt	attaaattaa	tggtgttcct	tggaaaagta	agttctgttt	t	gttttcagc	4740
ttatcacttc	atcaaacgga	aggaaaggtt	gattaaggaa	agtaaacata	t	tttatgttg	4800
ttcttgtcac	ttcctccatt	tcgcaataat	ataactcgag	aaatatagaa	t	tttgttcga	4860
agttttcttt	ttccttcaac	attttaaata	ttgttagtat	tacccagaaa	a	atagaaaaa	4920

atcgaagaaa	tttgcaaaaa	agcagacgta	gaggctacgt	acttcttaag	с	acgcccctt	4980
ttcttttaaa	tttgttcggt	cgtaccgaga	tccggtacct	tattttacaa	с	gttttctgt	5040
tccaaaaata	ataatgtact	gcagttgtca	caggatttat	tcgctgatga	t	caagagcta	5100
attgaatatc	caggaattat	gaaagacact	acaactcaac	tggatataac	a	gattctgaa	5160
gtggagactg	ctcaaaaaat	ggaaatgatt	gaagaaactg	aagcagattc	g	acatttgta	5220
ggcgaggatt	caaaagtgag	acaaaatcat	tctgacaagg	attcctgcga	g	cactcagtc	5280
aagagcgagt	cacggcaact	cggtccaaaa	ccatttctaa	ttagtaaact	С	tcaaaaacc	5340
acaactaaat	agcttaaaac	ctttgtaaat	tagcttattt	ttgctaatta	g	caatgattt	5400
taagctaatt	agttgtggtt	tttgagagtt	tactaattag	aaatggtttt	g	gaccgagtt	5460
gccgtgactc	gctcttgact	gagcacaagc	aaacttttgt	ggatgttgag	a	atcagcggc	5520
aaagtggcac	tactagtgac	gaagttgacg	cagattctca	gattaatttg	g	taagacaaa	5580
gaaaatataa	attttattac	ccagatgcat	attttcatga	ttctgatgca	a	aaaatacgg	5640
tacccgatct	ggatactaca	atttttgtaa	aatgcgaaaa	ggtttgcacc	t	ttaaaaaga	5700
actgcaattt	caaacacttg	ttgctgtgga	ttgtttatcg	gtttttaata	t	ttttggtg	5760
agagtaaatg	agaaaagcga	gttcccgcat	tatctgtgtg	cgatttggaa	t	acagtactt	5820
ttcaaagacg	cacaccattt	tgcatataac	aaacatttgt	cgtgtcgaaa	С	cgggtaccg	5880
tgattttgca	ttaaaagttg	caaaatttca	catagttttt	ataatttagg	С	tacgaaaac	5940
tgtgaggaca	tccagttcaa	gtttcctgtc	aactgtttca	acatgcgaag	с	ccctgcaaa	6000
aggacgagca	agaatgtatc	aaaaagagtt	ggaaaagcat	gtgattgcat	t	tactgaggg	6060
aaatctcaca	ctacaaccag	atttgaacaa	agttgatccc	gacagaaact	a	tcgatattg	6120
tacaattccg	aactttccag	cttcccaagg	aagtacgttg	ttcaataaaa	с	atactaggt	6180
atataattaa	ttatttcaga	acttcgagaa	gataatcgat	atggcccaaa	a	atcgttttg	6240
cctcaaagat	ggcgagaatt	tgattcggta	catttctatt	gaattaatta	t	atactactt	6300
actagaaaca	ccatggagaa	agaatgcaaa	aaattgaatt	ttaaaaacta	a	tttttaat	6360
tttggctaaa	ttttcagttt	gaatttaatc	caaaatgaaa	actgcgacca	a	tcaatgact	6420
tttcaaaatc	acttttcaac	caatcaaacg	gagtgtgctg	ggctcgaaga	с	gctgattgg	6480
ttcggaaatg	ggcgtggttt	ctcattttgg	agggaattca	aaaaaggca	t	ttggtcaca	6540
gttgaaaatc	atgttttcaa	aagatgcatt	ttttattcct	tctcgatttt	t	tttgatttt	6600
cttttgtggt	atttctgaat	ttaaaggtgg	tgtagtcgaa	ttttttatt	g	ctttattag	6660
actcaaaatt	ttctgaaaac	gccaaatttc	ataatgaaac	ttcttgaaaa	с	tcttcagca	6720
aaaagttatg	acggctcaaa	aaatggccta	aaattagtta	agattggaga	t	ttgaccgac	6780
ttgtcaatgt	cgcagcggct	ggaaacaatt	tttttgaaa	tcaccgtcaa	a	ttttaagta	6840
tacaacttga	ttattttgcg	ttttaaactt	tatttaggta	tttaaaagtc	g	atggacggc	6900
gagttttggc	tcaaaaaaat	taaaaatctc	gccgtccatc	gatttttaaa	t	accttaatc	6960
aagaataaaa	caaaaggtag	gcaacttgta	tattcaaaat	ttgacggtga	t	tgcaacttt	7020
taactaattt	caggccattt	tttgagccgt	cataactttt	ttctaaaaag	t	tttcaagaa	7080
gtttcattat	gaaattcggt	gttttcagac	aattttgagt	ctaataagga	a	ataaaaaaa	7140
attcgagtac	accaccttta	agaaaatttt	ggatttccgc	tacgctaatc	с	acctttaat	7200
caaaatatt	tgaagttatt	caaagttaaa	gaattatatt	ttcagagggg	с	cgtagaaga	7260
gactcatatt	tctatttcaa	acgtaagctc	gatggatatt	tgaaatgcta	с	aaaacaact	7320

ggatatttta	tgtttgttgt	aagtttttga	aatacaattc	gtttgaagat	t	tactctatt	7380
ttcagggact	tttgcacaac	atgtgggaat	ttgacccaga	catcacatat	a	aactgccag	7440
cactggaaat	gtattacaaa	gagatgtcgg	aacttgttgg	tagagaagag	g	ttttggaaa	7500
aatttgcacg	agttgcccgc	atcgcaaaaa	ctgctgaaga	tattctgcca	g	aggtatgat	7560
ttatgagata	tacagcattt	cctctaatag	tattgcatat	aaacatttca	С	tttgaggtt	7620
atatcttggt	ttattttaaa	aatatcaata	aatacaaaac	aatagaaaaa	t	gataaaaaa	7680
acattttgtc	agttgataat	ttgggtatag	tattcattca	taatttgatt	t	ttttagcga	7740
atttatcgtc	ttgttggtga	cgtcgaatca	gctaccttga	gccacaagca	a	tgtgctgca	7800
cttgttgcga	gaatgttttt	tgcccgaccg	gacagtcctt	tcagtttctg	с	cggtgagta	7860
atacaagaat	gctcatattt	ttagaatcaa	tatttgcaag	gaactttaat	с	ttacgtacg	7920
tcttaagatg	agcattttcg	cacatatctt	acgcgcacga	gtctcgacac	g	cgaacatcg	7980
agcttctgta	actcgtatca	atttacaagc	cgttattaca	tcagttttta	a	tgaatttta	8040
agaaaatcgt	gcaaaagtag	tgtcgagagc	cattcgcgta	agatatggtg	a	gatttatca	8100
ttttagacg	tctagtggat	atctaacaaa	actttataca	ttttatttc	a	gaattctct	8160
cgtctgataa	atctatttgt	gtggagaaac	ttaaattcct	gttcacttat	t	tcgacaaaa	8220
tgtcaatgga	tccaccggat	ggtgccgtca	gttttagact	tacaaaaatg	g	ataaagata	8280
cgttcaacga	agagtggaaa	gataaaaaat	tacgttctct	tcctgaagtt	g	aattctttg	8340
atgaaatgct	tattgaagac	acagctctct	gtacacaagt	tgattttgcg	a	acgaacatc	8400
ttggtggcgg	agttttaaat	catgggtctg	ttcaggtagt	tatttaaagg	a	atataagaa	8460
tttgaagttt	tattttttt	atgcaggagg	agatccgttt	cttgatgtgt	С	cagaaatga	8520
tggttggaat	gttgttgtgc	gagaaaatga	aacaactgga	agcgatttca	a	ttgttggag	8580
cttacgtttt	cagttcttat	actggttatg	gtaagtctag	actttcaaaa	a	aaactgttc	8640
caatatgtca	atatatttca	ggtcatactc	taaaatgggc	agaacttcaa	С	caaatcatt	8700
ctcgtcagaa	tacaaacgaa	tttcgagatc	gttttggacg	tcttcgggta	g	aaactattg	8760
caatcgatgc	aattctgttc	aaaggatcaa	aattagattg	tcagacggag	С	agttaaaca	8820
aagcaaatat	cattagggaa	atgaagaaag	catctatcgg	attcatgagc	с	agggaccga	8880
aattcacaaa	tattccaatt	gttactggat	ggtggggatg	tggagcattt	a	atggggaca	8940
agccactgaa	gtgtatgtta	tttcattcgt	taaatattga	agatggagga	g	agtgaatgg	9000
ggattttgct	tcttttgcaa	aatggcctcc	ctatgtacct	gaaaaaaaaa	t	gaaaaaatc	9060
gagaaatatt	gaaaaccaaa	caacgaattt	ttcacaattt	tgcctaaatt	t	ttgaatttt	9120
cgccaaaatc	ggaatcagcg	attcgctcca	cccatttttc	cgccaatcat	t	tataatgtg	9180
cggagctcaa	aaacactgat	tggctagaaa	gtgggcgtag	cttcttattt	С	ggaggaaat	9240
tcaaataggg	aagttaatct	aaattaaaac	aatctcgtta	aaaaatgttt	с	tttttcaa	9300
tcttccctat	ttgtttaaat	ttttctttt	aaagatcgtc	taaaagctac	С	agtatctga	9360
ttcaattatc	ggttttttc	agtcataatc	caagtaattg	ctgccggagt	С	gctgatcgt	9420
ccacttcatt	tctgttcatt	tggagaaccc	gagcttgccg	caaagtgcaa	g	aaaattata	9480
gaacgaatga	aacagaagga	cgtaacactt	ggtaagtcat	gtttttcaat	С	ttcagttga	9540
tttgaaaaag	ttgtatcgag	ttggaaacag	cttttaatct	aaattctgct	a	acttacagg	9600
catgctattc	agtatgataa	acaacaccgg	cttgccacat	aagcactttg	a	attctacgt	9660

cttcgataga	atttctactt	atctcagtag	ttcggaagat	gttgagtctt	С	gaaatcatc	9720
accttcagta	tcccgagcat	aattcgaatc	gcccacacgg	ccataaagac	с	ggttccttt	9780
cgattaaatt	ctgttaaata	tgcatgctcc	gtctttaaaa	aatcagtccc	с	gtattttaa	9840
acgttttgat	tttaatgttc	atattattat	ccgaaattag	tatactcgcc	g	tcatgaaag	9900
cccgagatat	ctagttcgca	agtcagaaat	ttttcggagc	atcgtcgtga	t	atatgaata	9960
aatacattcc	tgtttttcac	aagtgtagtg	tgaaaccaat	ccatgcagac	g	tttatttct	10020
gaattaattt	tgaaacagat	ttcagagaca	gtgaggttga	cattagatat	g	ggcaagtaa	10080
caataacagc	agggcagtta	ttatgattat	ggatgctgat	ataggaaagt	с	agaacagta	10140
taatcgacga	gaataaaaag	agatgagaag	ataggcgaga	ataaagaacg	t	taacgaaaa	10200
tcactgaaga	gctacatttc	caacagaata	agaaatgtag	ttggaaatcc	С	taatcaaac	10260
agaaaagcga	gaaatcatga	ctttcgagat	aaagagattt	atctgcaaac	a	attcttgaa	10320
cataaaatta	aagcaccaca	gactgtccaa	attataaaat	cagtttctcg	с	tacagtctg	10380
ggggtactct	agttccattc	aaaaacttct	tgcaaacaaa	gagaaataaa	с	agacttgta	10440
cgggacacat	ataaaatcta	agcatgcttt	gaaaagcgga	gaacatacga	t	ctattcggg	10500
gatatacata	tatatatata	tatttcatct	catctagagg	atcaccatcg	t	tactcatca	10560
aattggttgg	tgtggtggaa	gttatgaaaa	gagcaatttt	aaccgaaaat	с	accaaaaca	10620
gaaaccaaat	taatgtataa	tcgacgagaa	tcatgatgag	atgatgattt	g	cttctagca	10680
gaagtttaga	agcacatgct	atcattcatg	ctcacgatga	cgataggttc	g	ttatgcatt	10740
cttgaagcca	atgacacttc	cattgctcct	tctcttgcgc	tcacacaatt	t	ccattctcg	10800
tcgtaaatcg	ttcgactttc	gaatatccac	atcttaccgg	gcggcacttt	t	ggcctggtt	10860
tggcagatct	gaaataaaat	cttttcataa	tttaaagtct	gatatcccga	g	aaacaatag	10920
ctgaattgaa	acagaagaat	aaatctcacc	tgaatatcca	cgtttgcaag	t	gaagtttct	10980
ttcacaaacg	gctgtgtttc	ctcatagaga	tcatctgaac	cgtaggagaa	t	ggacggagc	11040
aagtcgttca	gcttcctcat	gtgctgttca	tttgccggtc	tcacgtgctt	с	tttacggga	11100
gcagtggcgg	cagcatacgc	tgatttagat	gctcgcatag	tgtcattcct	a	cgactttga	11160
ggcttccttt	cattgttgta	atgcggttgc	atttggaacg	gtgcgttttg	a	aatcctcgc	11220
atgacttgag	acgattgatg	atgcgatggt	ggaggaatgt	ctgcaagatt	a	tagttatgt	11280
attaaaaatc	aaaaatttgt	gtggttccca	ttttaaaata	aaaaaaaat	a	ttttacgc	11340
actttgctga	ggcaaccgat	aactatttcc	tcgctggcga	ctacttctct	t	attgtgagc	11400
attatagctc	atgttctcat	gattgagttg	acctgaacga	tcaaggttaa	a	actaggcct	11460
aaaactagtc	aaaattactg	agtttctcct	tccacgtcgt	ctgtcgagca	g	gctccgagt	11520
acatttttac	tggaaaacta	taataaatta	caaaaatcac	gccgaaaatg	g	ggaaaagaa	11580
ttgaaaaatt	gaaggaacac	agaacatttt	ttcaatgcgt	ctctcacgtt	с	gagactact	11640
gtattcgtgg	tgagacccaa	ctccctcata	aaagcatgcg	cctttagttt	t	ttaatttaa	11700
ttcatgttgc	caatattggc	caattaattt	caagagactc	tgattgaaag	t	gttataatt	11760
aaactacata	tatttaagct	ttcagcattt	ttttcaatgc	acttgagacg	с	aaattgaat	11820
aatcaggcac	gtaatgtgtt	ttcgaggacg	actataaatt	gtacctttgc	t	atccagtgg	11880
gttctttaat	tttcccattc	caatcgattt	tttctcccac	tctggcagtt	t	ctttgtcat	11940
cactggacga	gggcattgga	atgggagatg	attcatgtga	caatccacac	a	tcctgcaat	12000
aatgacatta	tttttaaaa	atgttaagat	gatatgctta	ccaggagtaa	a	tatcatatc	12060

cttttcttta	ttagttggct	tagccttgcg	gccacgttta	ccatttgaca	t	tatagttac	12120
ctgaaaattc	aaaaattag	atattcaaaa	aggtataaat	ataatataaa	t	gcgatttgg	12180
taaatacgga	tgtaatgggc	aacccattct	atacaggaaa	accaaaaaat	t	cccgcaaaa	12240
ttatttttt	ccgaataaaa	tgatctactt	tgttttatgg	tgccgctcta	t	gtgttatga	12300
cccttcgatt	agtagataga	aaagaaaaag	gaatgtacga	gaatatcgtt	t	attatttat	12360
tatttgaaaa	atcccagaga	cataaaaaat	cacacagaaa	agggaaacag	t	atttctgac	12420
aatgttcaaa	agtttggttt	caatcagcac	taataatgtg	aaaggtaacc	g	tatcaatag	12480
tgatatttc	ttattaaaaa	actgttcgag	actacaagaa	ggcctgaaaa	a	gcccgcaac	12540
gacgactaaa	ttcgaaattt	cgaattaggt	tttaaagatc	agaagatcgg	с	agaaaagta	12600
tctgataaaa	atataagaaa	tcggaatagg	aatgcgatga	ggaggtagaa	a	tatggtgaa	12660
gagatacaga	agaatgaggt	aagatcggat	gaacttgaag	cactttttga	g	atttttgat	12720
ggtgaagttg	gtggatgtag	acgtttcatg	gaacatctga	aaattaagat	t	tttctaaaa	12780
cacattttct	atagaatata	atagaatgcc	aaatagagaa	actagactta	с	ttgaatttc	12840
tttcgatttc	tgtctttcaa	ccttctaact	gaaatcaact	ttcgacgtgt	t	ctcggtgtt	12900
tcaacaacac	catcaacaga	acactcagca	ccaaattcag	catcggaatc	a	tcagaagaa	12960
gactcatcgg	aatccaaata	gaaattggat	ttagtattca	tcaattcaaa	a	gaatccaat	13020
gatactgtcg	attcagcaag	ttggactgaa	cttgatggtt	gactacgaac	С	cattgaggg	13080
cgtcgaggca	gaagtcgaga	gtatgaggat	gcaacgtgga	ttgatgatga	с	gtcaacaat	13140
ctttggtgtt	gagatgaaga	agtggctgat	gcagatgttg	acagacggaa	t	ggagatgag	13200
tgaagagcaa	gaagacatct	gaaaatttga	aacgttgttt	atgtggacag	t	actgtaaag	13260
atcttacctt	ggatcataac	tacttgccct	ctgttttctc	ttctcttgac	t	tctacttaa	13320
aagcatttcc	gtctcgattc	tccggttact	tgaaaatcca	actccagaat	t	ttcagcaca	13380
aagctgctct	cccgaaccgt	agactgttgc	accacgttga	ggggttgaca	a	ggatctgaa	13440
atcagatgtt	taaagcatgg	caagtagagc	aacaatgtta	accaaaattt	С	tgaaacttt	13500
ttcgaatata	gtcaaaaatt	gacaataact	cagtttcacc	tatcatagtt	t	tggaagtca	13560
accaaaaatt	tttgaaattt	cataaaaatt	ccaaactttc	taaaaatttg	g	aagattgat	13620
atgattgata	tgaaagtatt	tatatattt	ttaacctggc	agacgatact	t	caccattaa	13680
agacacacat	gtggagaaga	attatttac	ttttagtaat	ccaacgtttg	с	acttacctt	13740
ggagcatgca	agcttttagt	cattaaagct	ggaattctag	atggagttct	t	cttggtgtc	13800
gacattgttg	aaataaacat	tcgtggttca	ttgattgatg	atgacgtcat	a	gaaccacgc	13860
ccagatgaca	atggattacg	gtagtcatca	gaatcagtag	attcattcaa	t	tttctagtc	13920
atttcttctg	ttttctggaa	aattaaattt	taattaaaga	tctaacaaaa	a	tctggcact	13980
tacattaata	agataatcaa	catattctaa	ctcattcatc	gtttcattat	t	ttctaattc	14040
tggcttcttc	tcatcgaacc	gttcggtggc	attgtgtcgt	tgcgggcttg	a	ccgtttttt	14100
gaatttctga	aatgtttttc	atgcaatttt	tgttcttatt	tgtgtgtcat	a	tacagtgaa	14160
aatcaaaaac	tagtacaaac	taattccgtt	tagtaaataa	aaaatcgatg	t	aaaatctca	14220
gcaaagccaa	gatcttggcg	ggtccttata	tccaagtttt	gttgccattt	t	atttcagat	14280
attcttttcg	aaagtcagaa	aatttgaatt	tagaatcgaa	tggacccatt	t	cttgttttt	14340
ttttgttgca	tttttaact	gtacttttt	cgtcagcata	tattttcact	a	ttaaaacag	14400

				CONCIN	-u	cu	
aatattcatg	acaataattc	cacaaaaaaa	cgtactttaa	tatcatagtc	g	attggttca	14460
gaattggaac	gagaaccttc	gacgcgtcga	ttgtcagatt	ctcgattgat	g	gacgacgtg	14520
ctgactgaaa	atttctggat	tgaaaaaata	ttcaaatgaa	aaaataaatg	a	gaaactcaa	14580
agtctaaaaa	atgaatgttg	ttaataacga	atatttctga	tgagaagagg	a	tagagaaaa	14640
aaaacgagtc	taataaaatg	catgtgatat	cctgcataaa	aatcccttct	t	ttttcacta	14700
atccttcgct	caattcattc	aaatagaact	ttgatttcta	ttagagttga	g	gttgtttga	14760
acaattttaa	taaattaaca	ataagccata	aaacctcgaa	acgtaccatc	a	tcattgagt	14820
ttgaaaaagt	ggacggatcc	gagtcagtca	cctctggaac	aaatcgttcc	a	gagcactga	14880
aaacgacaac	gttctcccca	cagaatcgga	ttgtctcctc	gggaattgtc	g	cctcgacaa	14940
acgatcctga	acctgaaaat	tttcgatttt	tgtaagctca	atggatttta	a	actgaaaat	15000
gtagtcaaga	agtcaagaaa	aactgatgga	gttctaaatt	cggtgttagg	t	tttgaaaag	15060
atcgtcaaac	aaacaaatgc	ataaaactag	gtagggaaca	aatagtgaaa	t	agaaaaatg	15120
aaaggcgaca	actgccggga	gcaagagtac	acacaaagaa	aaaaagttgc	g	gaagagcac	15180
agagagcgtc	agtccatcag	aactgcatag	ataaatagat	aaagagaaac	a	tgaaacata	15240
aggccacccg	ggagagacga	caggccagtt	ttccggtgaa	gatgagagtg	С	gagaattag	15300
ataagaaaac	ggaaattgtg	atgaaacttt	ttcaatccaa	acttctagaa	t	tataagaga	15360
cacctaaagt	aattagataa	gtgttttaag	tgatattta	gattcactgt	a	tcatgttta	15420
aaaaagatat	ttcaaaaata	tatacctgat	ataggaggcc	tcctctgagc	a	ccgaattgt	15480
tctcgagctg	tttccacgag	catccgctca	cacattgaca	taggccgtcg	a	cagccagga	15540
gttgccacct	gaataaataa	ttattcaatt	taaacctaat	ttagtaatgg	t	aactttgta	15600
aatgatggtg	gatagctcat	ataaaatttg	aattggttct	aaagttatac	a	aattttaat	15660
ttcggtcaaa	cttatgaact	gtacttttga	gttatactat	tacaataata	t	tacccaaat	15720
tattgtattc	agatttttgt	aatcagtact	aacagatttt	aggcaacgtc	С	tgccagaaa	15780
catgggaata	tatttgagca	gtttttagta	agttgccaca	gcttgtataa	g	ggaattgta	15840
tcaaaatgta	cttaatactt	tctaagcact	gacatagtga	actacaaaag	t	cggtattat	15900
acaatgccac	tacaaataaa	aatattcaga	attcgactga	aaaatgagaa	a	aggaacaac	15960
tgaattggac	acacgatgtc	gtgattttca	agaacacaaa	aaaaagaaaa	a	gaaatcgaa	16020
aatgttgttt	gcctctttt	ctttttctat	atgagctaga	atctcgaatg	С	atgcctaat	16080
ggagccactc	gctctcgttt	ctctaagtct	cttctcacca	gtcttttgtc	С	aaaattgc	16140
gatgtcgcag	gcgtcccgtt	tccgccgctc	acggagacac	cactatcggc	a	ccagatgat	16200
cgtgtaaaga	caccgtcttc	gttgacttca	attgctgaaa	taagaggaat	t	agttttgaa	16260
ttggaaatct	gattaaataa	aagtccccta	ttcaatctaa	ttaattttta	a	acacaaaac	16320
ttactattgt	ttaatggtgt	tgacgaatta	gaagaagttg	attgaaatgc	g	ttaacattc	16380
cattcaaagc	tatcttcatt	ccattctgct	cgttcttta	tcctttcact	с	acgtctcga	16440
gggatgaagt	tttcaacaat	aagaagcctg	aaaacttata	ttattctatt	a	aaaaaatg	16500
aacatcaaat	cctaacgaaa	gaaaattctt	ctggggggaa	aaggagagaa	t	tgtgagaat	16560
aaagaacctg	cgctgtcggt	atcaaattac	actatttgaa	ttcaaattag	a	atacgaaag	16620
aaagtgaaag	aaatgaaaat	gagtgagaat	ctattaaatt	gtaattgaga	t	atcactgaa	16680
cttacttcaa	cttcaattcc	ttgctcactt	ccgcaattgt	ctgatccaga	t	cttgtcgtt	16740
cgtcggaata	tgctccagac	acatcacgaa	tctcattgcg	agcctgaaac	a	ttcacaaac	16800

#### -continued

cttatcttga cacctggtac atctgaagtc aaacctgtct caactttatc a acatcttct 16860 ttaacttttt tgtctttgcc tccacctctg tccttaaatc cgaaaatgtt t gtttcaaat 16920 ccacagtate etetteetge egtteeaatg etteaaceat ttetetttee e ttegttttt 16980 gttcggcaag ttctcttctc ttcttttcca gttgtgcatg ttgttctttt g tccttgatt 17040 ctaaccttcc atcttcttca gatcctacga taagtcgact ttgaatgttt g ctattcttt 17100 cagcaacccg tgcttgttct atccgttcct tttctaacag atcatgcttc t cttgaattt 17160 ctcttattaa tcgatccttt tcatgtttta tcagtgaatc atctttttga a ttgcttcaa 17220 tatcatcttc aagttttgct cgttcagcat cataaaaaact ttgagttgct c catccctcg 17280 atottgtott tototgotto agttgotoac ggagcattto aatttottot t ggaattoto 17340 gcagtaaagc atccttagga tcttcattaa ttttcggttg attcttgatg t ttttagctc 17400 gatttgcata tcgtaatgta ccaagtgtct cctcaaaatt gtaacttgca g gtccaatac 17460 aagcaaccat aactgtcttt gaatttccac cgagagaatc ttgaagaagt c gagtcagtt 17520 ttgaatctcg ataaggaata tgggcagatt tcgcatccac caatgcactg a ttacatttc 17580 caagagccga taatgaaaga ttgattttcg tagcttcttt aaatctttcg c cagttgctc 17640 ctgttttcga ttgccgttct gaaccagcta aatctacaag atttagtcga c caactgtaa 17700 tatgactttc tccgtcttca ccaattcggg aacattcaac agtaatgata a agatagcgt 17760 gggaacgaga cgaatgetea tteatgttgg ttegeetgaa aattttagta a aateaaate 17820 caacggcgac cacagaaata acttacccta cagaccgatg cccatttcct c gaatcatca 17880 cttcqtqtat ttcacctact qtccttqtta attttqactq aaactttqaa a tttataqtc 17940 gtcttctatt tcagaaaact atcacttacc gttaaatctt tcacataaac t cctccatct 18000 ggacgttctt taatttctaa tttcttattc gattcggctt ctaataaatc t cgaagttcc 18060 tcctaaagat ttcattttg taaatcacac atcctaacgc cttacctgat a aatttccaa 18120 atagetaget ctaactaaat actettgatt atgtgatget gecatgtget c aaaaatatg 18180 gtcaatacac ttatagatga cacctcgttg ttctggatcc gatgattttc c ttccattgt 18240 gtgagtettt ccagttecag tttgaccata tgcaaaaate gtggcattat a teegtttag 18300 aaccgaatca actagatctc gaaaggtttc ttcatataga tccgattgtg t ggaactata 18360 aaatatatat ttttaaaaaa gagaactcat aaaatcataa acataaaatt g tggagaaat 18420 aattttgaaa aatactaata tttctatagc aggtgaaaaa aaagtgatgt a ctcctagaa 18480 ataaataatc ttacttttca tcataaattg catcgaatgt aaaatccttc g atggctcat 18540 cttgctcttt tggatttttc agctcaattt gcccacgttg tggtcgcata t gtactattc 18600 tttgcaattt cttgtgaaga taacggtcga catctcacaa ttacctgtaa a cataaataa 18720 atacatttat ttgaatttgg aaatgtataa aactggatta tgaaattttt a agctggtgg 18780 tttttgtatg agaagtaacg aaaaaaagta caatttactt agagtcttgt g atttttctt 18840 tcaaatgcaa aactcaactg aatcataaat agtgatgctt cgaaaagttt t tagaggaaa 18900 attgtatttt tagtaaaaac taatatacgt tttggactta aaaaaaaatt a tgttaaaac 18960 ttgaaaaatt acgtttatta gtgcttatat taaaatacgg tttcaaatta a tttaaaatt 19020 aaaataactc accttttggt caaaatcaga cattttagaa actagcatgt a ctttattac 19080 gttgaatata acttatgttg gaaaatggaa aatttgaaga caggtgaatt t tagtttttt 19140

			-continued				
ttctttttcg tac	ttctaaa	aaatacttca	tttattttac	attttgagaa	c taatttttg	19200	
aacatgtttc gaa	acaaaaaa	aaagattttg	aaaaccccaa	aaaaacttac	t ttgacagtc	19260	
tcctgttttg aag	gatttttt	cattatttcc	accattttt	gtcactaaat	a tttggctat	19320	
caatgtaggt gto	aaggaaa	attttggtgc	attcctgatt	tagtgagagt	g gtctggaac	19380	
ttaagaagat tag	ytttaatg	tggaaaaata	atcatattgt	atcgagaaac	g gaattttga	19440	
agcaataacc gct	agagaaa	gtgactaaaa	accagaaatt	gtagtcgtgg	a atttcaata	19500	
tttttggttt tat	gtcacat	ctggacaatc	ggaaaaatat	gcatacattt	g aaattttta	19560	
gaaatatttt gaa	attaactt	taaaggaaaa	aaatgcatta	aaaagattga	a aacatcatt	19620	
gacgttgaaa aat	ggagaaa	atttctaatt	tctcatcaaa	atattaaaat	a ttaaagttc	19680	
ttcaataata tga	aaatgtg	aataaaatgt	ctaaataagc	aaaaaaaca	g atcctattc	19740	
attataaaat gtt	cacacaa	gtgttacatt	tcgtacaaag	aagtactaaa	a cggatggac	19800	
taaagtaata tto	Jtcactcc	cgaaaagacg	aggaagaagt	aatcggaaga	a gatgtcgga	19860	
agatgagtga tag	gtaaaaat	acgaagagac	gcagatagag	agtttgagag	a aggagactt	19920	
ctggaggaat aaa	aggtggt	ttcaagatgg	gggacagaga	gggagagggt	t aaaagagca	19980	
caaaatgtgc ata	atatcga	tcctgcgcag	ttgagagacg	cagacaatgt	g aagaatgga	20040	
gcatatgttt cta	agtgaaca	ctcagaagta	gttgttcatg	tgtccgaaac	t ttggaaaca	20100	
tatacatttt aaa	acttgacg	tttttgaatt	ataaagggat	ggaggtgctt	c aaaaagtaa	20160	
tcatagacat gtg	gtagattt	taaattaaaa	cacaactaga	cataggatga	a tcagaagct	20220	
taccataaca tto	gttgattt	atttaaaaat	gagaaaaagt	aaaattccgg	a tagtcttct	20280	
ttgaaaaat tca	acagagaa	gttataatgt	ttgatgatat	tcactgattt	g taatacatt	20340	
attagtagca tgg	gcttctat	gtatatagac	tattttata	tcacatacat	g aaaaagggt	20400	
taaggcatgc gcc	agggcct	gaaaacgcat	ctacctacca	ggggagctct	a gctcttagt	20460	
tattaattca aga	agactttt	gaaacttgat	tttttgagat	tttattcaat	g attggttta	20520	
aaaaaaaga tta	atttgcaa	aaattacaaa	ttttaatgtc	tatactctga	c atcggttta	20580	
gaacaatttt aga	acaggctg	caatgaaagc	aatgaaataa	aatttccttg	a aattataat	20640	
agagaatcag taa	aatgttg	cagattattt	gaaaatgcat	gcaagaattc	g cagaaaatt	20700	
cagtgaagca gaa	aagtgcg	acaggagacc	gaagtctaaa	aaagtgaatt	a tgaataaaa	20760	
acaaatcatg tga	actggata	taattgaagg	tcttgattcg	gaaaagataa	t tggagctct	20820	
ttgcttaggc cag	gctctag	atattttatt	gaagcttttc	agaaatgttc	a aaattatca	20880	
ggaacagttc tct	ttgcact	ttctctatgg	ctcaactacc	agggcttttc	c tttttcttc	20940	
aaaaagtaga att	ttaaatt	ataattttaa	aatttaaata	ccaagcaaaa	a atcatatac	21000	
tcatcatatc ato	gtgatcat	atcatataat	catatagggc	tcgttctttt	t tttttcaaa	21060	
aaattaaaaa ttt	actagaa	ccaagcatat	gacaataaaa	tattttgaat	t cactttaat	21120	
gggaaaaaaa caa	agaaaatt	tcattaacat	tattgaaaac	atcgttggca	a taggaatgt	21180	
agaaaatcaa ato	aaaatca	agtgagatta	ggaaagaatc	gaaattaggt	a gaattggaa	21240	
aatctcgatt ttt	taagttg	gattcttaca	cgatttttc	gggatatttt	t catttttat	21300	
tttgtagtat tto	agcctag	acggctgaga	attcttttca	aaccttccaa	t ttcaaagag	21360	
attcttccat aat	ttaatat	aattttcatt	cgatattagc	atccattata	t acgtatgat	21420	
tcccctttta aaa	atcgattc	tccttttcaa	ctgactcatc	acttaagaat	t gttgagtca	21480	
tcaactgata gtg	Jagcagac	accaacaacc	atctctttag	tttccgttcc	g tttatttta	21540	

							01600
	taacatattc						21600
	tcataagtat	-	-	-			21660
-	tatttttt			-	-		21720
-	aactagtttt			-			21780
	tttttaacga						21840
-	tttaaattct				-		21900
	aaaaatattt						21960
ttcttcaata	ttttcttctc	tgcgtttccc	acactcttat	tttctgactg	t	tgacttttc	22020
cattgtatag	actcaatttt	actttcgttt	tttcaatttt	tttttctgcg	a	agttcggtg	22080
ttaaacctcc	attttgcaat	attaaaaatt	tcaatattgc	ccgttttggc	t	tgaatctat	22140
taaaattatg	ctgtttttt	ttcagaaagc	accaaaacat	gccagatgat	a	ttccaaaat	22200
tgccacgaca	cagaggaaag	aaaaatcagc	cgaaaggttt	gaaaaattta	g	aaaatctg	22260
aagttacttt	tttaattctt	tagacacacc	ttggaaacaa	caaaaactgc	С	tgctttacg	22320
gcctcattat	aacataactt	cagcaattcc	agttactctg	ataacaggag	t	agccacgtt	22380
ggcaatggga	attgctcttt	atttcggaca	taatggatgt	gagtttttag	a	gtttattat	22440
cccaaaaaca	aaaatatcaa	ttactctttc	ctggtaataa	gtaagaaaaa	g	ctaaagaaa	22500
acaaatttct	tgtcaaaatt	ttacattgta	aaccgatagc	aacaaaaaac	a	agtgtcata	22560
aaaactgtaa	gaaaatcgat	aattttgcta	caatttcaca	aagctaaaaa	a	tattttta	22620
ttttaccgtg	ttagtaccgg	aatgttctgc	acttgagcct	tactattagt	t	acacaaaat	22680
ggatcaattt	tgagcaattt	gttgtgaatc	tgacaataat	tagtcctatt	g	atatagctt	22740
taggccactc	attcgtgttc	gtaattttcg	ttttccttga	acttgtaaag	g	tacagtttt	22800
tgaaaacagg	gatgtagtcc	aagtagtcaa	atattgattc	ttgtagcatt	a	gaacaagag	22860
attgtgtaca	cggattgtgc	tctttcaaat	ggaacacaag	cttcacgaat	t	atgagaact	22920
gaaatgggaa	atcaaacatt	taaatgtgca	tatacaatta	ctttgaatga	с	gattatact	22980
gtaagttgag	ttttaatttt	taaatcatca	aagaaaacat	atgtatattt	t	tgcgaagga	23040
aattttggat	ctggtcttag	gatgaaacga	cattgtaaca	ttttgattaa	a	gagccctta	23100
gttggaagtg	agtgtatctg	gtaaaaacac	aattcgaaaa	tatttaacca	a	atatgtata	23160
aagcctaggt	tgaacctgct	ctgcagttcc	taatttttca	cattatttt	с	ttcaaaata	23220
ttactatgat	atttcaaagc	ccggggtacc	atcttaaaat	catcatttgc	a	agtatcaca	23280
attaatgttc	aacattacag	ggcgaagtga	agttttatta	cggtctttcc	a	agttctatc	23340
aaaacaatcg	attatacttc	aactcacgaa	acgatcaaca	gctacgtgga	a	aagttactg	23400
aaactgacgg	atgtgatcca	ttagaatatg	tggatgttaa	tggaactaaa	g	ttcccattg	23460
cgccgtgtgg	gaaagtggct	gattcaatgt	ttaacggtgc	atttcaattg	a	ttgcttaat	23520
ttcagtattg	caacattttt	cattttttat	aatacatcta	acttcaaaat	t	tgtttttt	23580
ttcagatacc	ttcgaattat	tttatatcaa	tgataaagcc	tcaaacgcgg	t	aacacgggt	23640
tccatggaca	actcgtggag	tactcggtgc	aactgaaatg	aaaagaaaat	t	cagaaatcc	23700
	gaaaaccaga						23760
	aaactccatc						23820
	gggactaaac						23880
-					-		

				-		
attttatggt ttggatgaag	gttgcagctc	ttccaaaatt	cagaaaactg	t	atagaatac	23940
tgaatcgaca agttgatato	y ttcagtaatg	gattacctaa	aggacaatat	С	agttgacca	24000
ttaattacag tatgtttato	y ttaatgttga	atttatgtat	ttatgcaaaa	a	atttactgc	24060
aaaagttcac aataattcca	a cccaaacctg	cttaaatatg	gagatgcaag	t	tttttgttt	24120
cagataaaca gtggctccaa	a aaaaccaatc	tttgttataa	aacctcacaa	a	aatttctcg	24180
atatttcttt attatggtto	aaacttttga	gaaaaaaggg	aaatttagaa	a	attctttca	24240
agcgaaattg tcaaaattt	tcaaaaccaa	atttgatttt	ccagatttat	t	ttttgtcga	24300
cttgacaata gtaaagaaaa	a acaagttga	atttttctat	atgaattctt	a	tagctgaac	24360
atttttgatc aatttgaaaa	a taatcaatag	acaatttttc	tccatactac	t	gattttcag	24420
actatccagt ggatatgtat	tcgggcgaca	agtacttcgt	tatagccaat	g	aaaactggg	24480
ttggacccag gaatctgtt	: ctaccagtaa	tctatttggt	tgttggaaca	t	tcttacttc	24540
tcgttactat tctcttcata	a ttgatttggt	taaaacagag	actgtcgagg	g	ttcatccaa	24600
catgaattgg aaaaactaat	: tgaaaataga	cggatgaact	tcaaatttgt	t	tacaagagt	24660
tgaagtetea aaataagete	g gtagcatgta	ttgtacggga	acagatttgt	a	tactttgct	24720
ttgtaaataa aataaaatgt	: tattatatta	gtctgtaatt	ttatgtatag	t	tcaatttaa	24780
ttgaaataca taatacccco	: ttcagtttat	caattaaagc	tccaactatc	a	ttcgctggt	24840
tgagattaat tgtcgagtga	a gggcatctga	aatgtaaatt	taaaattaca	a	aataaataa	24900
ttgtaagtgc tatcagatat	: aacaaatgat	catttaatta	aggaggaaaa	a	caaaacatt	24960
aatttaaaaa atttatcaaa	a aaacaaaaaa	aaacggtcaa	atatttttc	a	aacaaacaa	25020
agtaaagcta atttctatta	a aagttgatct	aaatactggt	tgtgtaggca	t	actatagtt	25080
gatttcaacg ggaagaaggo	caaatcagca	agtgtacatt	gtgttctgaa	a	aattgaaat	25140
tcaacagttg aatataagta	a gaaactctac	ctattgctaa	catttattgc	a	attcttctg	25200
tgttttgaac aatatcgaga	tcgctccatc	catcggataa	ttccgtatga	t	ttgatgaca	25260
tctcatctac agcttccaat	: tctccaatta	tctgatcctt	cagtttcagc	t	taatatcaa	25320
acgatttttg aatttcctg	g atatttgctt	cataaactct	cgagatttca	g	atttaactt	25380
gttgaatctc tttaaattgo	: tctgaaatct	tcttctcaag	aactcttttc	t	gataatata	25440
gctcagtgat ttctcgagtt	ctttctttca	taatcatttc	agtattcatt	t	gttcttctt	25500
taacattttc ttcaagtttt	tcaatctttc	gtacataatc	acagaaatga	t	caaccacct	25560
gcaaccattg cgggtcatt	cgcatagttt	tgagtcctcc	gggttgttca	a	gaattgcga	25620
caagactttc tgtctgttca	a agtttcagtt	tttctaatgt	ttgctcaagt	g	ggaattctc	25680
tgacctcctg gtttgcctct	: tcggaaggat	cagaaatttt	ttcagaatgg	a	acgtcaaaa	25740
tttcttgttc caaatgggga	a tatgttctac	tagtcccttg	actagaagtc	t	cactagaga	25800
ttttaagtgt cagttctcga	a acattacgct	ccaatttcgg	agaatttcca	g	attcagtgc	25860
tcacatgact ctttaattto	g acaatctcat	cattcttatc	aaagatttga	t	tttccagtg	25920
cagagacctt cacttgacaa	a tcttttgtct	tccatgacaa	ttcatctgcc	a	acatcttga	25980
tcatgttctc attcgaatca	ı atcgttttt	tcatatcttt	tatcatgtct	t	catcagttt	26040
tgattgtaac attttgcttt	gaaatttcac	gtttcacaga	attcaaagca	a	ttttcaaag	26100
aattgttgaa attttcgago	atcaaacttt	caacaccttc	ggatttatca	t	tcttggcaa	26160
cattccgatc attatttagt	tcagttgata	tagaattggt	atcatcaact	g	agaatactg	26220
ttaaattctg gtgttgaagt	: tccaaaaatt	tctccatgac	tttttcaata	с	tatccttct	26280

#### -continued

gataaacatt gaaggattct tgaagcattt taatctcttc attctttttc t tgagttcgg 26340 aaaacagaat attettett ttttggaatt ceaetgteae taagagataa t eatetttgt 26400 tttccaaaga tgtaaccagc tgcgatggat tcaaactttc caagtttttc g taagatagt 26460 caacttogto ttoaagtttt tgaatgatot gtttgttgto ttocatottt t ttgttataa 26520 gtataggatc cttgaaataa agagaaaacg tgactatgat cttgtcaata g tttccagca 26580 agtggaaaat gtcataataa tctccatcat ttaatacttt taatttgtcc a aaagttgat 26640 ccatcaactt ctcttgtttc ggtgtttcat caccaattaa tattccaccg t aaccgttaa 26700 ccggatatgg cgacaaatca taaaattgtt tttgaagatc ctcatattta g ttttgagaa 26760 ttgagaaatc ttcatttctc attatcaaca acttcttcaa tcttctagct t ctgtctctg 26820 cttttatttg gaaaatttcg aattgcattt cagctagtat tatctcatct t cttgttcat 26880 cgattaattt ctcaacttct tcttttaatt ttttgatatt ttgatctttt t ctgccatag 26940 cattttgaaa atcttctagt gttgcaaact gatattcagt ggatgtactc g tggattctt 27000 gagtcgaaat ttcagtgttc ttgtttattc gttttacttc ggagcttctg a ctattttct 27060 ctggagtcca aaacttgtct acttccaaaa aatgtgtttt tttgcttctg a aaaacatat 27120 attaagtaac atctttaaga tattcaggtg cacttacatt tttgaaatat t tggtgacaa 27180 actttgaatt atcaatctga attcttctgc ggttccagtg aagcaagcat a attcttgaaa 27240 ataaaaatta cagcttttga aaccaatgaa acgaaacaac tattgtattt a aaaaatgct 27300 cacttcaact ccattctctt ccaccgctgc ttcttttttc acacttttcc a gtttatcaa 27360 ttaaaaattc aagtttctgt tgttcaggtg aaggctgaga tgctgtgaac g acatagttc 27420 tgaaaatagt taatttaaat gtagcagaaa aatcttttct agaaagtaaa a aaaatcagt 27480 aaaaacaagt actaagagaa attgaataaa ccaatcacaa taatgacttc t taacaagct 27540 gaaaaataat gcaatagcaa agaaaaacga gtagtttcgg taactccata g tacattatt 27600 tcgttattgg gatcatcata tcatttattg atgaggatat tatgagttaa t tctaataac 27660 ccgagagtaa aggcaaaaaa tagcatggag tgaaaaaacg gatcaagcaa a gaaatcgtg 27720 ttaactttta taacatctag ttgacactgt cagaccaaaa acttaataaa a ttttcactt 27780 gtacataaca gctagctgaa actgtaattt aattttatat tccctcggtc a attctagct 27840 aaattagcga ttctgagcta agccttcatt tcaaaattaa caaaaaaaat g caatgaaat 27900 tttcacttgt acataacagc tagctgaaac tgtaatttaa ttttatattc t ctcggtcaa 27960 ttctagctaa attagcgatt ctgagctaag acttcatttc aaaaataaca a aaaaaatga 28020 attgaaattt tcacttgtac ataacagcta gctgaaactg caatttaatt t tatattcct 28080 tcagtcaatt tcagctaaat tagcaatttt gagctaagtg ttgttgtttc t taaaacaat 28140 gcaaattttg atggtttttc gtgttcagtg aacaaacaaa caaacaaaa a attctggta 28200 aataaccaca agctgaaact gtgagataat tttttagtga ccattgagtg a ctgctcata 28260 gacagtggct tggaattaag actagaatga ttatctctca tgataacata t tatacagag 28320 aagttgggaa gaatgtaggt cattgtaaag cgacagacag gtcgcattga t caaagagaa 28380 tataagtcga actctttcgt ttggtaactt gagggccaat gttatttgct a ttagggaaa 28440 attaacattt aaggagcaaa ggattgcaaa caaaatgcga taagatatat g attatagta 28500 ttttatcttt tgtaagtgtt gccataattt cagtaacgaa aaaaataaca a ggcaatttt 28560 agatgttagg aaaatcgaat ttgtctgact agccaacgaa tgttctcaat t gaagttatt 28620

#### -continued

45

gttcttttt	aagatgtttt	catacaaatt	agtcagtttt	cgaagcttca	g	ccacactta	28680
tccgaattga	gcaatttcaa	aactatttt	tgtaaaataa	aatacatctc	С	gaaaattta	28740
catcgagttc	ccaacaatac	tgtatggata	gaaaatacct	accaatactg	с	acatgaaac	28800
gctctgaaaa	taatcggaaa	ggaaatgaga	accttttaaa	tataaaatga	g	cacaataag	28860
taatactaac	tttattgaga	aagaacataa	ttgttatgag	aatagttttt	a	aatgaggtg	28920
agaaacagaa	tatccctgag	aataagtgaa	gatacttgaa	aatttgtgaa	a	tagtaataa	28980
gtaaaatgtt	ttcacattag	tataaacaat	gacagagtca	cgcaaaagta	с	gggaaacat	29040
atgaagttta	taatacagtg	cagtacagaa	aaggtacaaa	gtttacaaga	a	tacaattgt	29100
ttttaaaaa	taatttttg	ttgaaggctt	aaggtaatac	gattaaagag	с	tactttctt	29160
ccaatacgaa	gttgaattta	aaatttaaaa	ggaaaaaagg	aaaaaatta	a	aaagcatat	29220
gaaaaatcgg	ggcgcatttt	tagtgcaaaa	aattagatgg	catttattt	a	tcccatcca	29280
tctgaatctt	cactgtgtgt	ggatttattg	tcgtcatctt	gatcgatcat	t	gtatcatca	29340
gcttctcctt	cttgattgat	aagaagacct	tgcagttttt	ccgaaagttc	с	gaaatcttc	29400
aaatccttct	ctctcaatgc	atcatgcatc	ttctgaattt	cagcggatcg	t	tcgctattt	29460
tgaataagtt	ccatcagaca	ctcaattttg	ctatctttt	ccatgatttc	t	cttttatga	29520
tttgcaatct	gttcttcttt	tgattcacat	tctctctttg	aattggctga	a	ataaaagaa	29580
aatgcttaca	gatgtgtgta	aaacccctag	aaaactttca	caagcttacc	t	gtcaatact	29640
tcaaattgcc	ccaataagtt	gtgcttccac	tcttcagttc	gaagtttaag	a	tcttcaact	29700
gatgtattaa	gcgtggcttt	ttcctgctga	gtgtttgcaa	gttgcatctc	t	aacgccatg	29760
acggtcgagt	tatgttgatc	caaaatatga	ctg				29793

We claim:

1. An isolated nucleic acid molecule which encodes a polypeptide which catalyzes release of ADP-ribose from an ADP ribose polymer, having a nucleotide sequence that is at <sup>40</sup> least 80% identical to the nucleotide sequence set forth at SEQ ID NO: 1.

**2**. The isolated nucleic acid molecule of claim **1**, which encodes a protein having a molecular weight of about 110 kilodaltons, as determined by SDS-PAGE.

**3**. The isolated nucleic acid molecule of claim **1**, wherein said isolated nucleic acid molecule encodes a protein having the amino acid sequence set forth in SEQ ID NO: 2, 4 or 6.

4. The isolated nucleic acid molecule of claim 1, having the nucleotide sequence set forth in SEQ ID NO: 1, 3 or 5.

5. An expression vector comprising the isolated nucleic acid molecule of claim 1, operably linked to a promoter.

6. A cell transformed with the expression vector of claim 5.

**7**. The cell of claim **6**, wherein said cell is a bacterial cell, <sup>55</sup> a yeast cell, an insect cell, or a mammalian cell.

8. A cell transformed with the isolated nucleic acid molecule of claim 1.

9. The cell of claim 8, wherein said cell is a bacterial cell, a yeast cell, an insect cell, or a mammalian cell.

10. An isolated nucleic acid molecule which encodes a protein which catalyzes release of ADP-ribose from an

ADP-ribose polymer, wherein said protein comprises the amino acid sequences set forth in SEQ ID NO: 11, 12, 13 and 14.

11. The isolated nucleic acid molecule of claim 10, the complementary sequence of which hybridizes, under stringent conditions to the nucleotide sequence set forth in SEQ ID NO: 1.

12. The isolated nucleic acid molecule of claim 10, comprising the nucleotide sequence set forth in SEQ ID NO: 1, 3 or 5.

**13**. The isolated nucleic acid molecule of claim **10**, which encodes a protein having the amino acid sequence set forth <sup>50</sup> in SEQ ID NO: 2, 4 or 6.

14. An expression vector comprising the isolated nucleic acid molecule of claim 10, operably linked to a promoter.

15. A cell transformed with the expression vector of claim 14.

16. The cell of claim 15, wherein said cell is a bacterial cell, a yeast cell, an insect cell, or a mammalian cell.

17. A cell transformed with the isolated nucleic acid molecule of claim 10.

**18**. The cell of claim **17**, wherein said cell is a bacterial 60 cell, a yeast cell, an insect cell, or a mammalian cell.

\* \* \* \* \*